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Background: Small abdominal aortic aneurysms (AAAs; 3.0–5.4 cm in diameter) are usually asymptomatic
and managed by regular ultrasound surveillance until they grow to a diameter threshold (commonly 5.5 cm)
at which surgical intervention is considered. The choice of appropriate surveillance intervals is governed
by the growth and rupture rates of small AAAs, as well as their relative cost-effectiveness.
Objectives: The aim of this series of studies was to inform the evidence base for small AAA surveillance
strategies. This was achieved by literature review, collation and analysis of individual patient data, a focus
group and health economic modelling.
Data sources: We undertook systematic literature reviews of growth rates and rupture rates of small AAAs.
The databases MEDLINE, EMBASE on OvidSP, Cochrane Central Register of Controlled Trials 2009 Issue 4,
ClinicalTrials.gov, and controlled-trials.com were searched from inception up until the end of 2009. We
also obtained individual data on 15,475 patients from 18 surveillance studies.
Review methods: Systematic reviews of publications identiﬁed 15 studies providing small AAA growth
rates, and 14 studies with small AAA rupture rates, up to December 2009 (later updated to September
2012). We developed statistical methods to analyse individual surveillance data, including the effects of
patient characteristics, to inform the choice of surveillance intervals and provide inputs for health economic
modelling. We updated an existing health economic model of AAA screening to address the
cost-effectiveness of different surveillance intervals.
Results: In the literature reviews, the mean growth rate was 2.3 mm/year and the reported rupture rates
varied between 0 and 1.6 ruptures per 100 person-years. Growth rates increased markedly with aneurysm
diameter, but insufﬁcient detail was available to guide surveillance intervals. Based on individual surveillance
data, for each 0.5-cm increase in AAA diameter, growth rates increased by about 0.5 mm/year and
rupture rates doubled. To control the risk of exceeding 5.5 cm to below 10% in men, on average a 7-year
surveillance interval is sufﬁcient for a 3.0-cm aneurysm, whereas an 8-month interval is necessary for a
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5.0-cm aneurysm. To control the risk of rupture to below 1%, the corresponding estimated surveillance
intervals are 9 years and 17 months. Average growth rates were higher in smokers (by 0.35 mm/year) and
lower in patients with diabetes (by 0.51 mm/year). Rupture rates were almost fourfold higher in women than
men, doubled in current smokers and increased with higher blood pressure. Increasing the surveillance
interval from 1 to 2 years for the smallest aneurysms (3.0–4.4 cm) decreased costs and led to a positive net
beneﬁt. For the larger aneurysms (4.5–5.4 cm), increasing surveillance intervals from 3 to 6 months led to
equivalent cost-effectiveness.
Limitations: There were no clear reasons why the growth rates varied substantially between studies.
Uniform diagnostic criteria for rupture were not available. The long-term cost-effectiveness results may be
susceptible to the modelling assumptions made.
Conclusions: Surveillance intervals of several years are clinically acceptable for men with AAAs in the range
3.0–4.0 cm. Intervals of around 1 year are suitable for 4.0–4.9-cm AAAs, whereas intervals of 6 months
would be acceptable for 5.0–5.4-cm AAAs. These intervals are longer than those currently employed in the
UK AAA screening programmes. Lengthening surveillance intervals for the smallest aneurysms was also
shown to be cost-effective. Future work should focus on optimising surveillance intervals for women,
studying whether or not the threshold for surgery should depend on patient characteristics, evaluating the
usefulness of surveillance for those with aortic diameters of 2.5–2.9 cm, and developing interventions that
may reduce the growth or rupture rates of small AAAs.
Funding: The National Institute for Health Research Health Technology Assessment programme.
ABSTRACT
vi
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Contents
. . . . . . . . . . . . . . List of abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Scientific summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chapter 1 Background
Abdominal aortic aneurysm screening
Surveillance for small abdominal aortic aneurysms
Growth rates of small abdominal aortic aneurysms
Rupture rates of small abdominal aortic aneurysms
Need for systematic review and individual patient data analysis
Costs and cost-effectiveness
Overall aim of the project
Chapter 2 Research objectives
Aims and objectives
Structure of the report
Chapter 3 Methods for systematic reviews of growth and rupture rates
Systematic literature review of small abdominal aortic aneurysm growth rates
Systematic literature review of small abdominal aortic aneurysm rupture rates
Chapter 4 Results of systematic reviews of growth and rupture rates
Systematic review and meta-analysis of small abdominal aortic aneurysm growth rates
Systematic review and meta-analysis of small abdominal aortic aneurysm rupture rates
Chapter 5 Methods for individual patient data analysis of existing
surveillance data
Data collection
Focus group
Statistical methods
Chapter 6 Results of individual patient data analysis of existing
surveillance data
Study characteristics
Small abdominal aortic aneurysm growth rates in men
Small abdominal aortic aneurysm rupture rates in men
Small abdominal aortic aneurysm growth and rupture rates in women
Predictors of small abdominal aortic aneurysm growth rates
Predictors of small abdominal aortic aneurysm rupture rates
Inputs to health economic modelling
Chapter 7 Methods for cost-effectiveness analysis of alternative
surveillance policies
Introduction
The initial model
Validation and recalibration of the previously published model to better reflect the 10-year
follow-up data from the Multi-centre Aneurysm Screening Study
ix
xi
1
1
1
2
3
3
3
3
5
5
5
7
7
8
11
11
17
29
29
30
31
33
33
33
39
40
44
46
48
51
51
52
52
DOI: 10.3310/hta17410 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 41
vii
© Queen's Printer and Controller of HMSO 2013. This work was produced by Thompson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed
to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
Adapting the model structure to fully incorporate unobserved ‘tunnel’ states
Re-estimation of current unit costs for screening interventions, and elective and
emergency surgery
Incorporating data from the NHS Abdominal Aortic Aneurysm Screening Programme
Incorporating size-specific growth and rupture rates from the RESCAN analyses
Analysis of cost-effectiveness using the adapted and updated model
Chapter 8 Results of cost-effectiveness analysis of alternative
surveillance policies
Alternative surveillance strategies
Uncertainty and sensitivity
Discussion and conclusions
Chapter 9 Discussion
Systematic review of small abdominal aortic aneurysm growth rates
Systematic review of small abdominal aortic aneurysm rupture rates
Analysis of individual patient data surveillance data sets
Factors influencing growth and rupture rates
Chapter 10 Conclusions
Clinical and policy conclusions
Research implications
Acknowledgements
References
Appendix 1 Protocol, search strategy and list of excluded studies for
systematic review of growth of small abdominal aortic aneurysms
Appendix 2 Protocol, search strategy and list of excluded studies for
systematic review of rupture of small abdominal aortic aneurysms
Appendix 3 Statistical methods and excluded studies for individual patient
data meta-analysis
Appendix 4 Statistical methods for cost-effectiveness analysis
54
59
63
63
65
67
67
69
69
73
73
74
75
76
79
79
80
83
87
95
105
113
117
viii
NIHR Journals Library www.journalslibrary.nihr.ac.uk
CONTENTS
List of abbreviations
AAA abdominal aortic aneurysm
ACE angiotensin-converting
enzyme
BMI body mass index
CENTRAL Cochrane Central Register
of Controlled Trials
CI conﬁdence interval
CT computerised tomography
EVAR endovascular aneurysm
repair
HDU high-dependency unit
HR hazard ratio
ICER incremental cost-
effectiveness ratio
ICU intensive care unit
IPD individual patient data
IQR interquartile range
MASS Multicentre Aneurysm
Screening Study
MCMC Markov chain Monte Carlo
n sample size
NAAASP NHS Abdominal Aortic
Aneurysm Screening
Programme
NICE National Institute for Health
and Care Excellence
ONS Ofﬁce for National Statistics
OR odds ratio
PRISMA Preferred Reporting Items
for Systematic reviews and
Meta-Analyses
PSA probabilistic sensitivity
analysis
QALY quality-adjusted life-year
RCT randomised controlled trial
SD standard deviation
SE standard error
UKSAT United Kingdom Small
Aneurysm Trial
US ultrasound
DOI: 10.3310/hta17410 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 41
ix
© Queen's Printer and Controller of HMSO 2013. This work was produced by Thompson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed
to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.

Scientiﬁc summary
Background
Small abdominal aortic aneurysms (AAAs; 3.0–5.4 cm in diameter) are usually asymptomatic and managed
by regular ultrasound surveillance until they grow to a diameter threshold (commonly 5.5 cm) at which
surgical intervention is considered. The choice of appropriate intervals for surveillance is governed by the
growth and rupture rates of small AAAs. Growth rates increase with AAA diameter, vary between people
and may depend to an extent on patient characteristics. Rupture rates for small AAAs are considered to be
low, but there is little evidence to quantify this and how they depend on AAA diameter and patient
characteristics. The intervals between surveillance scans should be chosen to control to acceptable levels both
the risk of rupture and the risk of growth to a size where surgery is indicated.
Various rescanning intervals are used in different surveillance programmes. Currently, in the NHS Abdominal
Aortic Aneurysm Screening Programme (NAAASP) for men aged 65 years, yearly intervals are employed
for 3.0–4.4-cm AAAs and 3-month intervals for 4.5–5.4-cm AAAs. These choices were based on the intervals
used in the large UK Multicentre Aneurysm Screening Study (MASS) randomised trial of men aged
65–74 years, which showed that AAA screening reduced AAA-related mortality by about a half and was very
cost-effective. Whether or not these intervals are optimal is not known, as there are no direct comparisons of
different surveillance policies. However, changing these intervals would inﬂuence both effectiveness and
costs. For example, lengthening the intervals would reduce surveillance costs, but would slightly increase
AAA ruptures leading to both greater mortality and increased costs through emergency surgery. The best
choice of surveillance intervals needs to take this balance into account.
Objectives
The aim of this series of studies was to inform the evidence base for choice of appropriate surveillance
intervals for small AAAs. This was ﬁrst attempted by (i) a systematic literature review of published small AAA
growth rates and (ii) a systematic literature review of published small AAA rupture rates. Since published
information proved insufﬁcient for detailed modelling of small AAA growth and rupture rates, the project
proceeded with (iii) analysis of individual patient data (IPD) from existing surveillance programmes, (iv) use of
these IPD to investigate individual characteristics associated with growth and rupture rates, and to
provide inputs for health economic modelling, and (v) development of a cost-effectiveness modelling
framework to assess the impact of different surveillance intervals on costs, life expectancy and costs per
quality-adjusted life-year (QALY) gained.
Methods
The databases MEDLINE, EMBASE on OvidSP, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov
and controlled-trials.com were searched from inception up until to the end of 2009. A systematic review of
small AAA growth rates in published studies identiﬁed 61 potentially eligible reports. Detailed review yielded
15 studies providing growth rates for aneurysms of 3.0–5.5 cm in diameter (14 expressed as mm/year, one
as percentage change/year). Additional studies published up to September 2012 were also reviewed.
Similarly, a systematic review of small AAA rupture rates in published studies identiﬁed 54 potentially
eligible reports. There were only 14 studies from which rupture rates (as ruptures per 100 person-years)
were available. Additional studies published up to September 2012 were also reviewed.
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We obtained IPD on 15,475 patients under surveillance for small AAA from 18 studies, harmonised the data
sets and developed novel statistical methods for their analysis. Individual AAA diameters in each study
were analysed using a random-effects model that allowed for between-patient variability in size and growth
rates. Rupture rates were analysed by joint proportional hazards regression to incorporate the modelled
AAA diameter as a time-varying covariate. Predictions of the risks of exceeding 5.5 cm in diameter, and of
rupture, within given time intervals were estimated, and pooled across studies in a second stage using
random-effects meta-analysis. Acceptable risks were informed by the views of a focus group.
The inﬂuence of covariates (including demographics, medical and drug history) on aneurysm growth and
rupture rates was investigated in each IPD surveillance data set. Growth rates were analysed using
longitudinal random-effects modelling and rupture rates by Cox proportional hazards regression with
adjustment for aneurysm diameter. The effects of covariates were combined across studies in a second stage
using random-effects meta-analysis.
To perform the cost-effectiveness analyses, we ﬁrst updated the original health economic model of AAA
screening based on 4-year follow-up data in the MASS trial to employ the 10-year follow-up data now
available, undertaking internal validation and parameter recalibration. We then modiﬁed the modelling
framework to incorporate unobserved ‘tunnel’ states to allow the investigation of different surveillance
intervals. Up-to-date (2010–11) unit costs were estimated for screening, surveillance, and elective and
emergency surgery, drawing on data from various sources. We also incorporated data from NAAASP on
the prevalence, attendance rate and distribution of AAA sizes at screening. Finally, we derived transition
rates for AAA growth and rupture applicable to modelling different surveillance intervals from bespoke
analyses of the 18 IPD surveillance data sets. We used a threshold value of £20,000 per QALY gained to
calculate net beneﬁt.
Results
In the systematic literature review of growth rates, the 15 studies included 7630 persons (predominantly
male) enrolled during 1976–2005. The pooled mean growth rate was 2.32mm/year [95% conﬁdence
interval (CI) 1.95 to 2.70mm/year] but there was very high heterogeneity between studies, with average
growth rates ranging from –0.33 to +3.95 mm/year. Six studies reported growth rates by
5-mm-diameter bands, which showed the trend for growth rate to increase with aneurysm diameter.
Naive methods to estimate linear growth rates (such as last measurement minus ﬁrst measurement/time
interval) were associated with higher growth rate estimates. Meta-regression analysis showed that a 1-cm
increase in aneurysm diameter was associated with a 1.62 mm/year [standard error (SE) = 0.20] increase in
growth rate. Neither mean age nor percentage of women in each study had a signiﬁcant effect. On average,
a 3.5-cm aneurysm would take 6.2 years to reach 5.5 cm, whereas a 4.5-cm aneurysm would take
only 2.3 years.
Detailed review of the 54 studies identiﬁed in the systematic literature review of rupture rates showed that
ascertainment of rupture, patient follow-up and causes of death were poorly reported. Diagnostic criteria for
rupture were never reported. The 14 studies in which rupture rates were available included
9779 patients (89% male) over the time period 1976–2006, but only seven of these studies provided
rupture rates speciﬁcally for the AAA diameter range 3.0–5.5 cm. These ranged from 0 to 1.61 ruptures per
100 person-years.
In the analysis of IPD data sets, growth and rupture rates varied considerably between studies. For each
0.5-cm increase in AAA diameter, growth rates increased on average by about 0.5 mm/year and rupture
rates doubled. For a 3.0-cm AAA the average growth rate in men was 1.3 mm/year (95% CI 1.0 to
1.5 mm/year), and for a 5.0-cm AAA it was 3.6 mm/year (95% CI 3.3 to 3.9 mm/year); the corresponding
average rupture rates were 0.05 per 100 person-years (95% CI 0.03 to 0.07) and 0.64 (95% CI 0.43 to
0.95). To control the risk of exceeding 5.5 cm to below 10% in men, on average a 7-year surveillance interval
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is sufﬁcient for a 3.0-cm aneurysm, whereas an 8-month interval is necessary for a 5.0-cm aneurysm. To
control the risk of rupture to below 1%, the corresponding estimated surveillance intervals are 9 years and
17 months.
Aneurysm growth rates were independent of age and sex. Average growth rates were higher in smokers
(by 0.35 mm/year; p < 0.001) and lower in patients with diabetes (by 0.51 mm/year; p < 0.001). Mean arterial
pressure had no effect and antihypertensive or other cardioprotective medications had only small,
non-signiﬁcant effects on aneurysm growth, consistent with the observation that calendar year of enrolment
was not associated with growth rates. Rupture rates were almost fourfold higher in women than men
(p < 0.001), doubled in current smokers (p = 0.001) and increased with higher blood pressure (p = 0.001),
with some evidence that the aneurysm size had decreased over calendar time (p = 0.03).
Compared with the current surveillance policy in NAAASP, increasing the surveillance interval for the smallest
aneurysms (3.0–4.4 cm) decreased costs and led to a positive net monetary beneﬁt. For example, increasing
the current 1-year interval to 2 years reduced costs by £2.57 and increased net monetary beneﬁt by
£1.33 per man invited to screening. Decreasing the interval from 1 year for these smallest aneurysms led to
higher costs and a negative net beneﬁt. For the larger aneurysms (4.5–5.4 cm), it was not similarly
cost-effective to increase surveillance intervals from the current 3 months. For example, an increase to
6 months decreased costs by £1.51 but this was offset by a decrease in life expectancy so that the net beneﬁt
was only £0.10 per man invited to screening.
Conclusions
From the systematic reviews, we conclude that there is considerable variation between studies in the
reported growth rates of small aneurysms beyond that explained by aneurysm diameter. Fuller evidence on
which to base surveillance intervals for patients in screening programmes requires an IPD meta-analysis.
We also conclude that rupture rates of small AAAs would appear to be low. However, most studies on
rupture have been poorly reported and did not have clear ascertainment and diagnostic criteria for
aneurysm rupture.
From the analysis of the IPD surveillance data sets, we conclude that surveillance intervals of several years are
clinically acceptable for men with AAA diameters in the range of 3.0 to 4.0 cm. Intervals of around 1 year are
suitable for 4.0–4.9-cm AAAs, whereas intervals of 6 months are appropriate for 5.0–5.4-cm AAAs.
These intervals are longer than those currently employed in the UK AAA screening programmes.
Recommendations for frequency of surveillance of individual patients could also consider diabetes and
smoking, in addition to aneurysm diameter, but this would be difﬁcult to organise in practice. Nevertheless,
information given to patients who continued smoking is likely to increase both growth and rupture rates may
be helpful in persuading them to quit. Our data also indicate differing risk factors for growth and rupture
and suggest that a lower threshold for surgical intervention in women than men may be justiﬁed.
No single class of drug used for cardiovascular risk reduction, including statins, was shown to have a major
effect on the growth or rupture rate of small aneurysms.
Our cost-effectiveness investigations showed that lengthening the surveillance intervals from 1 year for
3.0–4.4-cm AAAs was cost-effective. However, the differences in costs were small, up to about £4 within an
overall cost of £300 per man invited to AAA screening. Lengthening the 3-month interval for 4.5–5.4-cm
AAAs to 6 months was neutral in terms of cost-effectiveness. Our results may be susceptible to the detailed
modelling assumptions made and parameter estimates used, and the fact that our updated health economic
model did not validate very well on the 10-year MASS trial data. Nevertheless, the cost-effectiveness analyses
support some lengthening of surveillance intervals for the smallest aneurysms, in line with the clinical
conclusions above.
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Research implications
We draw the following conclusions about future research priorities:
l We identiﬁed that the deﬁnition and diagnostic criteria of AAA rupture were poorly reported in published
studies. There is a need for standardised deﬁnitions and reporting, so that rupture rates can be more
reliably estimated.
l We observed large variation in growth rates between studies, which was largely unexplained. The
identiﬁcation of both methodological reasons, for example how AAA diameters are measured, and
biological causes for this variation are important. The latter could lead to the identiﬁcation of factors and
biological pathways related to increased growth rates or rupture rates that were amenable to
intervention. Such interventions should then be assessed in randomised trials.
l We have shown that the clinical progression of AAA is different in women compared with men, with
women at substantially higher risk of rupture. Currently, women are not screened for AAA in the UK and
those with opportunistically detected AAA are usually entered into generic rather than sex-speciﬁc
surveillance programmes. In addition to obtaining evidence to investigate the efﬁcacy and cost-
effectiveness of AAA screening in women, surveillance programmes and criteria for considering surgery
need to be tailored for women.
l Although we have provided evidence about appropriate surveillance intervals for small AAAs, we have
always used the currently accepted diameter of 5.5 cm for considering elective surgery. Related
research could aim to determine whether or not it is possible to develop personalised criteria or
patient-speciﬁc thresholds for elective surgery.
l Comparable studies with data sets of substantial size are required for the kind of research undertaken
here. Future research should focus on the collection and use of large, well-structured and
internationally compatible data sets, along with statistical and epidemiological methods needed for their
harmonisation and analysis. The recent inception of national AAA screening programmes in several
countries may facilitate such research.
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Chapter 1 Background
Abdominal aortic aneurysm screening
Abdominal aortic aneurysm (AAA) is an important cause of mortality, with around 4500 deaths each year in
England and Wales.1 Death due to an AAA usually occurs as a result of rupture, the overall survival rate
from which is only about 20%.2,3 AAAs are usually asymptomatic until rupture occurs, but can be detected
by ultrasound (US) screening. Following detection of an AAA (aortic diameter of at least 3.0 cm), either
through screening or incidentally, the principal surgical strategy is to repair the AAA before rupture occurs.
However, elective open AAA repair is associated with a mortality rate in the region of 5%.4 Although
minimally invasive endovascular techniques can reduce this operative risk to < 2%,5 late complications
make the long-term outcomes similar whatever operative method is chosen.6
The evidence in favour of screening older men for an AAA by US has come from four population-based
randomised trials in different countries, with the evidence being summarised in a Cochrane review.7 In men,
offering screening reduces aneurysm-related mortality by almost half [odds ratio (OR) 0.60, 95%
conﬁdence interval (CI) 0.47 to 0.78]. The data in women are too few to draw conclusions. Longer-term
(10-year) follow-up of men randomised in the large UK Multicentre Aneurysm Screening Study (MASS)
conﬁrms a continued reduction in aneurysm-related mortality and indicates that offering screening is
cost-effective within a 10-year time horizon.4 Long-term modelling based on the MASS trial suggests that the
lifetime cost-effectiveness of a policy of offering screening to men aged 65 years is very favourable, with an
estimated incremental cost-effectiveness ratio (ICER) of £2970 (95% CI £2030 to £5430) per quality-adjusted
life-year (QALY) saved.8 Following this evidence, a national AAA screening programme for men aged 65
years was initiated in the UK.9 However, any national AAA screening programme must have clear policies for
intervention and surveillance protocols. Such policies will depend, in a large part, on the growth rate and
rupture rate of small aneurysms.
Surveillance for small abdominal aortic aneurysms
The two UK AAA screening trials used diameters of either 5.5 cm or 6.0 cm, as measured by US, as
the threshold for considering elective surgery, whereas the Danish screening trial used a threshold of 5.0 cm
and in the Australian screening trial the intervention threshold was decided by local vascular surgeons.7
A 5.5-cm threshold is being used in the UK NHS National Abdominal Aortic Aneurysm Screening
Programme (NAAASP).9
Screening programmes identify AAAs with a wide range of diameters, but the majority (about 90%) have
diameters < 5.5 cm.10 The evidence about managing these ‘small’ aneurysms has come from four randomised
trials of intervention by open or endovascular surgical repair compared with surveillance for aneurysms
4.0–5.4 cm in diameter.11 These trials did not show a survival beneﬁt associated with a policy of early surgery
below the 5.5-cm-diameter threshold, even after prolonged follow-up.12 One reason that these trials have
not shown a survival beneﬁt is because the risk of rupture is very low while the aneurysm is still small.
The majority of small AAAs grow relatively slowly, but there is substantial variation in growth rates between
different individuals.13 To prevent undetected progression of an AAA to a size where there is a high
risk of rupture, repeated radiological scanning is necessary. Most patients with small AAAs require
surveillance for many years and undergo multiple AAA measurements.
There is no randomised trial comparing different surveillance protocols, and no recent systematic review of
the growth and rupture rates of small AAAs. As a result, screening and surveillance programmes in
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different countries have adopted different intervals (Table 1), without a good evidence base for their choice.
NAAASP employs surveillance intervals of 1 year for 3.0–4.4-cm AAAs and of 3 months for 4.5–5.4-cm
AAAs. This choice corresponds to the intervals used in the large UK MASS trial, which has provided the
majority of the randomised evidence worldwide (in terms of participants, person-years of follow-up and
number of events) on the beneﬁt of AAA screening.4
Growth rates of small abdominal aortic aneurysms
Apart from the screening trials, many other observational studies have reported on growth rates of small
aneurysms and recommended different frequencies of follow-up examinations. Published studies report
estimates of AAA growth in different ways, making them difﬁcult to summarise. In addition, they only rarely
report the variability in growth rates between patients, which is crucial for determining appropriate
surveillance intervals.17 In many cases simple linear regression has been used to estimate growth rates.
This does not account for the tendency for aneurysm growth to accelerate with increasing aneurysm
diameter, nor for the bias introduced by termination of the available measurements after the threshold for
surgical intervention is reached. Unbiased estimation of growth rates requires more complex statistical
analysis using likelihood-based methods, for example based on multilevel modelling.13 Application of such
analytical techniques shows that aneurysm growth rates vary considerably between people. Although most
TABLE 1 Small AAA surveillance intervals in different countries
Country Diameter bands (cm)
Surveillance interval
(months) Source of information
Denmark 3.0–5.5 12 Stather et al., 201314
Englanda 3.0–4.4 12 NAAASP9
4.5–5.4 3
Italy 3.0–3.9 12b Giardina et al., 201115
4.0–4.9 6
New Zealand 3.0–5.5 12 Stather et al., 201314
Norway 3.0–3.9 24 Stather et al., 201314
4.0–4.5 12
4.5–5.5 3–6
Sweden 2.5–2.9 60 Stather et al., 201314
3.0–3.9 24
4.0–4.4 12
4.5–5.0 6
5.1–5.5 3
USA 2.5–2.9 60 Chaikof et al., 200916
3.0–3.4 36
3.5–4.4 12
4.5–5.4 6
SVS, Society for Vascular Surgery (USA).
a Same intervals proposed for Northern Ireland, Scotland and Wales.
b Reported as 6 months by Stather et al., 2013.14
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aneurysms show a pattern of accelerating growth with increasing aneurysm diameter, some show a slowing
of aneurysm growth, some linear growth, and some aneurysms even decrease in diameter over time.
Some studies report faster aneurysm growth in smokers and slower aneurysm growth in patients with
diabetes, but evidence is inconsistent about sex differences.13 Two recent systematic reviews have addressed
the efﬁcacy of pharmacotherapy for decreasing aneurysm growth rates.18,19 These reviews concluded that,
although beta blockers do not reduce growth rates, there is some promise that statins and other anti-
inﬂammatory agents may reduce aneurysm growth rates. There is inconsistent evidence about the effect of
blood pressure and other variables.
Rupture rates of small abdominal aortic aneurysms
The risk of rupture increases with AAA size. In patients with small aneurysms (< 5.5 cm in diameter), the risk
of surgery is considered greater than the risk of rupture and a policy of surveillance is usually adopted. The
low risk of rupture makes it difﬁcult either to obtain reliable estimates of rupture rates of small aneurysms or
to investigate how these rupture rates vary according to aneurysm size, sex and other patient characteristics.
Reliable estimates of rupture rates are essential for planning the management of small aneurysms.
Although some synthesis of data for rupture in large aneurysms has been reported previously,20 systematic
reviews and meta-analyses of studies focused on the rupture rate of small aneurysms (< 5.5 cm) have not
been reported. Randomised trials have reported aneurysm rupture rates of 1% per annum or less for
aneurysms of 4.0–5.5 cm in diameter.21,22 The rupture rate of smaller aneurysms appears to be even lower.23
Need for systematic review and individual patient data analysis
To bring together the evidence on growth and rupture rates for small AAAs, a systematic review is required.
However, individual studies publish their results in many different ways, making a quantitative synthesis
problematic. This is compounded by the misuse of simple linear regression as an analysis tool, and
by the selective (or lack of) information presented on how growth and rupture rates vary with patient
characteristics. Thus, analysis of individual patient data (IPD) is likely to be necessary to obtain reliable
estimates of small aneurysm growth and rupture rates, and for modelling the impact of different
surveillance intervals.
Costs and cost-effectiveness
Different surveillance intervals lead to different associated costs, in terms of both the number of screens and
the number of elective and emergency operations carried out. They also have different beneﬁts in terms of
life expectancy. Costs and beneﬁts therefore have to be formally traded against each other by estimating the
cost-effectiveness of different screening intervals, and expressing this as the incremental cost per
QALY gained.
Overall aim of the project
This project has therefore sought to evaluate the available evidence pertinent to designing an evidence-
based surveillance programme, by means of systematic reviews of the literature and analysis of IPD from
surveillance studies. The choice of surveillance intervals should balance the frequency of rescreening intervals
against their cost, and will depend on both aneurysm growth rates and aneurysm rupture rates. Although we
focus on the UK context, and the NAAASP, our work clearly also has implications for other population-based
screening and surveillance programmes.
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Chapter 2 Research objectives
Aims and objectives
The overall aim is to synthesise the available evidence on the growth and rupture rates of small AAAs, in such
a way that can inform the appropriate choice of surveillance intervals.
The following questions are addressed:
l What are the growth rates of small AAAs?
l What are the rupture rates of small AAAs?
l How does aneurysm size inﬂuence growth and rupture rates?
l How do other individual characteristics affect growth and rupture rates?
l What are the clinical implications of varying the surveillance intervals for small AAAs?
l What are the cost implications of varying the surveillance intervals for small AAAs?
l What is the incremental cost-effectiveness of changing the surveillance intervals from those currently
implemented in the NAAASP?
To answer these questions we have:
1. conducted a systematic literature review of studies using US to monitor the growth of small AAAs
2. conducted a systematic literature review of the rates of rupture of small AAAs.
As this published information was not sufﬁcient for detailed modelling of AAA growth and rupture rates,
we then:
3. identiﬁed studies from these systematic reviews that could provide IPD to investigate AAA growth and
rupture rates
4. collated and harmonised individual data from 18 surveillance studies
5. developed an extensive statistical modelling framework to analyse the growth rates of small AAAs by size
and sex using likelihood-based multilevel modelling
6. undertook IPD meta-analyses of growth rates and of rupture rates
7. identiﬁed important patient characteristics associated with aneurysm growth and with aneurysm rupture
8. modelled surveillance intervals for persons identiﬁed with small AAAs, according to aneurysm size and sex.
We used bespoke statistical analyses from the IPD meta-analyses to provide inputs for health economic
modelling, and:
9. developed an extended health economic modelling framework to estimate the incremental costs and
cost-effectiveness of a range of surveillance strategies.
Structure of the report
Two systematic literature reviews were conducted: one of AAA growth rates and one of AAA rupture rates.
The methods of these reviews are presented in Chapter 3, with results in Chapter 4. The protocols,
search strategies and lists of excluded studies for these reviews are given in Appendices 1 and 2.
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Under the name of the RESCAN Collaboration, IPD on small AAA surveillance were obtained from
collaborating study groups. We collated data on both AAA diameters over time, to estimate growth rates,
and ruptures. The collating and analysis of these data are described in Chapter 5 (with detailed statistical
methods in Appendix 3). The results, given in Chapter 6, are expressed in a way that is directly relevant to the
choice of surveillance intervals for different sized aneurysms.
The cost implications of different surveillance strategies, and the comparative cost-effectiveness of using
them in an AAA screening programme, are then studied. The methods used for this are given in Chapter 7
(and additional details in Appendix 4), with results in Chapter 8.
Chapter 9 provides a discussion of all these component studies and conclusions are given in Chapter 10. A list
of published papers arising from this work is provided in Acknowledgements.
RESEARCH OBJECTIVES
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Chapter 3 Methods for systematic reviews of
growth and rupture rates
The project began with systematic literature reviews of small AAA growth rates and rupture rates. Theirmethods are described here (Systematic literature review of small abdominal aortic aneurysm growth rates
and Systematic literature review of small abdominal aortic aneurysm rupture rates, respectively) and their
results in Chapter 4.
Systematic literature review of small abdominal aortic
aneurysm growth rates
Literature search
The systematic review followed quality reporting guidelines set by the Preferred Reporting Items for
Systematic reviews and Meta-Analyses (PRISMA) group (www.prisma-statement.org/).24 A review protocol,
that outlined every step of the systematic review, was developed (see Appendix 1). The protocol was
reviewed and approved by one collaborator (FGRF).
The following databases were searched from inception up until the end of 2009 using search strategies
shown in Appendix 1: MEDLINE, EMBASE on OvidSP, Cochrane Central Register of Controlled Trials
(CENTRAL) 2009 Issue 4, ClinicalTrials.gov and controlled-trials.com. There were no ﬁlters used to restrict
study designs, nor were there any language restrictions. In addition, reference lists were also searched
for further studies to be included. Additional studies published up to September 2012 are discussed in
Chapter 9.
Two researchers (JTP and SMG) independently reviewed potential studies according to a set of eligibility
criteria. The studies (minimum sample size n = 50; men or women; aged ≥ 50 years) must include participants
with a small infrarenal AAA (baseline anterior–posterior or transverse diameter of between 3.0 and < 6.0 cm)
and with either serial US or computerised tomography (CT) scans assessed on at least two occasions
separated by at least 6 months. Studies which encompassed wider diameter ranges were included provided
growth rate estimates were available separately within the range of 3.0 to 5.5 cm. At this stage, to enable
reading in house, languages were restricted to English, Spanish, French, Swedish, Danish and Norwegian.
In addition, the following were excluded: review articles, studies in which patient data were duplicated (in
which case the most recent or comprehensive study was used), non-human studies, editorials and letters
(since they are often not peer reviewed), case reports, studies using patients previously treated by AAA
surgery or aneurysms of other arteries, and studies reporting on patients with Marfan syndrome. Study
authors were contacted in cases where aneurysms could not easily be separated according to size range.
Data extraction
A data extraction form to record variables and potential biases in the eligible studies was designed. In
particular, the following were identiﬁed: the study design (prospective, retrospective, randomised,
multicentre); source of patients (population screening, hospital screening); deﬁned intervention policy;
method of follow-up (US, CT); frequency of follow-up; patient recruitment (number of patients with two or
more scans, excluded patients); presence of a mortality review committee; length of follow-up [mean,
median, standard deviation (SD)]; inclusion criteria; recruitment period; trial using a particular drug; baseline
data including age, sex, ethnicity and other cardiovascular risk factors (e.g. blood pressure, smoking status,
drugs, ischaemic heart disease, peripheral arterial disease, diabetes); outcomes (how was aortic diameter
measured, measurement variability, if growth was reported by size band, number of non-AAA deaths,
number of AAA repairs, who carried out the aortic measurements); analysis (statistical methods used); author
afﬁliation; date of publication; and country (where study was undertaken). The same two researchers
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(JTP and SMG) independently extracted data of the potentially eligible primary studies and cross-checked
their results. Any disagreements between the two reviewers were settled by a third person (LCB).
If any studies failed to provide essential variables (growth rates, frequency and length of patient follow-up)
either the study was rejected or the study authors were contacted and asked to provide the missing data. If
study authors did not respond to the reviewers' repeated correspondence, these studies were withdrawn
from the selected publications. In addition, reasons for exclusion of particular studies were given.
Analysis
The reported overall mean growth rate (mm/year) and its standard error (SE) were extracted from each study,
together with mean growth rates reported in size bands, by two statisticians (LCB and MJS). Median growth
rates were used if means were not reported (3/15 studies). If percentage changes in AAA size were reported,
these were converted to mean growth rates by using the mid-point of the reported size band.
Where 95% CIs were quoted in place of SEs, these values were converted by assuming normality and using
the formula SE = (UCL − LCL)/3.92, where UCL and LCL are the upper and lower limits of the 95% CI. If a
sample SD and number of patients (n) was quoted, then this was converted to a SE of the mean using the
formula SE = SD/√n. If a 95% reference range was quoted, then this was ﬁrst converted to a SD using
the formula SD = (URR − LRR)/3.92, where URR and LRR are the upper and lower limits of the 95% reference
range, and then to a SE of the mean, as above. Similarly, studies that reported interquartile ranges (IQRs)
were ﬁrst converted to SDs using the formula SD = IQR/1.35.
Studies that reported a number of different growth rates by size band (within the 3.0–5.5 cm range) but no
overall growth rate were subjected to their own initial meta-analysis in which the size band estimates were
pooled (using a ﬁxed-effect meta-analysis) to obtain an additional overall growth rate estimate for that study.
Studies with estimates from two treatment arms also were pooled in this way to obtain an overall study
estimate. The overall estimates (one for each study) were then combined in a conventional random-effects
meta-analysis.25 Between-study heterogeneity was assessed using the I2 measure,26 which indicates the
percentage of total variation across studies due to heterogeneity rather than chance.
Separate meta-analyses were also conducted for growth rates reported in 5-mm size bands in an attempt to
account for some of the heterogeneity between study estimates. To account more comprehensively for
heterogeneity due to varying AAA diameter ranges, a meta-regression model was ﬁtted to the data using
average AAA diameter as an explanatory variable.27 Size band-speciﬁc estimates were included by using the
mid-point of the size band as a proxy for average AAA diameter. Studies with only an overall estimate
were included by using the mean baseline aneurysm diameter as the covariate value. A three-level model was
then used to account for heterogeneity between studies, and between size bands within a study, after
adjusting for average AAA diameter.28 Average age and proportion of women in each study were also
investigated as explanatory variables. All analyses were conducted using Stata version 11.0 (StataCorp LP,
College Station, TX, USA) and R version 2.15.0 (The R Foundation for Statistical Computing, Vienna, Austria).
Systematic literature review of small abdominal aortic
aneurysm rupture rates
Literature search
The systematic review followed quality reporting guidelines set by the PRISMA group (www.prisma-
statement.org/).24 Therefore a review protocol, that outlined every step of the systematic review including
exclusion criteria, was developed before starting the literature search and subsequent data extraction
(see Appendix 2). The protocol was reviewed and approved by one collaborator (FGRF).
The databases MEDLINE, EMBASE on OvidSP, CENTRAL 2009 Issue 3, ClinicalTrials.gov and controlled-trials.
com were searched from inception up until the end of 2009 using search strategies shown in Appendix 2.
METHODS FOR SYSTEMATIC REVIEWS OF GROWTH AND RUPTURE RATES
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Initially, there were no ﬁlters used to restrict study designs, nor were there any language restrictions. In
addition, reference lists were also searched for further studies to be included. Additional studies published up
to September 2012 are discussed in Chapter 9.
Two researchers (JTP and SMG) independently reviewed potential studies according to a set of eligibility
criteria. Studies eligible for inclusion had participants (men or women, aged ≥ 50 years) with a small
infrarenal AAA, spanning the baseline diameter range of between 3.0 and < 6.0 cm; for some studies this
was a subgroup of the total patient group described. At this stage, languages were restricted to English,
Spanish, French, Swedish, Danish and Norwegian (so that data could be extracted by the project team). In
addition, review articles, studies in which patient data were duplicated (in which case the most recent or
comprehensive study was used), non-human studies, editorials, letters, case reports, studies using patients
previously treated by AAA surgery or aneurysms of other arteries, and studies reporting on patients with
Marfan syndrome were all excluded.
There was no restriction on either the minimum number of ruptures or the timing when preceding aneurysm
diameter measurements were recorded, although small studies of < 50 patients recruited over more
than 3 years where rupture was not a primary outcome were excluded (because of probable patient selection
and publication biases); although this proved never to be the sole reason for exclusion. In addition,
study authors were contacted in cases where aneurysms could not easily be separated according to size
range of interest. It also was essential that mean length or person-years of follow-up were reported in the
eligible studies in order to calculate rupture rates; if these were not reported authors were contacted.
Data extraction
A data extraction form to record variables and potential biases in the eligible studies was designed. In
particular, the following characteristics were identiﬁed: the study design; source of patients; deﬁned
intervention policy; method of follow-up; frequency of follow-up; patient recruitment; presence of a
mortality review committee; length of follow-up (mean, median or total person-years); inclusion criteria;
enrolment date; number of included patients (with more than one US scan or CT); age; sex; ethnicity; other
baseline data (blood pressure, smoking status, drugs, ischaemic heart disease, peripheral artery disease,
diabetes); outcomes (number of ruptures, how ruptures were diagnosed, whether or not ruptures were
reported by size band, number of non-rupture deaths, number of AAA repairs, category of professional who
carried out aortic measurements); analysis (statistical methods used); author afﬁliation; date of publication;
and country (where study was undertaken). The same two researchers (JTP and SMG) independently
extracted data from the eligible primary studies and cross-checked their results. Any disagreements between
the two reviewers were settled by a third person (LCB).
Any studies that failed to provide essential variables (number of ruptures and length of follow-up) were either
rejected or, if the study was published in the previous 15 years (1994–2009), the authors were contacted
for this information. If study authors did not respond to the reviewers' repeated correspondence, these
studies were withdrawn from the selected publications. The reasons for exclusion of studies are shown
in Appendix 2.
Analysis
Rupture rates (per 100 person-years) were calculated from each study by extracting the number of reported
ruptures and person-years of follow-up. For studies that reported mean follow-up, person-years were ﬁrst
calculated by multiplying the mean follow-up by the number of patients under surveillance. Any additional
surveillance after aortic surgery was not included in the calculation of person-years. Rupture rates were
estimated by dividing the number of ruptures by the person-years of follow-up and multiplying by 100. In
addition, a small aneurysm rupture rate was calculated if the paper quoted the number of small aneurysm
ruptures (last recorded measurement in the range of 3.0 to 5.5 cm) and person-years of follow-up in the small
aneurysm range. This required the study to have recorded AAA diameter at regular intervals throughout
follow-up, and crucially to have reported conditional follow-up within the diameter range of 3.0 to 5.5 cm. A
95%CIwas calculated for each rupture ratebyassuming thenumberof ruptures followedaPoissondistribution.
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Chapter 4 Results of systematic reviews of growth
and rupture rates
The results of the systematic reviews are presented here, in Systematic review and meta-analysis of smallabdominal aortic aneurysm growth rates and in Systematic review and meta-analysis of small abdominal
aortic aneurysm rupture rates.
Systematic review and meta-analysis of small abdominal aortic
aneurysm growth rates
Identiﬁcation of relevant studies
A total of 10,160 study titles were identiﬁed by the initial search strategy and, of these, 9951 were excluded
after title searching (Figure 1). A total of 209 potential papers were selected, of which two had been
identiﬁed by searching reference lists. In the next stage, abstracts were reviewed and 61 papers were
selected for further review of full-text publications, while 148 were excluded. Of the eligible full-text
publications, 46 were excluded for one or more of the following reasons: language (n = 2); duplicated data/
patients (n = 12); no original data/data synthesis only (n = 2); growth rates not available/no longitudinal study
(n = 11); selection criteria unspeciﬁed (n = 1); patient selection bias (n = 8); incorrect aneurysm size range
(n = 13); no deﬁned intervention policy (n = 2); too few patients (n = 6); growth rates not according to
size range (n = 2); not restricted to AAA (n = 1); no frequency of follow-up (n = 2); and retrospective
intervention policy (n = 1). A full list of excluded studies, with reasons, is provided in Appendix 1. Fifteen
studies13,22,29–41 were identiﬁed as potentially eligible for inclusion in the systematic review and these are
summarised in Table 2.
Study characteristics
The publication dates of the 15 potentially eligible studies13,22,29–41 ranged from 1994 to 2009, with patient
recruitment from 1976 to 2005. Of these, 10 were prospective studies13,22,34–41 (including three randomised
trials), four included both retrospective and prospective data29,30,32,33 and one study reported only
retrospective data.31 Aneurysm growth was the primary outcome measure in 10 of the 15 studies. Overall,
there were 7630 persons included in these 15 studies (although the two Spanish studies32,33 may have
included some duplicated patients). Some studies did not report accurately on the sex of participants,30,34 but
in those that did the proportion of women ranged from 0% to 24% of the study population. The mean
baseline age ranged from 65 to 71 years, although age was not reported in two studies.29,30 The study size
ranged from 134 to 1743 patients, with most patients followed up for between 1 and 5 years; not all of
these studies stated the mean length of follow-up or patient-years of follow-up.
Most studies used US to monitor aortic diameter, but the plane and cursor positioning (internal vs. external)
varied across the different studies and, for some studies, the precise plane of reference was not speciﬁed.
Some studies used CT as well as US.22,29,33 Most of these studies included aortic diameters from 30mm
(at baseline), except three studies, which reported from either 25mm31,35 or 28 mm.13 Not all studies
restricted their reporting to the aneurysm diameter range of interest (3.0–5.5 cm) and in some instances
substudies were identiﬁed, which reported on a more restricted range.13,29,33 Different methods were used to
estimate aneurysm growth, usually reported as mm/year, with linear regression or (last–ﬁrst diameter)/time
being the most common; two studies did not report how they estimated aneurysm growth.29,36 One study
only reported percentage changes in aneurysm diameter and used data from two screening programmes
(Chichester and Huntingdon).34 Two studies were more than 10 years old, so that requests to authors
for further information met with little success. These and other details of the included studies are shown in
Table 2. Quality indicators for both imaging and design of the 15 included studies13,22,29–41 are listed in Table 3.
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Other patient characteristics, such as ethnicity, history of smoking, prevalence of diabetes, blood pressure,
proportion of participants with ischaemic heart disease and peripheral arterial disease, were reported variably
across the 15 studies.13,22,29–41
Comparison of small aneurysm growth rates
Overall average growth rate estimates are shown in Figure 2, with separate estimates for the Huntingdon
and Chichester studies.34 There was very substantial heterogeneity between study estimates (I2 = 98%), with
reported growth rates ranging from –0.33 mm/year to +3.95 mm/year. The Huntingdon study34 was
reported as having a negative growth rate and the largest growth rate was reported from a study which only
included 40- to 49-mm-diameter aneurysms.33 One study could not be included because no SE could be
calculated from the information reported.30 The random-effects meta-analysis estimate of the average
aneurysm growth rate was 2.32mm/year (95% CI 1.95 mm/year to 2.70 mm/year). Restriction of the meta-
analysis to those studies that only used ultrasonography imaging after 1990 (reﬂecting potentially better
imaging quality), the growth rate reduced slightly to 2.05 mm/year (95% CI 1.64 mm/year to 2.45 mm/year),
although the heterogeneity remained high (I2 = 97%).
Rates are summarised in Figure 3 for those studies that reported mean growth rates by 5-mm-diameter
bands.29,32,35–38 Estimates within these size bands generally were more homogeneous than the overall
estimates, although heterogeneity still remained (I2 ranged from 11% to 91%). Growth rates increased
steadily with aneurysm diameter band, with a pooled mean growth rate of 1.81 mm/year (95% CI
1.55 mm/year to 2.07 mm/year) for individuals whose baseline diameter measured 3.0–3.4 cm compared
with 4.96 mm/year (95% CI 4.25 mm/year to 5.66 mm/year) for individuals whose baseline diameter
Titles identified through
database searching
(n = 12,598)
Additional titles identified
through other sources
(n = 41)
Titles screened
(n = 10,160)
Full-text articles
assessed for eligibility
(n = 61)
Full-text articles
excluded, with reasons
(n = 46)
Titles after duplicates removed
(n = 10,160)
Abstracts excluded
(n = 148)
Titles excluded
(n = 9951)
Abstracts screened
(n = 209)
Author requests
(n = 2) Studies potentially
eligible for inclusion in
meta-analysis
(n = 15) Author replies
(n = 2) 
FIGURE 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram – small AAA
growth studies.
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measured 4.5–4.9 cm. The greater number of patients in the smaller diameter bands is one reason why the
widths of the CIs increase with aneurysm diameter.
The statistical method used to calculate growth rates and the study design (retrospective or prospective) were
signiﬁcantly associated with growth rates. Studies that used hierarchical modelling or linear regression
had, on average, growth rates that were respectively 1.52 mm/year (SE 0.51 mm/year) and 0.40 mm/year
(SE 0.40 mm/year) smaller than studies that used (last–ﬁrst diameter)/(time elapsed) to report growth rate.
Prospective studies had, on average, growth rates that were 1.11mm/year (SE 0.39 mm/year) smaller than
either retrospective or partially retrospective designs, although this effect was no longer signiﬁcant after
adjusting for the method used to calculate growth rate.
A meta-regression with average aneurysm diameter as an explanatory variable resulted in a strong trend
between diameter and growth rate (Figure 4). After adjusting for average diameter, between-study
heterogeneity was estimated to be about twice that of the heterogeneity between estimates within a study.
A 1-cm increase in AAA diameter was found to be associated with a 1.62mm/year (SE 0.20 mm/year)
increase in growth rate. The age and sex of included patients was available for nearly all studies and were
assessed as explanatory variables but found to be not statistically signiﬁcant; a 10% increase in the
percentage of women in a study increased the growth rate by a modest 0.13 mm/year (SE 0.26 mm/year),
whereas a 5-year increase in mean study participant age decreased the growth rate by 0.01mm/year
(SE 0.56 mm/year).
Based on the linear relation between growth rate and aneurysm diameter (see Figure 4), the size of
aneurysms is expected to grow exponentially with time. Given the meta-regression relationship shown,
aneurysms with diameters of 3.0, 3.5, 4.0, 4.5 and 5.0 cm would be expected, on average, to take 9.6, 6.2,
4.0, 2.3 and 1.1 years, respectively, to reach 5.5 cm.
However, there was insufﬁcient published data for the detailed modelling of AAA growth rates necessary to
better inform surveillance intervals. For this, IPD are necessary, as described in Chapters 5 and 6.
Systematic review and meta-analysis of small abdominal
aortic aneurysm rupture rates
Identiﬁcation of relevant studies
A total of 10,160 study titles were identiﬁed by the initial search strategy and, of these, 9951 titles were
excluded (Figure 5). In the next step, a total of 209 potential abstracts were reviewed and 54 selected for
further review of the full-text publication (155 were excluded). Of the 54 eligible full-text publications,
40 were excluded for the following reasons (see Appendix 2): (1) language (n = 3); (2) duplicated patients/
data (n = 7); (3) modelling, no original data (n = 5); (4) person-years' follow-up not available (n = 21); (5)
inaccurate diagnostic criteria of either aneurysm size or rupture (n = 3); (6) patient selection bias (n = 6);
(7) ruptures in incorrect size range (n = 11); and (8) small studies (< 50 patients collected over more than
3 years) (n = 4). Some studies were excluded for more than one reason and some reasons were ascertained
by author enquiry or after statistical review. A total of 14 eligible studies22,23,29,32,36,37,40–47 were identiﬁed for
inclusion in the systematic narrative review and are shown in Table 4.
Study characteristics
The 14 included studies22,23,29,32,36,37,40–47 were published from 1991 to 2008 (with patients enrolled from 1976
to 2006); 11 of these were prospective studies22,23,29,32,36,37,40,41,43–45 (including four randomised trials), whereas
the remaining three studies42,46,47 had both retrospective and prospective contributions. Only ﬁve of the studies
had aneurysm rupture as a primary outcome measure23,41,43,45,46 and even in these studies the diagnostic
criteria for aneurysm rupture were not reported. Overall, 9779 patients (8662 men, and 1117 women) were
included, with study size ranging from 176 to 2257 patients and average length of follow-up ranging from
1.6 to 4.6 years. Most studies used US to monitor aortic diameter, but some studies used CT as well as
US29,32,41,46,47 and one study also used magnetic resonance imaging.47 Many studies included patients with
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TABLE 3 Quality assessment of studies included in the systematic review
Quality aspect
Brady et
al., 200413
Brown
et al.,
200329
Karlsson
et al.,
200939
Propranolol
Aneurysm Trial
Investigators,
200240
Lederle et
al., 200222
Lindholt
et al.,
200035
McCarthy
et al.,
200337
After 1990
(image quality)
Y N Y Y Y Y Y
Standardisation
of imaging
Y N Y Y N Y Y
Variability of
diameter given
Y N N Y For CT only Y N
Study type
(P, R, PR)
P PR P P P P P
Study type
(RCT/obs)
RCT + obs Obs RCT RCT RCT RCT + obs Obs
Inclusion to obs
comprehensive
N Y N Y
Intervention policy
stated at start
(diameter, cm)
Y
(randomised
at 4.0 or
5.5a)
N N Y (either 5
or 5.5)
Y
(randomised
at 4.0 or
5.5a)
Y (5.0) Y (5.5)
Patient censorship
deﬁned
Y N Y Y Y Y Y
C, Chichester; H, Huntingdon; N, no; obs, observational study; P, prospective; PR, both prospective and retrospective;
R; retrospective; RCT, randomised controlled trial; U, unclear; Y, yes.
a To observation or surgery.
Author
Brady 200413
Brown 200329
Karlsson 200939
Propranolol 200240
Lederle 200222
Lindholt 200035
McCarthy 200337
Santilli 200236
Schlosser 200841
Schouten 200631
Solberg 200538
Vardulaki 199834
Vardulaki 199834
Vega de Céniga 200632
Vega de Céniga 200833
Overall (I 2 = 97.9%, p < 0.001)
Baseline
28−85 mm
30−49 mm
35−49 mm
30−50 mm
40−54 mm
30−49 mm
30−39 mm
30−39 mm
30−55 mm
25−53 mm
30−> 49 mm
30−49 mm
30−59 mm
30−49 mm
40−49 mm
Group
Huntingdon
Chichester
AAA growth, cm (range)
−0.33 (−0.79−0.14)
2.60 (2.54−2.66)
3.82 (3.51−4.14)
2.20 (1.93−2.47)
2.38 (2.13−2.63)
3.20 (3.04−3.36)
2.80 (2.41−3.19)
1.90 (1.72−2.07)
1.60 (1.46−1.74)
2.50 (1.99−3.01)
2.95 (2.50−3.40)
1.82 (1.55−2.09)
 0.92 (0.64−1.21)
 2.87 (2.42−3.32)
 3.95 (3.11−4.79)
 2.32 (1.95−2.70)
−1 0 1 2 3 4 5
AAA growth (mm/year)
FIGURE 2 Overall AAA growth rate estimates, one for each study, by baseline AAA diameter size range. Estimates are
pooled using a random-effects meta-analysis, due to considerable heterogeneity (I2 = 98%). An estimate from
Schewe et al.30 could not be included due to no SE being available.
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Santilli et
al., 200236
Schewe
et al.,
199430
Schlosser
et al.,
200841
Schouten
et al.,
200631
Solberg
et al.,
200538
Vardulaki et
al., 199834 aVega de
Céniga et al.,
200632
Vega de
Céniga et al.,
200833C H
Y N Y Y Y N Y N Y
N N N N N N N N N
N N N Y N N N N N
P PR P R P P P PR PR
Obs Obs Obs Obs Obs Obs Obs Obs Obs
N N Y N N U U Y Y
Y
(randomised
at 4.0 or
5.5a)
Y (5.0) Y (5.5) Y (5.0) N Y (6.0,
later
5.5)
Y
(4.5)
Y (5.0) Y (5.0)
Y N Y U Y Y N U Y
aortas < 3.0 cm in diameter or with aneurysms > 5.5 cm in diameter and for many studies it was not clear if
patients with aortas either < 3.0 cm or > 5.5 cm were included in the years of follow-up reported. Only one
study44 unambiguously reported conditional follow-up for the diameter range of 3.0 to 5.5 cm, although this
could be estimated in six further studies.22,23,29,43,45,47 These seven studies comprised 5934 patients
(86% male).22,23,29,43–45,47 Many studies were more than 10 years old, so that requests to authors for further
information met with little success.
The diagnostic criteria for aneurysm rupture were not reported in any study and methods for the
ascertainment of rupture were reported in only two studies;22,23 only these studies and one other40 had any
independent audit of deaths. One randomised trial22 reported 11 ruptures in the surveillance group;
however, two cases were reported as being discovered at laparotomy for elective surgery (one as ‘a hole in
the aortic wall covered by a thin layer of connective tissue’, the other as ‘a hole plugged by thrombus’), rather
than ﬁndings made on pre-operative imaging. This information was reviewed independently by two
professors of vascular surgery; in the absence of information about intramural or extramural haematoma,
their decision was that these two cases should not be considered as ruptures for the purposes of this review.
Causes of death other than from aneurysm rupture were often not collected systematically and were
reported variably, which might have led to under-reporting of aneurysm rupture rates in several studies (only
three studies had any independent review of causes of death22,23,41).
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The mean or median age of patients was reported as between 65 and 75 years in most of the included
studies,22,23,29,32,36,37,40–43,45,46 but age was not speciﬁed in two studies.44,47 The majority of the studies included
both sexes, although women were always in a minority. Three population-screening studies reported
exclusively on male participants.36,37,44 Details of the included studies (e.g. age, inclusion criteria, description
of study follow-up and intervention policy, last diameter and time between last diameter and rupture) are
summarised in Table 5.
Other characteristics, such as ethnicity, history of smoking, prevalence of diabetes, blood pressure and other
clinical history, were not available for all studies.
Comparison of small aneurysm rupture rates
The seven studies reporting on aneurysms in the baseline diameter range of 3.0 to 5.5 cm, and with
follow-up restricted to this range (conditional follow-up to 5.5 cm in diameter, larger aneurysms excluded),
provided rupture rates estimated as varying from 0 to 1.61ruptures per 100 person-years (Figure 6).
The studies in the ﬁgure are sorted according to the mid-point of the diameter range and exhibit a slight
trend towards higher rupture rates for larger diameters (for example, no ruptures were reported within
12 months of a measurement of < 4.0 cm). Nevertheless, the size range only partly explains the considerable
heterogeneity between the rupture rate estimates, demonstrated by an I2 value of 89%. Two studies
estimate the rupture rate to be greater than 1.0 rupture per 100 person-years,23,43 whereas the point
estimates from the remaining ﬁve studies22,29,44,45,47 are all below 0.5 ruptures per 100 person-years.
Owing to the large statistical and clinical heterogeneity, a formal synthesis of the results (meta-analysis) was
not carried out.
AAA growth (mm/year)
Author
30−34 mm
Brown 200329
Lindholt 200035
McCarthy 200337
Santilli 200236
Solberg 200538
Vega de Céniga 200632
Overall (I 2 = 78.3%)
35−39 mm
Brown 200329
Lindholt 200035
McCarthy 200337
Santilli 200236
Solberg 200538
Vega de Céniga 200632
Overall (I 2 = 91.0%)
40−44 mm
Brown 200329
Lindholt 200035
Solberg 200538
Vega de Céniga 200632
Overall (I 2 = 81.0%)
45−49 mm
Brown 200329
Lindholt 200035
Solberg 200538
Vega de Céniga 200632
Overall (I 2 = 11.2%)
n
191
86
330
578
87
155
204
34
166
212
58
91
306
24
23
62
194
7
11
44
AAA growth, cm (range)
2.80 (2.21−3.39)
2.00 (1.67−2.33)
1.60 (1.40−1.80)
1.50 (1.34−1.66)
1.80 (1.31−2.29)
1.65 (1.28−2.02)
1.81 (1.55−2.07)
3.40 (2.81−3.99)
3.20 (2.02−4.38)
3.20 (2.79−3.61)
2.00 (1.75−2.25)
1.75 (1.48−2.02)
2.80 (1.94−3.66)
2.66 (2.06−3.27)
4.50 (3.91−5.09)
4.20 (3.00−5.40)
2.31 (1.37−3.25)
4.50 (3.17−5.83)
3.86 (2.75−4.97)
5.20 (4.42−5.98)
5.30 (3.77−6.83)
3.36 (1.50−5.22)
5.02 (3.04−7.00)
4.96 (4.25−5.66)
1 2 3 4 5 6 7
FIGURE 3 Aneurysm growth rate by 5-mm size ranges of baseline aneurysm diameter: random-effect meta-analyses
conducted within subgroups.
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Rupture rates estimated from total reported ruptures and follow-up (including aneurysms > 5.5 cm) from all
14 studies22,23,29,32,36,37,40–47 (Figure 7) ranged from 0 to 2.51ruptures per 100 person-years. In this ﬁgure,
the studies are sorted according to the mid-point of the baseline diameter range. The between-study
variation is even more extreme, with an I2 value of 96%.
The published information on rupture rates is thus inadequate for the detailed modelling needed to inform
surveillance intervals. For this, IPD are necessary, as described in Chapters 5 and 6.
Author
Brady 200413
Brown 200329
Karlsson 200939
Propranolol 200240
Lederle 200222
Lindholt 200035
McCarthy 200337
Santilli 200236
Schlosser 200841
Schouten 200631
Solberg 200538
Vardulaki 1998 Chichester34
Vardulaki 1998 Huntingdon34
Vega de Céniga 200632
Vega de Céniga 200833
35
0
1
2
3
4
5
40
Average AAA diameter (mm)
A
A
A
 g
ro
w
th
 r
at
e 
(m
m
/y
ea
r)
45 50 55
FIGURE 4 Meta-regression of AAA growth rate estimates by AAA diameter. The overall regression line is shown by
the solid bold line. The mid-point of the reported size range is used to calculate AAA diameter for range-specific
estimates, whereas the mean baseline diameter is used for overall estimates. Estimates from the same study are
joined by a dotted line. The circles have an area in proportion to the amount of information (inverse variance of
the estimate).
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Titles identified through
database searching
(n = 12,598)
Additional titles identified
through other sources
(n = 41)
 Titles screened
(n = 10,160)
Full-text articles read
(n = 54)
Full-text articles
excluded, with reasons
(n = 40)
Titles after duplicates removed
(n = 10,160)
Abstracts excluded
(n = 155)
Titles excluded
(n = 9951)
Abstracts screened
(n = 209)
Eligible studies
(n = 14)
Rupture rates estimated
in a diameter range of
3.0 to 5.5 cm
(n = 7)
FIGURE 5 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram – small AAA
rupture studies.
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TABLE 4 Studies reporting on the rupture rate of small AAAs (3.0–5.5cm in diameter)
Author,
year and
country
Total number
of patients
(women)
[baseline
AAA
diameter]
Total
ruptures
per total
person-
years
reported
Total small aneurysm
ruptures per small
aneurysm person-years
[diameter range for
subgroups] (fatal
ruptures by 30 days)
Rate of small
aneurysm
ruptures per
100 person-
years
(95% CI) Comments
Brown,
199923
2257 (465)
[3.0–9.7 cm]
103/4102 67/3215 [3.0–5.9 cm] 2.08
(1.62 to 2.65)
1. Person-years for the
3.0–4.9 cm size range
calculated from number
of ruptures per reported
rupture rate
UK
27/2600 [3.0–4.9 cm]
(fatal NR) 1.04
(0.68 to 1.51)40/615 [5.0–5.9 cm]
(fatal NR) 6.50
(4.65 to 8.86)
Buckenham,
200742
198 (50)
[2.8–7.8 cm]
5/325.05 3/unknown (3 fatal) Unknown 1. Threshold diameter
for surgery changed
from 5.5 cm to 5.0 cm
in June 2004
2. Person-years
estimated from
median follow-up
New Zealand
Brown,
200343
372 (99)
[5.0–5.4 cm]
9/560 9/560 [5.0–5.4 cm]
(fatal NR)
1.61
(0.73 to 3.05)
Canada
Scott,
200544
1333 (0)
[3.0–5.4 cm]
36/5465.3 12/3110.8
[3.0–5.4 cm]
(fatal NR)
0.39
(0.20 to 0.67)
England
Brown,
200329
895 (207)
[3.0–4.9 cm]
0/3088 0/3088 0.00
(0.00 to 0.12)
1. Some patients also
may be reported in
study Brown 200343Canada
Santilli,
200236
790 (0)
[3.0–3.9 cm]
0/3071.32 0/unknown Unknown 1. Cause of death only
available in 43% of
patients, so some
deaths from rupture
may have been
excluded
2. Only included
patients with more
than one scan
USA
Reed,
199745
176 (64–69)
[<3 to >6 cm]
11/862 1/333 [3.0–5.0 cm]
(fatal NR)
0.30
(0.01 to 1.67)
1. Rupture rates
calculated from last
US diameter
2. Only included
patients with more
than one scan
USA
Guirgius,
199146
300 (89)
[2.5–5.0 cm]
14/850 2/unknown (fatal NR) Unknown
Canada
Armstrong,
200747
334 (3)
[4.0–5.4 cm]
2/946 2/946 [4.0–5.4 cm]
(1 fatal)
0.21
(0.03 to 0.76)
1. Surveillance group
only
USA
continued
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TABLE 4 Studies reporting on the rupture rate of small AAAs (3.0–5.5cm in diameter) (continued )
Author,
year and
country
Total number
of patients
(women)
[baseline
AAA
diameter]
Total
ruptures
per total
person-
years
reported
Total small aneurysm
ruptures per small
aneurysm person-years
[diameter range for
subgroups] (fatal
ruptures by 30 days)
Rate of small
aneurysm
ruptures per
100 person-
years
(95% CI) Comments
Vega de
Céniga,
200632
352 (19)
[3.0–5.0 cm]
2/1619 0/unknown Unknown 1. Only includes patients
with more than one
scan
Spain
Propranolol
Aneurysm
Trial
Investigators,
200240
552 (88)
[3.0–5.0 cm]
At least
3/1380
At least 2/unknown
(<5.5 cm fatal NR 2/3
total ruptures)
Unknown 1. Excluded patients
whose AAA had
grown by <2mm in
previous year
2. No sudden deaths
reported as rupture
after mortality
committee review
Canada
McCarthy,
200337
1423 (0)
[2.5–4.0 cm]
2/5045 2/unknown (2 fatal) Unknown 1. Unclear how many
person-years are
included beyond
5.5 cm
England
Lederle,
200222
567 (5)
[4.0–5.4 cm]
surveillance
group only
11/1833 9/1833 [4.0–5.4 cm]
(8 fatal)
0.49
(0.22 to 0.93)
1. Two covered ‘hole in
wall’ at elective repair
cases excluded: not
true ruptures
USA
Schlosser,
200841
230 (23)
[3.0–5.5 cm]
7/755 6/unknown (<5.5 cm
fatal NR; 6/7 total
ruptures)
Unknown
Netherlands
NR, not reported.
For many studies the conditional follow-up for an aneurysm diameter of 3.0 to 5.5 cm, to aneurysm rupture or death
could not be established.
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FIGURE 6 Rupture rates (per 100 person-years) for small AAAs in each study, reporting conditional follow-up to
5.5-cm threshold, sorted by reported size range (total 5934 patients). Aneurysms reaching > 5.5cm have been
excluded. These studies are depicted in order of increasing aneurysm size range, but the distribution of diameters
within these size ranges is not available.
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FIGURE 7 Total rupture rates (per 100 person-years) for small AAAs in each study, sorted by baseline diameter range
(total 9779 patients). Including follow-up > 5.5cm. These studies are depicted in order of increasing aneurysm
baseline size range, but the distribution of diameters within these size ranges and over time is not available.
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Chapter 5 Methods for individual patient data
analysis of existing surveillance data
As revealed by the literature reviews (see Chapters 3 and 4), published data were insufﬁcient for thedetailed modelling of small AAA growth rates and rupture rates necessary to better inform surveillance
intervals. Therefore, IPD were sought for this purpose. This chapter describes the methods used and
Chapter 6 provides the results.
In addition, surveillance intervals should be chosen to control to acceptable limits the risk of a small AAA
reaching 5.5 cm, or of rupture, before the next scan. Such acceptable limits were informed by a focus group
that we organised and which is also described in this chapter.
Data collection
Under the name of the RESCAN Collaboration, requests for IPD were addressed to the corresponding
authors of 25 studies, each including more than 100 patients with small AAAs (3.0–5.5 cm in diameter) in a
surveillance programme. Data sets for potential inclusion had been identiﬁed through a systematic literature
search up to the end of 2009, as described in Chapters 3 and 4, and manual searching of abstracts from
vascular surgical meetings during the interval 2007–10. Additional studies published up to September 2012
are discussed in Chapter 9.
The items requested included patient age, sex, sequential aneurysm diameters, ethnicity, smoking history,
body mass index (BMI), presence of diabetes, dates of aneurysm repair, aneurysm rupture or death. The
method used for US AAA diameter assessment was recorded for each study as internal (inner to inner luminal
surface) or external (outer to outer aortic wall). A few studies used CT scans for some AAA measurements.
Supplementary information for baseline histories of medication use, coronary and peripheral arterial disease
as well as blood pressure was requested, if available. To allow for changing environmental factors (e.g.
smoking), improvements in imaging quality as well as improving cardioprotective drug therapy, we also
included year of patient enrolment as a variable. Additional information regarding AAA rupture (including
death due to rupture), operative AAA repair and non-AAA death was collected for each patient where
this was available. The deﬁnition of aneurysm rupture was pragmatic, based on locally used deﬁnition
and reporting.
The RESCAN collaborators provided data for 18 studies, which were then subject to cleaning through an
iterative process of correspondence with the study investigators to improve data quality, prior to the
harmonisation of the data sets. All data sets were anonymised and, therefore, the study was subject to an
ethical waiver.
For each individual, the baseline measurement was deﬁned as the ﬁrst measurement recorded between
3.0 and 5.4 cm. Measurements taken prior to a patient reaching a threshold of 3.0 cm were removed
from the data sets. All data following baseline measurement were used until either a rupture event or
censoring occurred. Censoring was deﬁned as the ﬁrst occurrence of: (1) a diameter measurement
≥ 5.5 cm (with this measurement included in the data set to properly account for informative dropout);17
(2) non-rupture-related death; (3) an elective AAA operation; or (4) the administrative censoring date of the
data set. A patient's series of measurements was not censored if the aneurysm diameter dropped to
< 3.0 cm, thus allowing some patients to have negative growth rates.
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Focus group
In order to determine the level of risk of rupture or progression to 5.5 cm that would be acceptable to
patients with small AAA, we conducted a patient focus group meeting. Men with small AAAs under
surveillance in the Leicestershire AAA Surveillance Programme were invited to attend a meeting with a
consultant vascular surgeon (MJ Bown) after verbal and written information about the RESCAN project was
provided. A further explanation of the aims of the RESCAN project and its potential outcomes was given to
the patients who attended the meeting prior to discussing the speciﬁc points below. Although the main aim
of this focus group was to determine what risk of rupture and what risk of progression to a size threshold of
5.5 cm was acceptable to patients, a number of other issues relating to the surveillance of small AAA were
discussed and these results are included below. The issues directly discussed were the acceptability of
different intervals between surveillance scans, whether or not surveillance should be personalised, what
factors patients think would improve surveillance, and what risks of rupture/progression were acceptable.
Surveillance intervals
The patients identiﬁed that the opinion of their surgeon was the most important factor that should inﬂuence
the interval between surveillance scans. The patients expressed a wish to have surveillance intervals
personalised depending on previous scan results and that any known factors inﬂuencing AAA growth should
be taken into account when deciding surveillance intervals on an individual basis. The patients stated that
sudden increases in AAA growth should mandate an expedited follow-up scan before their next scheduled
scan and that AAA sizes of > 5 cm should also result in more frequent surveillance. The patients could not
agree on a suitable time interval for such ‘early recall’ scans but felt that their surgeon should decide on the
interval on an individual basis, taking absolute AAA size and rate of growth into account. The group stated
that for the purposes of surveillance programmes (where vascular surgeons may not be directly involved in
the decision-making process), the intervals between scans in the event of rapid growth should be
standardised in a protocol to be followed by the surveillance programme.
Personalised surveillance
The group agreed that there was not enough evidence to base surveillance intervals on factors such as
diabetes and smoking habits (summary data from a RESCAN publication48 were presented to the group). It
was noted that there were no smokers in the group. However, the patients felt that size should not be the
only guiding factor in the timing of scans, and that other factors should also be considered if there proved to
be good evidence for these factors in the future.
Improving surveillance
The focus group participants stated that too much information is given to them in verbal format at the
time of surveillance scans. The group felt that a personal written record would be informative for some,
even though it might not be practically useful to the patient directly. Participants agreed that they wish to
know the AAA measurement at the time of the scan and, also, what the implications of that measurement
are. The group felt that this information could be formulated into a booklet that could include their
personal measurements.
Acceptable risks of reaching 5.5 cm between surveillance scans
In order to determine the acceptable risk of attaining an AAA measurement of 5.5 cm between surveillance
scans, the patients were asked what chance of reaching a threshold size of 5.5 cm was acceptable. There
was a mixed response from the group in response to this. All patients agreed that there was always some risk
of reaching 5.5 cm at the time of his or her next scan. All present agreed that a risk of up to 10% was
acceptable, with some stating that this chance could even be as high as 20%. The patients pointed out that
reaching a size of 5.5 cm was the threshold for referral to a vascular surgeon for consideration of surgery
rather than being a size where surgery had to be performed. The patients stated that if they were not aware
of this then the acceptable risk of reaching 5.5 cm would be likely to be much lower. The group stated that
the general public, uneducated about aneurysmal disease, may say that no risk is acceptable, regardless
of cost.
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Acceptable risks of abdominal aortic aneurysm rupture between
surveillance scans
The risk of AAA rupture before the next surveillance scan was discussed. Some patients felt that some
risk of rupture was unavoidable as they recognised that even small AAAs can rupture. This section of the
group felt that the risk should be < 2–3%. Some members of the group felt that there would be no point in
participating in a surveillance programme unless the risk of rupture could be reduced to < 1%. All present
felt that a surveillance interval that resulted in a 5% risk of rupture by the time of their next scan would
be unacceptable.
Conclusion
This patient focus group indicated that patient experiences of AAA surveillance are generally positive. Patient
satisfaction may be improved through more use of written information or individual patient-held records,
but this would need to be determined in a larger patient group before widespread adoption. All patients
stated that a 10% risk of reaching an AAA size of 5.5 cm between surveillance scans, and a 1% risk of
rupture between scans, were acceptable. These risk thresholds (10% risk of expansion to 5.5 cm and 1%
risk of rupture) were therefore used in the analyses of the IPD data sets, as described below.
Statistical methods
Full details of the statistical methods are provided in Appendix 3. A summary is given here.
Growth rates
Each study was analysed separately. Linear random-effects models were used, since linear and quadratic
models had previously been shown to provide similar predictions over the period required to assess AAA
surveillance intervals.17 This method allows for individual variation in baseline diameters and growth rates,
modelled as correlated random effects from a bivariate normal distribution, and independently normally
distributed within-person variation (measurement error). Where both US and CT scans had been used to
measure AAA diameter within the same study, an additive adjustment to the CT measurements was
estimated within the analysis noting that scanning modality did not affect the estimated rate of growth.48
Growth rates were estimated separately for men and women, through the inclusion of an interaction
term. Results are primarily shown for men alone since this is the usual population of interest for AAA
screening programmes.
Rupture rates
A joint model of AAA rupture and growth was employed.49 The longitudinal AAA diameter measurements
were ﬁtted using a linear random-effects growth model as above, while a proportional hazards model with
constant baseline hazard was used for the time-to-event rupture data. A log-linear effect of underlying
diameter on risk of rupture was assumed. At least two ruptures per study were required to ﬁt these models.
An effect of sex on risk of rupture was included for studies that recruited both sexes.
Meta-analysis of growth and rupture rates
The following quantities were estimated from the growth and rupture models for each study: (1) mean
growth rate given a baseline AAA diameter; (2) time taken to reach a 10% chance (as indicated by the focus
group) of crossing the threshold for surgery (5.5 cm) given a baseline diameter; (3) the risk of rupture given
underlying AAA diameter; and (4) the time taken to reach a 1% chance (as indicated by the focus group) of
rupture given an underlying diameter. These outcomes were calculated for patients with an AAA between
3.0 and 5.4 cm, at 0.1 cm intervals, ignoring the risk of competing mortality from non-AAA causes of death.
The estimates from each study were combined using random-effects meta-analysis,25 and overall means,
95% CIs and 95% prediction intervals for each AAA diameter were calculated. Ninety-ﬁve per cent
prediction intervals give the range of values between which values in a new study, similar to those in the data
set, would be expected to lie.50 Between-study heterogeneity was assessed using the I2 measure,26 which
indicates the percentage of total variation across studies that is due to heterogeneity rather than chance.
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Predictors of growth
Each predictor of growth was considered in a quadratic random-effects model through the inclusion of a
main effect and an interaction term with the linear component of time, thus allowing an assessment of the
effect on the growth rate. Indicator variables were used for binary covariates, whereas other covariates were
considered as continuous variables. To allow studies that recorded both US and CT measurements to be
included, a dummy variable was added to distinguish between the two modalities. The effect of modality on
both the overall size and the growth rate was investigated. Both univariate and multivariate (adjusted)
analyses were considered for each predictor variable. The multivariate model adjusted for baseline age,
calendar year, sex, smoking, diabetes, mean arterial blood pressure/pulse pressure, history of cardiovascular
disease, and additionally any recorded use of angiotensin-converting enzyme (ACE) inhibitors, beta blockers,
calcium channel blockers, statins or lipid-lowering drugs, and antiplatelet agents. The use of these drugs was
generally recorded only at entry into each study. History of cardiovascular disease included angina,
myocardial infarction, cardiac revascularisation, transient ischaemic attack, stroke and peripheral arterial
disease. Studies that did not collect all these covariates were adjusted for as many covariates in the
list as possible. Patients who had missing data on any of their study's covariates were excluded in the
multivariate analyses.
Predictors of rupture
Cox regression models were used to assess the effect of each predictor variable on the risk of rupture in each
study. All analyses were adjusted for AAA diameter, which was entered as a time-varying covariate. Owing to
the small number of ruptures in each study, some covariate effects were not estimable.
Meta-analysis of effects of predictors
The parameter estimates and SEs were extracted from the above analyses for each study. Estimates for each
predictor variable were pooled across all studies that provided an estimate, using random-effects
meta-analysis as above.
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Chapter 6 Results of individual patient data
analysis of existing surveillance data
Study characteristics
Individual patient data were obtained from 18 different studies from Europe, Canada, the USA and Australia,
with patients being admitted to these studies between 1983 and 2008; a summary of these studies is given
in Table 6. A total of 15,475 patients are included, with an average of 4617 AAA measurements and
4.0 years of follow-up per study (Table 7). Not all patient demographics were available from all studies, and
in some studies the data were incomplete for some individuals. Ethnicity was poorly reported. Baseline
drug history was fully available in seven studies (see Table 7). Prevalence of drug use varied considerably
between these studies (ACE inhibitors 9–41%, beta blockers 14–52%, calcium channel blockers 12–28%,
statins/lipid-lowering drugs 0–78%, antiplatelet agents 27–94%). Data were not available from two
randomised controlled trials (RCTs) and ﬁve other studies with a total of 2487 persons (see Appendix 3).
Study-speciﬁc thresholds for surgical intervention varied from 4.5 cm up to 6.0 cm (see Table 6). The majority
of studies measured external (outer-to-outer) wall diameters, although three studies10,37,53 measured
internal diameters. Rupture and censoring events were recorded in 14 out of the 18 studies allowing rupture
rates to be investigated. The remaining four studies were used in the growth analysis only (see Table 6).
Four studies, Leeds (Professor D Julian A Scott, University of Leeds, 2010–12, personal communication),
PIVOTAL,51 Galdakao32 and Stirling (Mr Richard Holdsworth, Stirling Royal Inﬁrmary, 2010–12, personal
communication), measured diameters using both US and CT scans. CT measurements were on average
signiﬁcantly larger than US measurements [Leeds 3.91 mm (SE 0.33mm), PIVOTAL 1.75mm (SE 0.21mm),
Galdakao 1.77mm (SE 0.10mm), Stirling 2.46 mm (SE 0.27 mm)]. However, there was no evidence of an
effect of modality on estimated growth rates (i.e. a CT measurement was found to be larger than an US
measurement throughout follow-up by a constant amount). Therefore, within each study an additive
adjustment could be applied so that all measurements were included in the analysis of growth rates.
Small abdominal aortic aneurysm growth rates in men
The overall pooled estimates of AAA growth in men increased by about 0.5 mm/year for each 0.5-cm
increase in baseline AAA diameter (Figures 8 and 9). The average estimated growth rate in men was
1.3 mm/year (95% CI 1.0 mm/year to 1.5 mm/year) for a 3.0-cm aneurysm and 3.6 mm/year (95% CI
3.3 mm/year to 3.9 mm/year) for a 5.0-cm aneurysm (Table 8). However, there was also substantial
heterogeneity in growth rates between studies, so the 95% prediction intervals were wide. Much of this
heterogeneity is unexplained. Although smokers and non-diabetics have higher rates of growth (see
Predictors of abdominal aortic aneurysm growth rates), these factors did not explain the heterogeneity
between studies: adjusting for baseline AAA diameter, smoking and diabetes only reduced the overall
percentage of variation due to heterogeneity from 97.5% to 94.1%. Excluding the three studies
(Chichester,53 Gloucestershire37 and MASS10) that measured internal diameters, the pooled mean growth
rates decreased by between 0.10 mm/year and 0.13mm/year, depending on baseline diameter, but the
percentage of variation due to heterogeneity only decreased by between 1.5% and 3.3%.
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(e)
FIGURE 8 Forest plots of mean AAA growth rate (estimate and 95% CI) in men according to baseline AAA diameter.
(a) Mr Simon Parvin, Royal Bournemouth Hospital, 2010–12, personal communication; (b) Professor D Julian A Scott,
University of Leeds, 2010–12, personal communication; (c) Mr Matthew J Bown, University of Leicester and the NIHR
Cardiovascular Biomedical Research Unit, 2010–12, personal communication; (d) Professor Charles N McCollum,
University Hospital of South Manchester, 2010–12, personal communication; and (e) Mr Richard Holdsworth, Stirling
Royal Infirmary, 2010–12, personal communication. UKSAT, United Kingdom Small Aneurysm Trial.
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FIGURE 9 Estimated mean growth rate given baseline AAA diameter, in men, by study and overall (with 95% CIs and
prediction intervals). The area of each symbol is inversely proportional to its SE. (a) Mr Simon Parvin, Royal Bournemouth
Hospital, 2010–12, personal communication; (b) Professor D Julian A Scott, University of Leeds, 2010–12, personal
communication; (c) Mr Matthew J Bown, University of Leicester and the NIHR Cardiovascular Biomedical Research Unit,
2010–12, personal communication; (d) Professor Charles N McCollum, University Hospital of South Manchester, 2010–12,
personal communication; and (e) Mr Richard Holdsworth, Stirling Royal Infirmary, 2010–12, personal communication.
UKSAT, United Kingdom Small Aneurysm Trial.
TABLE 8 Pooled (meta-analysis) estimates of AAA growth and rupture for men and women separately, with 95% CIs
(round brackets) and 95% prediction intervals [square brackets]
Meta-analysis
estimate of: Sex
AAA diameter (cm)
3.0 3.5 4.0 4.5 5.0
Growth rate (mm/year) Men 1.28
(1.03 to 1.53)
[0.17 to 2.40]
1.86
(1.64 to 2.08)
[0.85 to 2.88]
2.44
(2.22 to 2.65)
[1.47 to 3.41]
3.02
(2.79 to 3.25)
[2.00 to 4.04]
3.61
(3.34 to 3.88)
[2.45 to 4.77]
Women 1.46
(1.07 to 1.85)
[0.03 to 2.89]
1.98
(1.65 to 2.32)
[0.75 to 3.22]
2.51
(2.22 to 2.81)
[1.47 to 3.56]
3.06
(2.80 to 3.33)
[2.18 to 3.95]
3.62
(3.36 to 3.89)
[2.79 to 4.45]
Time taken to reach a
10% chance that the
threshold for surgery
has been crossed (years)
Men 7.4
(6.7 to 8.1)
[4.9 to 11.3]
5.0
(4.6 to 5.4)
[3.4 to 7.1]
3.2
(3.0 to 3.4)
[2.3 to 4.4]
1.8
(1.7 to 2.0)
[1.3 to 2.5]
0.7
(0.6 to 0.8)
[0.4 to 1.2]
Women 6.9
(6.1 to 7.8)
[4.5 to 10.6]
4.8
(4.3 to 5.3)
[3.3 to 6.8]
3.1
(2.9 to 3.4)
[2.3 to 4.3]
1.8
(1.7 to 2.0)
[1.3 to 2.5]
0.7
(0.6 to 0.8)
[0.4 to 1.3]
Rate of rupture
(per 1000
person-years)
Men 0.5
(0.3 to 0.7)
[0.3 to 0.7]
0.9
(0.6 to 1.3)
[0.5 to 1.5]
1.7
(1.1 to 2.4)
[0.6 to 4.3]
3.2
(2.2 to 4.6)
[1.0 to 10.0]
6.4
(4.3 to 9.5)
[1.7 to 23.5]
Women 2.2
(1.3 to 4.0)
[0.9 to 5.7]
4.5
(2.8 to 7.2)
[2.1 to 9.7]
7.9
(4.5 to 13.9)
[1.7 to 36.1]
14.7
(8.1 to 27.7)
[2.3 to 95.1]
29.7
(15.9 to 55.4)
[3.9 to 222.9]
Time taken to reach
a 1% chance of
rupture (years)
Men 8.5
(7.0 to 10.5)
[5.1 to 14.2]
5.5
(4.4 to 6.8)
[2.8 to 10.7]
3.5
(2.8 to 4.3)
[1.8 to 6.9]
2.2
(1.8 to 2.8)
[1.1 to 4.4]
1.4
(1.2 to 1.8)
[0.7 to 2.8]
Women 3.5
(1.9 to 6.4)
[0.8 to 14.6]
2.1
(1.2 to 3.6)
[0.4 to 11.1]
1.4
(0.9 to 2.1)
[0.3 to 5.8]
0.9
(0.6 to 1.4)
[0.2 to 3.5]
0.7
(0.5 to 1.1)
[0.2 to 3.3]
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The length of time taken for men under surveillance to have a 10% chance of reaching the threshold
size of 5.5 cm decreased substantially with baseline AAA diameter (Figure 10). For men with a
3.0-cm aneurysm, the estimated mean time taken to have a 10% chance of reaching 5.5 cm was
7.4 years (95% CI 6.7 years to 8.1 years). The corresponding mean times for 4.0-cm and 5.0-cm aneurysms
were 3.2 years (95% CI 3.0 years to 3.4 years) and 0.7 years (95% CI 0.6 years to 0.8 years), respectively
(see Table 8). Again, the prediction intervals were substantially wider than the CIs because of the
heterogeneity between studies.
Small abdominal aortic aneurysm rupture rates in men
Overall the number of ruptures was small, with 178 reported events among 11,262 men under
surveillance and 50 among 1314 women. Crude rupture rates in men in each study varied between
0 and 0.77 ruptures per 100 person-years (see Table 6). There were 12 studies with at least two
ruptures available to assess the relationship between rupture rates and AAA diameter in men, and
ﬁve studies in women (see Table 6). Rupture rates in men increased with baseline AAA diameter,
approximately doubling for every 0.5-cm increase (Figures 11 and 12). The average rupture rates
were 0.05 per 100 person-years (95% CI 0.03 to 0.07 per 100 person-years) for a 3.0-cm AAA and
0.64 (95% CI 0.43 to 0.95 per 100 person-years) for a 5.0-cm AAA. The degree of heterogeneity between
studies also increased with baseline AAA diameter; I2 ranged from 0% to 82% for diameters 3.0–5.4 cm.
It was not possible to investigate the cause of this heterogeneity, due primarily to the small number of
ruptures observed in each study making multivariate modelling infeasible. The time taken for men under
surveillance to reach a rupture risk of 1% decreased with baseline AAA diameter (Figure 13). For AAA
diameters in the range 3.0–4.5 cm the average time to reach a rupture risk of 1% was more than 2 years
(see Table 8). For a 5.0-cm AAA, a 1% risk of rupture was reached on average in 1.4 years (95% CI 1.2 years
to 1.8 years).
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FIGURE 10 Estimated time given baseline AAA diameter for which there is a 10% chance that the threshold diameter
for surgery (5.5cm) has been reached, in men, by study and overall (black diamonds represent 95% CIs, error bars are
95% prediction intervals). (a) Mr Simon Parvin, Royal Bournemouth Hospital, 2010–12, personal communication;
(b) Professor D Julian A Scott, University of Leeds, 2010–12, personal communication; (c) Mr Matthew J Bown,
University of Leicester and the NIHR Cardiovascular Biomedical Research Unit, 2010–12, personal communication;
(d) Professor Charles N McCollum, University Hospital of South Manchester, 2010–12, personal communication; and
(e) Mr Richard Holdsworth, Stirling Royal Infirmary, 2010–12, personal communication. UKSAT, United Kingdom
Small Aneurysm Trial.
DOI: 10.3310/hta17410 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 41
39
© Queen's Printer and Controller of HMSO 2013. This work was produced by Thompson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed
to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park,
Southampton SO16 7NS, UK.
Small abdominal aortic aneurysm growth and rupture rates
in women
The dependence of growth and rupture rates on AAA diameter was very similar in women and men
(Figures 14 and 15 compared with Figures 8 and 11). Heterogeneity between studies was slightly less for
women. Although absolute growth rates were similar for women and men (particularly for larger baseline
AAA diameters), there were marked differences in the absolute risks of rupture. Women had about a
fourfold greater rupture risk for all AAA sizes (see Predictors of abdominal aortic aneurysm growth rates), and
reached a rupture risk of > 1% in a much shorter time than men (see Table 8).
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FIGURE 11 Forest plots of rupture risk (estimate and 95% CI, log-scale) in men according to underlying AAA
diameter. (a) Professor Charles N McCollum, University Hospital of South Manchester, 2010–12, personal
communication; and (b) Mr Richard Holdsworth, Stirling Royal Infirmary, 2010–12, personal communication.
UKSAT, United Kingdom Small Aneurysm Trial. (continued)
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FIGURE 11 Forest plots of rupture risk (estimate and 95% CI, log-scale) in men according to underlying AAA
diameter. (a) Professor Charles N McCollum, University Hospital of South Manchester, 2010–12, personal
communication; and (b) Mr Richard Holdsworth, Stirling Royal Infirmary, 2010–12, personal communication.
UKSAT, United Kingdom Small Aneurysm Trial.
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FIGURE 12 Rupture risk according to underlying AAA diameter, in men, by study and overall (log-scale, with 95% CIs
and prediction intervals). The area of each symbol is inversely proportional to its SE. (a) Professor Charles N McCollum,
University Hospital of South Manchester, 2010–12, personal communication; and (b) Mr Richard Holdsworth,
Stirling Royal Infirmary, 2010–12, personal communication. UKSAT, United Kingdom Small Aneurysm Trial.
Study
Western Australia52
Chichester53
Gloucestershire37
Huntingdon34
Manchestera
MASS10
Tromsø38
Propranolol40
Galdakao32
Stirlingb
UKSAT13
Viborg55
20
19
18
16
17
14
15
13
12
11
10
8
9
6
7
5
3
4
2
1
3.0 3.5 4.0 4.5 5.0
Baseline diameter (cm)
Ti
m
e 
(y
ea
rs
)
FIGURE 13 Estimated time given underlying AAA diameter for which there is a 1% chance of rupture, in men,
by study and overall (black diamonds represent 95% CIs, error bars are 95% prediction intervals). (a) Professor
Charles N McCollum, University Hospital of South Manchester, 2010–12, personal communication; and (b) Mr Richard
Holdsworth, Stirling Royal Infirmary, 2010–12, personal communication. UKSAT, United Kingdom Small
Aneurysm Trial.
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(c)
FIGURE 14 Forest plots of mean AAA growth rate (estimate and 95% CIs) in women according to baseline
AAA diameter. (a) Professor D Julian A Scott, University of Leeds, 2010–12, personal communication; (b) Professor
Charles N McCollum, University Hospital of South Manchester, 2010–12, personal communication; and (c) Mr Richard
Holdsworth, Stirling Royal Infirmary, 2010–12, personal communication. UKSAT, United Kingdom Small
Aneurysm Trial. (continued)
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Predictors of small abdominal aortic aneurysm growth rates
Unadjusted analysis of each demographic variable on aneurysm growth revealed signiﬁcant effects among a
number of individual study estimates. However, there was considerable heterogeneity between study
estimates for many of the demographics considered (as measured using I2). When estimates were pooled
using random-effects meta-analysis (with adjustment for initial aneurysm diameter), current smoking was
signiﬁcantly associated with faster aneurysm growth rates, whereas increased BMI, diabetes, increased pulse
pressure, and history of cardiovascular disease were associated with slower growth rates (Table 9). After
adjustment for all demographics, medical history and drug history, only current smoking and diabetes
remained signiﬁcant predictors of aneurysm growth (see Table 9). The growth rate in current smokers
was on average 0.35mm/year (SE 0.07 mm/year; p < 0.001) faster than in ex or never smokers, whereas
diabetics had growth rates that were on average 0.51 mm/year (SE 0.10 mm/year; p < 0.001) slower than
non-diabetics. This evidence is consistent across the studies as demonstrated in Figure 16. Men and women
had similar growth rates.
Associations between baseline use of cardiovascular drugs and aneurysm growth rate are shown in Table 10.
Univariate analyses suggest that many of the drugs could be protective against aneurysm growth, with
the largest effect coming from the use of statins/lipid-lowering drugs. However, the magnitude of these
effects was relatively small and could be confounded with their prescription in speciﬁc risk populations.
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(e)
FIGURE 14 Forest plots of mean AAA growth rate (estimate and 95% CIs) in women according to baseline
AAA diameter. (a) Professor D Julian A Scott, University of Leeds, 2010–12, personal communication; (b) Professor
Charles N McCollum, University Hospital of South Manchester, 2010–12, personal communication; and (c) Mr Richard
Holdsworth, Stirling Royal Infirmary, 2010–12, personal communication. UKSAT, United Kingdom Small
Aneurysm Trial.
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FIGURE 15 Forest plots of rupture risk (estimate and 95% CIs, log-scale) in women according to underlying
AAA diameter. (a) Professor Charles N McCollum, University Hospital of South Manchester, 2010–12, personal
communication; and (b) Mr Richard Holdsworth, Stirling Royal Infirmary, 2010–12, personal communication.
UKSAT, United Kingdom Small Aneurysm Trial. (continued)
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Indeed, after adjustment for other demographics, the pooled meta-analysis estimates were no longer
statistically signiﬁcant for any class of drug investigated (see Table 10). Although the use of many of these
drugs increased over time, calendar year of enrolment did not appear to inﬂuence aneurysm growth rate.
Predictors of small abdominal aortic aneurysm rupture rates
The differences in the crude rupture rates between the studies were large (from 0.07 up to 1.1 per
100 person-years). However, some of these differences could be explained by different baseline diameter
ranges, different lengths of follow-up after last diameter measurement and proportions of women in each
study. After adjustment for aneurysm diameter, the inﬂuence of demographics and medical history on
rupture rates revealed a strong association between smoking and rupture [pooled hazard ratio (HR) 2.02,
95% CI 1.33 to 3.06; p = 0.001], and a far higher risk of rupture for women than men (pooled HR 3.76, 95%
CI 2.58 to 5.47; p < 0.001) (Figure 17). The risk of rupture was also found to increase signiﬁcantly for older
patients, patients enrolled earlier in calendar time, those with lower BMI, and with higher mean arterial blood
pressure or pulse pressure (Table 11). It was not possible to conduct fully adjusted analyses of these effects
because of the small number of ruptures observed. However, effects did remain consistent after adjustment
for age and calendar time.
Any association between cardiovascular drugs and aneurysm rupture was difﬁcult to investigate with the
present data because of the low prevalence of rupture and insufﬁcient reporting of the drugs. Only six
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FIGURE 15 Forest plots of rupture risk (estimate and 95% CIs, log-scale) in women according to underlying
AAA diameter. (a) Professor Charles N McCollum, University Hospital of South Manchester, 2010–12, personal
communication; and (b) Mr Richard Holdsworth, Stirling Royal Infirmary, 2010–12, personal communication.
UKSAT, United Kingdom Small Aneurysm Trial.
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TABLE 9 Meta-analysis of the inﬂuence of patient characteristics on small aneurysm growth rates
Characteristic
Number
of
studies
Unadjusted analyses Adjusted analyses
Total
number
of
patients
Estimate
(SE)
mm/year p-value I2 (%)
Total
number
of
patients
Estimate
(SE)
mm/year p-value I2 (%)
Age at baseline
(per year)
18 15,482 −0.004
(0.007)
0.559 76 13,966 −0.001
(0.006)
0.820 66
Calendar year at
baseline (per year)
17 14,432 0.001
(0.021)
0.965 86 12,914 0.012
(0.022)
0.590 85
Sex (female vs.
male)
11 9262 0.156
(0.144)
0.278 78 8472 0.142
(0.150)
0.344 78
Smoking (current
vs. ex/never)
12 8196 0.375
(0.081)
< 0.001 57 7486 0.354
(0.065)
< 0.001 24
BMI (per kg/m2) 5 3756 −0.017
(0.008)
0.039 0 3439 −0.008
(0.009)
0.348 0
Diabetes 10 6268 −0.596
(0.092)
< 0.001 0 5697 −0.505
(0.097)
< 0.001 0
Mean arterial
blood pressure
(per 10mmHg)
8 6723 0.003
(0.024)
0.886 74 5957 0.013
(0.021)
0.531 62
Pulse pressure
(per 10mmHg)
8 6723 −0.040
(0.018)
0.024 67 5957 −0.027
(0.014)
0.060 46
History of
cardiovascular
disease
10 6638 −0.177
(0.075)
0.017 38 6302 −0.105
(0.088)
0.230 46
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FIGURE 16 Effect of (a) smoking status (current vs. ex/never) and (b) diabetes on aneurysm growth rates (mm/year) in
individual studies and meta-analysis: adjusted estimates with 95% CI. (a) Professor D Julian A Scott, University of
Leeds, 2010–12, personal communication; and (b) Mr Matthew J Bown, University of Leicester and the NIHR
Cardiovascular Biomedical Research Unit, 2010–12, personal communication. UKSAT, United Kingdom Small
Aneurysm Trial.
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studies13,39,40,51,52,55 reported both rupture events and use of drugs. Of these, only two estimates, on average,
could be obtained for each class of drug, none of which showed statistical signiﬁcance (Table 12).
Inputs to health economic modelling
These IPD from 18 surveillance studies (see Table 6) were next used to provide inputs relating to growth and
rupture rates for the health economic modelling, as described in Chapters 7 and 8.
TABLE 10 Meta-analysis of the inﬂuence of cardiovascular drugs on small aneurysm growth rates
Drug
Number
of
studies
Unadjusted analyses Adjusted analyses
Total
number
of
patients
Estimate
(SE)
mm/year p-value I2 (%)
Total
number
of
patients
Estimate
(SE)
mm/year p-value I2 (%)
ACE inhibitors 7 4826 −0.125
(0.143)
0.379 61 4269 0.002
(0.128)
0.986 42
Beta blockers 7 4824 −0.189
(0.076)
0.013 0 4269 −0.111
(0.083)
0.183 0
Calcium channel
blockers
6 4124 −0.199
(0.082)
0.015 0 3723 −0.081
(0.088)
0.358 0
Statins/lipid-
lowering drugs
6 4621 −0.341
(0.133)
0.010 47 4118 −0.205
(0.132)
0.121 32
Antiplatelets 6 4137 −0.187
(0.101)
0.065 32 3723 −0.125
(0.106)
0.241 19
Any antihypertensive 7 4826 −0.189
(0.064)
0.003 0 4271 −0.108
(0.075)
0.149 0
0.5 1.0 2.0
Hazard ratio
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Chichester53
Manchestera
Tromsø38
Galdakao32
UKSAT13
Stirlingb
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FIGURE 17 Effect of (a) sex (female vs. male) and (b) smoking (current vs. ex/never) on aneurysm rupture rates in
individual studies and meta-analysis: HRs (95% CI) adjusted for aneurysm diameter. (a) Professor Charles N McCollum,
University Hospital of South Manchester, 2010–12, personal communication; and (b) Mr Richard Holdsworth, Stirling
Royal Infirmary, 2010–12, personal communication. UKSAT, United Kingdom Small Aneurysm Trial.
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TABLE 11 Meta-analysis of the inﬂuence of patient characteristics on small aneurysm rupture rates: HR (95% Cl)
adjusting for current aneurysm diameter
Characteristic Number of studies
Number of
AAA ruptures HR (95% CI) p-value I2 (%)
Age at baseline (per year) 14 228 1.04 (1.01 to 1.07) 0.004 0
Calendar year at baseline (per year) 13 226 0.96 (0.92 to 1.00) 0.033 0
Sex (female vs. male) 6 141 3.76 (2.58 to 5.47) < 0.001 0
Smoking (current vs. ex/never) 4 103 2.02 (1.33 to 3.06) 0.001 0
BMI (per kg/m2) 5 80 0.93 (0.88 to 0.99) 0.029 0
Diabetes 2 66 1.27 (0.45 to 3.54) 0.653 0
Mean arterial blood pressure
(per 10mmHg)
7 157 1.32 (1.11 to 1.56) 0.001 31
Pulse pressure (per 10mmHg) 7 157 1.11 (1.02 to 1.22) 0.019 0
History of cardiovascular disease 3 73 1.32 (0.77 to 2.27) 0.319 0
TABLE 12 Inﬂuence of cardiovascular drugs on small aneurysm rupture rates in individual studies: HRs (95% CI)
adjusting for current aneurysm diameter
Study
ACE
inhibitors
Beta
blockers
Calcium
channel
blockers
Statins/lipid-
lowering
drugs Antiplatelets
Any
antihypertensive
Western
Australia52
1.25
(0.13 to 12.14)
a 1.94
(0.20 to 18.96)
0.66
(0.07 to 6.31)
a 0.42
(0.04 to 4.12)
PIVOTAL,
USA51
a a a a a
Propranolol,
Canada40
a 1.99
(0.18 to 22.12)
6.03
(0.54 to 67.16)
2.33
(0.20 to 26.52)
0.77
(0.07 to 8.54)
Gävle,
Sweden39
a a a a a a
UKSAT,
UK13
1.17
(0.50 to 2.72)
1.28
(0.66 to 2.46)
1.42
(0.82 to 2.49)
a 0.83
(0.46 to 1.52)
1.08
(0.64 to 1.82)
Viborg,
Denmark55
a a a a a
Blank cells indicate data not available.
a Not estimable because of low number of ruptures.
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Chapter 7 Methods for cost-effectiveness analysis
of alternative surveillance policies
In this chapter we describe the methods and preparatory work involved in assessing the cost-effectivenessof different surveillance policies. This includes how the information on small AAA growth rates and
rupture rates from the IPD meta-analyses (see Chapters 5 and 6) is used to provide inputs for this health
economic modelling. The results of the cost-effectiveness analyses are given in Chapter 8.
Introduction
Previous studies have estimated the cost-effectiveness of the screening strategy that was evaluated in the
MASS trial. Estimates of the cost-effectiveness of this strategy have been adjusted over time, principally to
reﬂect the emerging long-term data from the trial. The original cost-effectiveness estimates were based
simply on 4 years of follow-up and estimated a mean cost per life-year gained within that truncated period of
£28,400 (95% CI £15,000 to £146,000)56 at 2000–1 prices. Using the observed data at 10 years of
follow-up, the estimate had fallen to £7600 (95% CI £5100 to £13,000) despite revaluing costs to 2008–9
prices.4 Based on informal modelling, the original cost-effectiveness paper had suggested that the
cost-effectiveness over 10 years would indeed be around £8000 per life-year saved.56
However, it is clearly recognised that an investment in a screening programme needs to be assessed over a
longer period that does not cut short the beneﬁts from avoided aneurysm-related mortality and will
require a formal model. Such a model, taking a 30-year perspective but initially based on the 4-year MASS
results, was developed and this estimated the cost per life-year gained over a 30-year period as £2320
(with a 95% uncertainty interval of £1600 to £4240).8 As the period of follow-up of the MASS trial
has extended, the uncertainty associated with the longer-term effects of screening has been reduced, and
scope now exists to compare the model results at 10 years and as necessary to recalibrate the model to
more accurately reﬂect the longer-term observed data.
All these estimates have assumed a screening programme in elderly men with a surveillance pattern of: no
recall for patients with an aortic diameter of < 3.0 cm; yearly rescanning of patients with an aortic diameter
of 3.0–4.4 cm; 3-monthly rescans for patients with an aortic diameter of 4.5–5.4 cm; and consideration for
surgery if an aortic diameter of ≥ 5.5 cm. This surveillance strategy adopted in MASS was based on the data
available and expert clinical opinion at the time of the planning of the trial in 1995–6. The same pattern was
subsequently adopted by the NAAASP. The analysis of growth and rupture rates in this RESCAN project
provides an evidence base and opportunity to investigate whether or not a different surveillance strategy
might be better than that used in MASS and subsequently by NAAASP.
Other economic models of AAA screening have of course been published. A systematic review of the models
to 2006 emphasised the variability in their estimates of cost-effectiveness.57 Since that review, a number of
further modelling studies have been published drawing on data from a variety of sources: for example studies
relating to Italy,15 to the Netherlands and Norway,58 to Canada59,60 and to Denmark.61 These have all
concluded that screening is acceptably cost-effective, with the exception of a study using data from Denmark
and other sources, which concluded that screening did not seem to be cost-effective.62 A recent modelling
study, again using Danish data, contradicts that previous conclusion, suggesting that screening men at
age 65 years is highly cost-effective compared with no screening and, additionally, that rescreening after
5 years may be a cost-effective extension to the programme.63 However, no models of cost-effectiveness of
AAA screening have been published that have speciﬁc relevance to NAAASP, other than those already
cited relating to and derived from the MASS study, which is the largest randomised trial of AAA screening
and contributes most to the international evidence.7
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The focus of the cost-effectiveness element of the current study is to analyse the implications of the
RESCAN analyses, relating to the international evidence on growth rates and rupture rates, for the most
cost-effective surveillance strategy following AAA screening. Cost-effectiveness is of course a function not
only of these clinical parameters but also the behavioural, resource-use, and cost data relevant to a
particular screening programme. Hence, we have chosen to use such country-speciﬁc data relevant to the
current UK programme.
The work speciﬁcally undertaken on the model for this study consisted of the following elements:
1. Validation and recalibration of the previously published model8 to best reﬂect the accumulated 10-year
follow-up data from MASS, including incorporation of time-dependent parameter values.
2. Adaption of the model structure to fully incorporate unobserved ‘tunnel’ states to reﬂect the growth and
rupture probabilities for all aneurysms, whether or not reobserved and remeasured at a recall scan.
3. Re-estimation of current unit costs for screening interventions and elective and emergency surgery.
4. Incorporation of data from NAAASP, including attendance rates, prevalence of identiﬁed aneurysms, and
distribution of aneurysm sizes at initial screening.
5. Incorporation of size-speciﬁc growth and rupture rates from the analysis of the IPD surveillance data sets
reported in Chapters 5 and 6.
Each of these aspects of our development of the model is to enable us to address the issue of the
cost-effectiveness of alternative surveillance strategies, in the context of the NAAASP, and each aspect is
addressed in turn in this chapter.
The initial model
The starting point for the economic analysis in this project was the economic model that had previously been
developed by members of the research team, to estimate the long-term cost-effectiveness of a screening
programme using the MASS trial screening and surveillance protocol. Details of this model have
previously been published.8 In summary, it used a Markov model, with 3-monthly cycles, to compare the
introduction of a formal screening programme of an invitation for a one-off US scan for men aged 65 years,
and the MASS surveillance strategy described above if an aneurysm is identiﬁed, with the policy of no
systematic screening. The original model is represented in Figure 18.
The model used a 30-year time horizon (so approximating lifetime results). The methods were consistent with
those recommended for the National Institute for Health and Care Excellence (NICE)'s Technology Appraisal
Programme.64 The cost perspective was that of the NHS and the model estimated life-years gained and
adjusted these for age-speciﬁc utility values relating to the UK population to provide ICERs in terms of QALYs.
For this model, parameter values were estimated from patient-level data from the 4-year analysis of the
MASS study and the model structure was internally validated by comparing its results against observed event
and cost-effectiveness data over the 4-year time period. In addition, it was externally validated against key
outcomes from the Cochrane review of AAA screening and surveillance.7
Validation and recalibration of the previously published model
to better reﬂect the 10-year follow-up data from the
Multi-centre Aneurysm Screening Study
The ﬁrst step in the current study was to revalidate the model comparing the 10-year model outcomes
against the 10-year observed data from the follow-up of MASS, and, where necessary, to adjust or
‘recalibrate’ the model parameters to better reﬂect that observed data. We used the 8.9–11.2 years of
observed follow-up (mean 10.1 years) to better estimate the values for the parameterisation of the economic
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model. Outputs of the model were compared against those observed in the trial, by considering the numbers
of key observed events and cost-effectiveness results at the end of this follow-up period.
Given the staggered recruitment of participants into the trial and the range of follow-up periods for
individual patients, for the purpose of comparing numbers of key events the model replicated censoring
patterns by removing equal proportions as observed in the trial of numbers in each state for every 3-month
cycle, so that the total person-years of follow-up were comparable. The model was then run over 11.25 years
to provide comparability. To produce estimates of costs and life-years at 10 years comparable with those
observed in MASS, the model was run for 10 years with costs based on 2008–9 prices and survival based on
all-cause mortality. Given the characteristics of the MASS trial population, it might be expected that mortality
Non-AAA
death
Incidental
detection
Dropout from
follow-up
No AAA
Screen invite 
No screen invite 
Contra-
indicated Consultation
Rupture
Elective operation
AAA
death
Survived
surgery
DetectedUndetected
Small
AAA
Medium
AAA
Large
AAA
Small
AAA
Medium
AAA
Large
AAA
Emergency
operation
Elective
operation
pending
FIGURE 18 Original health economic model structure. Reproduced with permission from figure 1 of Kim LG,
Thompson SG, Briggs AH, Buxton MJ, Campbell HE. How cost-effective is screening for abdominal aortic aneurysms?
J Med Screen 2007;14:46–52. http://dx.doi.org/10.1258/096914107780154477.8
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rates would not be comparable with the national statistics, and so for the internal validation exercise
MASS-speciﬁc mortality data were used to estimate the probability of mortality in each 3-month cycle, rather
than using national mortality statistics that were incorporated into the model to give it greater external
validity or generalisability.
Initially the model did not appear to perform particularly well against observed data in terms of key events or
cost-effectiveness results over the longer follow-up period. As the length of follow-up had increased, trends
may have emerged in key parameter values and differences between modelling and observed outputs could
be partly attributed to the use of time-constant parameters. Time-dependent transition probabilities were
therefore estimated using ‘logistic’ and ‘Poisson’ regressions, to improve the ﬁt of the model. The differences
between the observed and modelled data may also have been in part due to parameters used to inform
the modelling that could not be observed in MASS. In particular, two parameters, the probability of
opportunistic detection among those not in active screening and the rupture rate of undetected large
aneurysms, were seen as potentially unreliable. The ﬁrst had been based on calculations utilising data from
the control arm of the trial, to give a crude estimate of the detection rate. The latter had been estimated to ﬁt
the 4-year data, assuming it lay between the rupture rate in detected large aneurysms and the rupture
rate among aneurysms contraindicated for elective surgery. A recalibration exercise was conducted using a
range of ﬁgures for both these parameters, to obtain model results that gave more similar numbers of key
events (i.e. elective operations, emergency operations and AAA deaths) to those observed in MASS.
It was not easy to achieve complete consistency between the observed and modelled clinical outcomes.
Given that the long-term ICER was the primary outcome for the cost-effectiveness modelling, the
recalibration focused on eliminating disparities in the modelled and observed differences between the arms.
Table 13 shows key event rates as observed in MASS, as estimated by the original model and as estimated by
the model following recalibration. The pattern of events over time from the observed data, the initial model
estimates and the recalibrated estimates are shown in Figure 19a–h.
This recalibration process achieved similarity between the modelled and observed differences in key events
between the arms, as well as in the resultant ICERs (Table 14). The ICER was £7600 per life-year based on
observed 10-year data: the original model estimated an ICER at 10 years of £18,000, the recalibrated model
estimated the ICER at £8900, closer to that from the observed data. This suggested that, though imperfect,
the model would be suitable for extrapolation of cost-effectiveness results over the long term.
Adapting the model structure to fully incorporate unobserved
‘tunnel’ states
The previously constructed Markov model8 needed adaption to account more explicitly for the incidence of
rescans. The original model, with 3-monthly cycles, was built with a view to considering one surveillance
policy (that pertaining to the MASS data of yearly recall for AAAs measuring 3.0–4.4 cm and 3-monthly recall
for medium AAAs measuring 4.5–5.4 cm). The model averaged out the surveillance for the smaller
aneurysms, effectively assuming that surveillance scans were being conducted every cycle but assigning only
one-quarter of the rescan costs to each cycle. This meant that individuals were able to transition to larger
aneurysmal states in each 3-month cycle and on reaching the large state they could be considered for
elective surgery or returned to screening. However, in reality, those in a small AAA state (3.0–4.4 cm) are not
rescanned every cycle and cannot move into the surveillance pattern for a larger aneurysm until the increased
size of their aneurysm has been identiﬁed through a scan. In the original model, costs associated with
rescanning were averaged across the cycles, 0.25 of a rescan cost per cycle for the small aneurysmal state
and assigned as one per cycle for the medium-sized AAA. Although this approximation was adequate when
considering the one surveillance strategy, the model needed to be adapted for the purposes of answering
questions around different surveillance policies.
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This adaption was achieved through the inclusion of ‘tunnel’ states for aneurysm growth, accounting for
patients in whom aneurysm growth occurred but was not observed or acted on. The structure of the
extended model is represented diagrammatically in Figure 20. These tunnel states allow aneurysms to grow
in between scans, where the individual is subject to the relevant rupture rate. An individual can stay in the
tunnel state that they have entered in subsequent cycles, or transition to larger AAA tunnel states. Only
when a scheduled surveillance scan occurs are individuals then able to be move out of these unobserved
tunnel states into observed states. On this they can then be subject to more frequent scanning, or events that
occur as a result of entering the large AAA state (i.e. consideration for elective surgery). This provides a more
accurate representation of reality and most importantly can allow for the effects of differing policies by
adjusting the number of cycles that individuals spend in these states before a rescan and a return to observed
states. Aneurysms that are detected opportunistically are assumed to enter an observed state before moving
into tunnel states. However, given that this opportunistic detection can occur in every cycle, an
approximation in the cycles immediately following opportunistic detection is used to bring these individuals
into the same rescanning schedule as the rest of the detected aneurysm cohort. This retains programming
efﬁciency and has the effect that some opportunistically detected patients will be assumed to receive their
ﬁrst 1-year scans after a shorter period than a full year.
TABLE 13 Comparison of key events observed in MASS
and economic model
10-year cumulative key events
Observed
in MASSa
Original
modelb
Model after
recalibrationc
Control group
Elective
operations
226 256 213
Emergency
operations
141 140 168
AAA deaths 296 305 385
Non-AAA deaths 10,185 10,139 10,148
Invited group
Elective
operations
552 607 539
Emergency
operations
62 88 97
AAA deaths 155 202 248
Non-AAA deaths 10,119 10,185 10,189
Difference between invited and control groups
Elective
operations
326 351 326
Emergency
operations
–79 –52 –71
AAA deaths –141 –103 –137
Non-AAA deaths –66 46 41
a Key events observed in MASS at 10-year follow-up.
b Economic model using time-constant parameter
estimates from MASS 10-year follow-up.
c Economic model, with time-dependent parameter estimates
from MASS 10-year follow-up and post-calibration exercise.
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FIGURE 19a Number of elective operations in control group over 10 years' (mean) follow-up.
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FIGURE 19b Number of emergency operations in control group over 10 years' (mean) follow-up.
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FIGURE 19c Number of AAA-related deaths in control group over 10 years' (mean) follow-up.
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FIGURE 19d Number of non-AAA deaths in control group over 10 years' (mean) follow-up.
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FIGURE 19e Number of elective operations in invited group over 10 years' (mean) follow-up.
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FIGURE 19f Number of emergency operations in invited group over 10 years' (mean) follow-up.
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It may be useful to consider the current screening policy of 1 year and 3 months for small and medium AAAs,
respectively, as an example of the way the new structure works. An individual invited to and having
attended screening, with a small aneurysm observed at baseline, would be invited to return for another scan
in 1 year, equivalent to four cycles in the model. Assuming the AAA had not grown, nor ruptured and the
individual had not dropped out of surveillance or died, they would move into the small (unobserved)
tunnel state in cycle 2. If no transition had occurred in cycles 3 and 4, the individual would then move out of
the small unobserved ‘tunnel’ state back into the small observed state where a rescan takes place.
They would then move into tunnel states again following this scan. Alternatively, the aneurysm could have
grown and the patient transitions into the tunnel state for medium aneurysms in cycle 2 and possibly
into the tunnel state for large aneurysms in cycle 3. The tunnel states mean that this individual will not
be treated as having a large aneurysm as regards the surveillance policy until this growth has been observed
at the next scan in cycle 4.
0.
00
0
50
150
100
200
300
250
0.
50
1.
50
1.
00
2.
50
2.
00
3.
50
3.
00
4.
50
4.
00
5.
50
5.
00
6.
50
6.
00
Follow-up (years)
C
u
m
u
la
ti
ve
 n
u
m
b
er
7.
50
7.
00
8.
50
8.
00
9.
50
9.
00
10
.5
0
10
.0
0
11
.0
0
(g)
Observed in MASS
Estimated by model
Estimated by model
after calibration
FIGURE 19g Number of AAA-related deaths in invited group over 10 years' (mean) follow-up.
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FIGURE 19h Number of non-AAA deaths in control group over 10 years' (mean) follow-up.
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These techniques for modelling growth also mean that the accrual of costs due to rescanning should be
more accurate. Costs will accrue as rescans occur over time, as opposed to averaging costs over a number of
cycles. By implementing these changes the model can be used to investigate a range of potential new
surveillance policies and compare their cost-effectiveness.
Re-estimation of current unit costs for screening interventions,
and elective and emergency surgery
The various estimates of cost-effectiveness based on MASS, referred to earlier, have so far all used original
unit cost estimates at 2000–1 prices, updated as necessary only for general health service inﬂation.
There was a clear need for a more thorough update of costs to reﬂect a range of changes in practice. All
costs were re-estimated at 2010–11 price levels.
Screening intervention costs
The original costs for the elements of screening came directly from the costs of the services in the trial.
These have now been superseded by costs directly provided by the NAAASP. Table 15 shows the original
ﬁgures, those ﬁgures updated to 2010–11 price levels, and the current unit costs, again at 2010–11 price
levels from the NAAASP.
Costs for elective and emergency aneurysm repair
The MASS estimates for the cost of elective and emergency procedures were calculated using very detailed
bottom-up costing using patient notes and other detailed hospital records of 577 patients from the four
surgery centres involved in the MASS study.56 It was not feasible to re-estimate the costs using the same
resource-intensive methods for this study. Rather we chose to estimate unit costs for surgery using more
recent published studies where available and where more recent, relevant studies were not available by
making explicit adjustments to the mean per patient costs previously calculated to reﬂect more recent routine
data on resource use.
The most recent and largest (sample size) costing exercise was completed as part of the analysis of the
endovascular aneurysm repair (EVAR)-1 trial, which we have used to estimate the costs of open repair and
TABLE 14 Comparison of discounted mean costs and effects observed in MASS and estimated in economic model
Cost-effectiveness at 10 yearsa
Observed in MASS Original model Model after recalibration
Control group
Life-years (mean) 7.509 7.291 7.282
Cost, £ (mean) 108 118 124
Invited group
Life-years (mean) 7.523 7.297 7.293
Cost, £ (mean) 208 233 225
Difference between invited and control groups
Difference in life-years, £ (mean) 0.014 0.006 0.011
Difference in costs, £ (mean) 100 115 101
ICER (life-years), £ 7600 18,000 8900
ICER (QALYs), £b 9700 23,000 11,400
a Costs based on 2008–9 prices; costs and mortality discounted at 3.5%. Survival based on all-cause mortality.
b Life-years adjusted using population norms.
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endovascular repair in an elective setting.65 As per NICE guidance,66 we assumed that emergency EVAR
operations are only being performed in a research environment and, so, we have only included costs for
open emergency repair in our estimates. For emergency open repair an estimate of per patient costs was
updated from the MASS trial, in the following way:
(a) First, the major costs components were removed from the total mean per patient estimates for elective
open repair and elective EVAR (from EVAR 1 trial65 estimates) and emergency OR (from MASS trial56 cost
estimates). In each case, this constituted the removal of costs attributable to hospital stay and operation
time. For EVAR this also included the cost of the stent. This cost was updated using more recent data
from centres involved in the screening programme and correspondence with manufacturers.
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FIGURE 20 Extension of original model structure to include unobserved ‘tunnel’ states.
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(b) The residual cost, made up of more minor resource-use items, such as blood products used and
consumables, was inﬂated to 2010–11 prices according to Personal Social Services Research
Unit indices.67
(c) The resource-use data were then updated for operation length and total hospital stay (apportioned
using the same proportions for intensive care unit (ICU) and normal ward as had been observed in
EVAR 1 trial or MASS, respectively) using recent data provided for us from the National Vascular
Database (January 9 March 2012).68 New unit costs for ICU, high-dependency unit (HDU) and vascular
ward stay were all obtained from NHS reference costs for 2010–11.69 A new unit cost estimate per
hour of time in operating theatre was obtained.70 These updated estimates were applied to the new
resource-use estimates.
(d) The elective cost has been weighted according to the proportion of cases that are EVAR and OR in the
National Vascular Database sample (approximately 70/30 for EVAR and OR, respectively).
Tables 16–18 illustrate this process for updated components of resource use and unit costs, for elective open,
elective EVAR, and for emergency procedures, respectively. Tables 19–21 show the magnitude of the residual
component of each of these three costs, which was simply inﬂated to 2010–11 prices. Table 22 summarises
TABLE 15 Costs for elements of screening
Element
Original MASS56
cost 2000–1 (£)
MASS56 cost inﬂated
to 2010–11 (£)
Updated unit
costa (£)
Invitation to screen 1.31 1.84 1.70
Cost of ﬁrst scan 19.08 26.80 32.20
Surveillance scan 46.04 64.67 68.00
a Source: UK NAAASP, personal communication, 2012.
TABLE 16 Components of resource use and unit costs for elective open repair
Component EVAR 165 resource use EVAR 165 unit cost (£) Updated resource use Updated unit cost (£)
Theatre time 215 minutes 17.58 181.97 minutes 20.67
HDU 1.88 days 832.00 1.65 days 883.00
ITU 2.47 days 1165.00 2.16 days 1226.00
Vascular ward 11.41 days 268.00 9.98 days 266.00
Total days 15.76 days 13.79 days
TABLE 17 Components of resource use and unit costs for elective EVAR
Component EVAR 165 resource use EVAR 165 unit cost (£) Updated resource use Updated unit cost (£)
Theatre time 191 minutes 17.58 147.04 minutes 20.67
HDU 0.83 days 832.00 0.63 days 883.00
ITU 0.59 days 1165.00 0.44 days 1226.00
Vascular ward 8.34 days 268.00 6.29 days 266.00
Total days 9.76 days 7.36 days
Stent cost 5219.00 6500.00
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TABLE 19 Calculation of residual costs component inﬂated to 2010–11 prices for elective open repair
Component Residual cost (£)
Total open repair cost as per EVAR 1 trial65 11,842
Length of stay component 7214
Operation time component 3647
Total of components 10,861
Residual costs to inﬂate 981
Residual costs inﬂated to 2010–11 prices 1014
TABLE 20 Calculation of residual costs component inﬂated to 2010–11 prices for elective EVAR
Component Residual cost (£)
Total EVAR cost as per EVAR 165 13,019
EVAR stent and parts component 5219
Length of stay component 3543
Operation time component 3255
Total of components 12,017
Residual costs to inﬂate 1002
Residual cost inﬂated to 2010–11 prices 1036
TABLE 18 Components of resource use and unit costs for emergency open repair
Component
MASS trial56
resource use
Updated
resource use
Updated unit
cost (£)
Theatre time 182 minutes 161.94 minutes 20.67
ITU 4.74 days 7.12 days 1226.00
Vascular ward 7.66 days 11.51 days 266.00
Total days 12.4 days 18.63 days
TABLE 21 Calculation of residual costs component inﬂated to 2010–11 prices for emergency open repair
Component Residual cost (£)
Total open repair cost as per MASS56 11,176
Length of stay component 6932
Operation time component 794
Total of components 7726
Residual costs to inﬂate 3450
Residual cost inﬂated to 2010–11 prices 4846
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the new cost estimates and compares them with the original estimates, and the original estimates inﬂated to
2010–11 prices.
Costs of pre-surgical consultations
No newer estimates were available for the costs of consultations when referred to surgery which included
costs of associated tests. The original MASS56 estimates for these costs were simply inﬂated from 2000–1 to
2010–11 prices (£309.88 inﬂated to £435.25).
Incorporating data from the NHS Abdominal Aortic Aneurysm
Screening Programme
To reﬂect current AAA screening in the UK, data from the NAAASP were utilised in the economic
modelling. The attendance rate from those invited to screening in the NAAASP has been lower than that
of the MASS trial (which was 83%); a ﬁgure of 73% from the NAAASP has been used in the modelling.71
A lower prevalence of AAAs has also been noted in data from the NAAASP, which might have some effect
on cost-effectiveness results. In the MASS trial the prevalence was 4.9%, but the current prevalence
observed in the NAAASP is 1.6% and this rate was used in the modelling. Data were provided to us from
the NAAASP on the distribution of aneurysm sizes detected in the screening programme, to reﬂect
possible changes in aneurysm sizes observed at baseline compared with the MASS data used in the
original model.
In addition, non-AAA mortality rates were estimated using data from Hospital Episodes Statistics72 and
the Ofﬁce for National Statistics (ONS) for 2010,73 incorporated into the modelling as age-speciﬁc
3-month probabilities.
Incorporating size-speciﬁc growth and rupture rates from the
RESCAN analyses
Growth rates
From the reanalysis of existing surveillance data (see Chapter 6) we have developed random-effects models
to describe AAA growth in each of the studies. These models are utilised to calculate how individuals pass
through the size states of the Markov model used for the cost-effectiveness modelling. The methods are
described fully in Appendix 4, with a summary given here.
Firstly, 3-month transition probabilities were calculated between 5-mm-wide size states (3.0–3.4 cm,
3.5–3.9 cm, 4.0–4.4 cm, 4.5–4.9 cm, 5.0–5.4 cm and 5.5+ cm). To achieve this, a cohort is envisaged with
screening distribution of small aneurysm sizes taken from the Chichester screening study (shown to have an
almost identical distribution to the NAAASP small diameters, as shown in Figure 21). This distribution is
skewed towards small aneurysms with the mode close to 3.0 cm. The aneurysms in this envisaged cohort are
TABLE 22 Summary of updated unit costs for surgical procedures
Type of
surgery
Updated
cost per
patient (£)
Cost per
patient
(EVAR 165) (£)
Cost per patient
inﬂated to 2010–11
prices (EVAR 165) (£)
Cost per
patient
(MASS56) (£)
Cost per patient
inﬂated to 2010–11
prices (MASS56) (£)
Elective OR 11,532.69 11,842.00 12,241.17 6909.00 9704.24
Elective EVAR 13,345.66 13,019.00 13,457.84
Elective weighted 12,806.21
Emergency OR 19,984.75 11,176.00 15,697.59
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then allowed to grow over time using the baseline size-speciﬁc growth rates estimated from each study
separately. For any 3-month period following screening, the estimated occupancy probabilities in each
5-mm-wide size state were calculated using the predictive distribution of aneurysm sizes. Those screened as
normal are assumed to account for 98.3% of the screened population9 and are also allowed to grow, with
an estimated 0.207% reaching 3.0 cm every 3 months and, thereafter, growing at a rate equivalent to a
screen detected patient with baseline diameter 3.0 cm. The occupancy probabilities from the cohort are then
used to calculate 3-month transition probabilities between size states using the Chapman–Kolmogorov
equations and assuming a progressive only Markov model.74 The log-odds of the transition probabilities for
each 3 months over a 30-year time period after screening are obtained together with their SEs, and these
study-speciﬁc estimates are then pooled in a second stage using random-effects meta-analysis.
‘Equivalence’ probabilities
Different choices of small aneurysm states are considered in the Markov transition models to allow
comparisons of different screening strategies. It is therefore necessary to calculate 3-month transition
probabilities between any size states of interest. Given the 3-month transition probabilities calculated above
for the 5-mm-wide size states we can obtain ‘equivalent’ transition probabilities for any concatenation of
these states (e.g. 3.0–4.4 cm, 4.5–5.4 cm, 5.5+ cm). These ‘equivalence’ probabilities are deﬁned by the
requirement that two Markov models with different small aneurysm size states produce the same proportion
of large aneurysms (> 5.5 cm) over time if no external intervention, deaths or censoring takes place. Hence,
this facilitates a fair comparison of the different surveillance strategies since the rate of growth to large AAAs
without intervention will be the same across all models. The method used to calculate these ‘equivalence’
probabilities is described in Appendix 4.
Rupture rates
To obtain 3-month transition probabilities of rupture over a 30-year time period, as required by the health
economic model, we ﬁt a parametric survival model to the data in each study. Only men are considered for
this analysis (since men are the focus of the screening policy). Speciﬁcally, a Weibull proportional hazards
model with time-updated covariate (AAA diameter) is used. Events other than rupture that terminate
follow-up (lost to follow-up, non-rupture-related death or surgery) are classiﬁed as censored observations.
The (transition) probability of rupturing over any 3-month time period given AAA diameter at the beginning
of the period is then approximated from the survival distribution. The log-odds of these probabilities are
obtained together with their SEs, and these study-speciﬁc estimates are pooled in a second stage using
random-effects meta-analysis.
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Analysis of cost-effectiveness using the adapted and
updated model
These developments enable us to use the model to estimate the life-years, QALYs, costs and net monetary
beneﬁts for a series of strategies with different recall frequencies, compared initially with the base case of
the existing strategy, and by looking at differences in net beneﬁt to extend to comparisons between any
two strategies.
In this particular context, a probabilistic sensitivity analysis (PSA), as might typically be provided as a
representation of the overall uncertainty in the estimates of cost-effectiveness, would not adequately
characterise that overall uncertainty. In particular, it is not readily feasible to estimate the correlated
uncertainty around the very many (480) age- and size-related aneurysm growth and rupture rates derived
from the IPD meta-analysis incorporated into the model, or to provide evidence-based estimates of
uncertainty distributions around other parameters, or to characterise the underlying structural uncertainty in
this complex model. Therefore, rather than provide a potentially misleading PSA, we have chosen to employ
simple one-way sensitivity analyses to characterise the effects on net beneﬁt of uncertainty around growth
rate and rupture rate estimates, and to check whether or not the conclusions regarding the preferred
strategy are sensitive to this uncertainty. For comparison we illustrate the effects of uncertainty around other
important parameters in the model.
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Chapter 8 Results of cost-effectiveness analysis of
alternative surveillance policies
The current surveillance strategy used in the NAAASP follows that of the MASS trial. The strategy wasbased on the expert judgement informed by the limited data available at the planning stage of the trial.
The analysis in this study of growth rates and rupture rates enable us now to analyse the cost-effectiveness of
alternative surveillance in terms of the frequency of recall for men screened as having an aneurysm
between 3.0 and 5.4 cm.
In this chapter we present the comparative cost-effectiveness of a number of alternative surveillance
strategies using the revalidated, and extended model with updated unit costs and key characteristics from
the NAAASP (uptake rates and distribution of aneurysm sizes at screening).
Alternative surveillance strategies
We used the adapted and updated model described in Chapter 7 to examine the health beneﬁts (in terms of
life-years) and overall costs, modelled over a 30-year period, for a range of alternative surveillance strategies
as compared with the current strategy which we refer to as strategy A. Table 23 summarises the values
and sources of clinical and cost parameters used. The alternative strategies included both lengthening and
shortening the current time intervals between rescans for those identiﬁed with aneurysms between 3.0 and
4.4 cm (base case 1 year) and 4.5 and 5.4 cm (base case 3 months). We assumed that a recall more
frequent than 3 months would be unworkable, so did not consider any such options. In analysing any of the
different surveillance strategies we assume that the same strategy would also apply to all opportunistically
identiﬁed aneurysms in both arms. This assumption explains the very small difference in the control
arm life-years and cost between strategies.
Table 24 sets out the key comparison, which is illustrated on the cost-effectiveness plane in Figure 22.
Strategy A represents the base case of the current screening strategy, with an ICER against no formal
screening of £5572 per life-year gained and £7143 per QALY gained. To identify whether or not an
alternative strategy was an improvement, and which was best, we focused on the ICERs (for both life-years
and QALYS) and the net monetary beneﬁt calculated as (Net QALYs×£20,000)–Net costs. We used the
threshold value of £20,000 per QALY to be consistent with the opportunity cost of interventions within the
NHS as articulated by NICE.75
Each of the alternative strategies demonstrated appropriate directional changes in the life-years gained from
screening and the QALYs gained from screening. The strategies, which extend one or more intervals, slightly
reduce the QALY gain (by missing a small proportion of aneurysms that would go on to rupture) and slightly
reduce the cost (by avoiding additional scans), whereas strategies that decrease intervals increase the QALY
gain and increase the costs. This effect is shown in Figure 22, where the strategies that increase intervals
(strategies B, C, D and G) fall in the south-west quadrant of the cost-effectiveness plane (where both costs
and QALYs are reduced), whereas a strategy that decrease intervals (strategy E) falls in the north-east
quadrant (where both QALYs and costs increase). Strategy F, in which all aneurysms between 3.0 and 5.5 cm
are recalled at 6-monthly intervals, can be eliminated from further consideration in that it reduces QALYs and
increases costs, so is dominated by existing strategy A which is clinically more effective and cheaper.
The economic question for strategy E is whether or not the increase in QALYs is sufﬁcient to justify the
increase in costs, while for each of strategies B, C, D and G it is whether or not the reductions in cost are
sufﬁcient to compensate for the QALY losses. This is assessed against a view of the acceptable cost per QALY
or threshold. Using the threshold of £20,000 per QALY, we can see that strategy E far exceeds the
acceptable threshold and is not cost-effective. Given the only other practical strategy, to increase frequency
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TABLE 23 Parameter estimates for adapted economic model
Clinical parameters Estimate Source
Proportion reinvited to screening 0.1360 MASS8
AAAs at ﬁrst screen – attenders 0.0166 NAAASP71
AAAs at ﬁrst screen – non-attenders 0.0166 NAAASP71
Non visualised AAAs 0.0166 NAAASP71
Proportion of scans non-visualised 0.0121 MASS8
Proportion of screen invited attending 0.730 NAAASP71
Proportion of AAAs at ﬁrst screen – small 0.809 NAAASP71
Proportion of AAAs at ﬁrst screen – medium 0.106 NAAASP71
Proportion of AAAs at ﬁrst screen – large 0.0854 NAAASP71
Transition probabilities (3-monthly)
Grow from no AAA to small AAA 0.00207 Chichester53
Grow from small AAA to medium AAA TDTPa RESCAN
Grow from medium AAA to large AAA TDTP RESCAN
Probability of dropout 0.0142 MASS
Rupture probability – no AAA 0 Assumption
Rupture probability – small AAA TDTP RESCAN
Rupture probability – medium AAA TDTP RESCAN
Rupture probability – detected large AAA 0.0125 MASS
Rupture probability – undetected large AAA 0.0282 Calibration
Rupture probability – contraindicated for surgery 0.0282 MASS
Probability of opportunistic detection 0.0114 Calibration
Probability of emergency surgery following rupture 0.368 MASS
Probability of death following emergency surgery 0.342 MASS
Proportion of large AAAs receiving surgery 0.681 MASS
Proportion of large AAAs returned to screening 0.221 MASS
Proportion of large AAAs contraindicated for elective surgery 0.0977 MASS
Probability of death following elective surgery – screen detected 0.0298 MASS
Probability of death following elective surgery – opportunistically detected 0.0717 MASS
All-cause mortality – contraindicated for surgery 0.0599 MASS
Age-speciﬁc all-cause mortality Age speciﬁc ONS73
Cost parameters
Invitation to screen (£) 1.70 See Chapter 7
Cost of ﬁrst scan (£) 32.20 See Chapter 7
Surveillance scan (£) 68.00 See Chapter 7
Pre-surgical consultation (£) 435.25 See Chapter 7
Elective repair (£) 12,806.21 See Chapter 7
Emergency repair (£) 19,984.75 See Chapter 7
TDTP, time-dependent transition probabilities.
a Time-dependent transition probabilities, applied to each 3-month cycle.
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of scans, strategy F, was dominated by the present screening strategy, we can conclude that decreasing recall
intervals is unlikely to be cost-effective. Looking at the strategies (B, C, D and G) that increase screening
intervals, we are seeking a strategy that releases at least £20,000 in cost savings per QALY lost. All options
meet that test, and of these we need to choose the one with the highest net beneﬁt (highest excess in
value of cost savings minus value of lost QALYs). Strategy C, with a recall pattern of 2 years for aneurysms
between 3.0 and 4.4 cm and 3 months for aneurysms between 4.5 and 5.4 cm, has the highest net beneﬁt,
and is the most cost-effective strategy. Increasing intervals beyond this does not provide sufﬁcient
additional cost savings to justify the additional QALY losses.
To summarise these ﬁgures as clearly as possible, our analysis suggests that the effect of changing from the
current surveillance strategy to surveillance strategy C, the best of the options considered, would mean
that the loss of value from the QALY gain per man invited would be equivalent to a loss of £1.24, but that
the cost would be reduced by £2.57 per man invited, giving a net monetary beneﬁt gain of £1.33.
Uncertainty and sensitivity
As was indicated in Chapter 7, in this particular case it is not feasible, given available data and analytical
possibilities, to provide a robust, meaningful PSA that encompasses all the parameter and structural
uncertainty. We have therefore focused on a more appropriate series of one-way sensitivity analyses. These
are summarised in Table 25.
The ﬁrst of these applies growth and rupture rates drawn from the three UK population-based screening
studies that used internal aortic diameter measurements (as does the NAAASP), namely MASS, Gloucester
and Chichester (see Chapter 6), and which could therefore be seen as most applicable to the UK
programme. Strategy C clearly remains the preferred option and, although it is slightly less cost-effective than
in the base case, the net beneﬁt is still positive and substantial. As an alternative way to address the
uncertainty around growth and rupture rates, the next sensitivity analyses reduce or increase growth rates by
10% and rupture rates by 30%. These ranges approximate one SD in the estimates of the value of the
relevant parameter. Again, in each case, the preference for strategy C, over all other strategies, remains
unchanged. Using an estimate of operative mortality rates from the NAAASP, similarly does not change the
choice of strategy. Further sensitivity analyses consider the possibility that dropout rates (from recall) might be
affected by different recall strategies but again the preference for strategy C is unaltered. Finally, we consider
the effect of (arbitrarily) different relative costs for elective and emergency surgery and for the cost of
rescanning. In no case does the choice of strategy change, although, not surprisingly, the magnitude of the
cost savings from less frequent recall in strategy C (and hence its net beneﬁt) are somewhat affected
by the unit cost of rescans.
Discussion and conclusions
Long-term modelling of the implications of screening programmes is always difﬁcult and typically involves
unveriﬁable assumptions and estimates that have long-term implications. Screening for AAA is an
unusual case in that we have been able to compare results from a long-term model initially based on 4-year
data with 10 years of observation. The resultant problem was to identify a set of model parameters that
would replicate the observed results at 10 years. We were able to do this imperfectly, but nevertheless can
have more conﬁdence in the recalibrated model than would otherwise have been appropriate with the
original model. Then, with the systematic reviews and the RESCAN analyses of growth and rupture rates,
we were able to go further in estimating the cost-effectiveness implications of alternative
surveillance strategies.
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TABLE 24 Adapted economic model cost-effectiveness results (30-year results) for alternative recall strategies
Strategy A
(1 year,
3 months)
Strategy B
(2 years,
6 months)
ICER B
compared
with A
Strategy C
(2 years,
3 months)
ICER C compared
with A
Strategy D
(1 year,
6 months)
Control arm
Life-years 12.7157 12.7155 12.7157 12.7156
Cost (£) 271.65 260.23 265.87 265.46
Invited arm
Life-years 12.7244 12.7240 12.7242 12.7241
Cost (£) 319.89 305.03 311.54 312.20
Difference
Life-years 0.008659 0.008502 −0.0001578 0.008580 −0.00007983 0.008569
QALYS 0.006754 0.006631 −0.0001231 0.006692 −0.00006226 0.006683
Cost (£) 48.25 44.80 −3.45 45.68 −2.57 46.74
ICER £ per LY 5572 5270 21,853 5324 32,236 5454
ICER £ per QALY 7143 6756 28,016 6825 41,329 6993
Net beneﬁt (λ=£20,000
per QALY)
0.99 1.33
Costs based on 2010–11 prices – costs and mortality discounted at 3.5%. Survival based on deaths related to AAA
deaths, accounting for other causes of death.
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FIGURE 22 Cost-effectiveness plane for new screening interval strategies.
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ICER D
compared
with A
Strategy E
(6 months,
3 months)
ICER E
compared
with A
Strategy F
(6 months,
6 months)
ICER F
compared
with A
Strategy G
(3 years,
3 months)
ICER G
compared
with A
12.7158 12.7156 12.7155
279.92 273.40 262.17
12.7244 12.7241 12.7240
331.49 323.35 306.64
−0.00009086 0.008674 0.00001455 0.008576 −0.00008350 0.008449 −0.0002103
−0.00007087 0.006766 0.00001135 0.006689 −0.00006513 0.006590 −0.0001640
−1.51 51.57 3.32 49.95 1.70 44.47 −3.78
16,650 5945 228,111 5824 −20,365 5263 17,972
21,346 7622 292,450 7467 −26,109 6748 23,041
0.10 −3.09 −3.00 0.50
These show that from a cost-effectiveness perspective lengthening the surveillance interval for aneurysms
of 4.5–5.4 cm reduces net monetary beneﬁt and we have argued that decreasing that interval would
not be practical. However, increasing the interval for recall of men with aneurysms between 3.0 and
4.4 cm from 1 year to 2 years improves cost-effectiveness, but increasing it further to 3 years worsens
cost-effectiveness compared with 2 years and (marginally) compared with the current 1-year interval.
It is important to recognise that the absolute differences in outcomes and costs between the surveillance
options we have considered are small, as are the absolute values of the net monetary beneﬁt per man
invited. They can be put into perspective by multiplying them up to reﬂect the impact on a large-scale
screening programme. With a programme inviting around 260,000 men per year as will broadly be the
situation when the NHS programme covers the whole of England,73 the (present value of the) cost difference
for the preferred option would be of the order of £660,000 per year, but the QALY loss would be
equivalent to around 16 QALYs. Given the remaining uncertainties there has to be a question of whether or
not the differences involved justify a change from the existing surveillance programme particularly as it
would have to be explicit that this strategy was expected to be slightly inferior in terms of
clinical effectiveness.
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TABLE 25 Adapted economic model cost-effectiveness results (30-year results): sensitivity analyses of growth and
ruptures rates, operative mortality rates, dropout rates, costs of surgery and cost of rescans. Incremental net beneﬁt
(INB) of each strategy is given compared with strategy A (1 year, 3 months)
Strategy C
(2 years,
3 months),
INB (£)
Strategy B
(2 years,
6 months),
INB (£)
Strategy G
(3 years,
3 months),
INB (£)
Strategy D
(1 year,
6 months),
INB (£)
Strategy F
(6 months,
6 months),
INB (£)
Strategy E
(6 months,
3 months),
INB (£)
Base case 1.33 0.99 0.50 0.10 −3.00 −3.09
Growth and rupture rates from three UK population screening studies10,37,53 that used internal aortic
diameter measurements
Three UK screening
studies
1.09 0.61 −0.11 −0.04 −3.01 −2.96
Growth rates
Growth rates ↓10% 1.52 1.29 0.94 0.23 −2.95 −3.19
Growth rates ↑10% 1.13 0.68 0.03 −0.04 −3.05 −3.00
Rupture rates
Rupture rates ↓30% 1.33 0.96 0.47 0.08 −3.02 −3.10
Rupture rates ↑30% 1.33 1.01 0.53 0.11 −2.99 −3.09
Operative mortality rate – base casea 0.029 and 0.074
0.024 (NAAASP) 1.36 1.16 0.58 0.25 −2.85 −3.10
Dropout rate from rescanning – base case 1.4%
Dropout rate ↓20% 1.47 1.20 0.73 0.20 −3.06 −3.26
Dropout rate ↑20% 1.20 0.80 0.30 0.01 −2.95 −2.94
Costs of elective and emergency surgery – base case £19,985 and £12,806
Elective ↑10%
Emergency ↓10%
1.38 1.07 0.63 0.14 −2.96 −3.10
Elective ↑30%
Emergency ↓30%
1.47 1.25 0.88 0.24 −2.87 −3.12
Elective ↓10%
Emergency ↑10%
1.28 0.90 0.37 0.05 −3.05 −3.08
Elective ↓30%
Emergency ↑30%
1.18 0.72 0.11 −0.05 −3.13 −3.07
Cost of rescanning – base case £68
Cost of rescan ↓10% 1.10 0.69 0.20 −0.03 −2.81 −2.77
Cost of rescan ↓30% 0.64 0.11 −0.41 −0.28 −2.42 −2.11
Cost of rescan ↑10% 1.56 1.28 0.80 0.22 −3.20 −3.42
Cost of rescan ↑30% 2.02 1.87 1.41 0.47 −3.59 −4.07
↓, decreased by; ↑, increased by.
a In the base case, 0.029 relates to the mortality following surgery for screen-detected individuals, whereas 0.074 relates
to those opportunistically detected. The data available from the NAAASP do not make a distinction.
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Chapter 9 Discussion
In this chapter we discuss the results and interpretation of the two systematic literature reviews (seeSystematic review of small abdominal aortic aneurysm growth rates and Systematic review of small
abdominal aortic aneurysm rupture rates), the analyses of the IPD surveillance data sets (see Analysis of
individual patient data surveillance data sets) and the patient factors inﬂuencing growth and rupture rates
(see Factors inﬂuencing growth and rupture rates).
Systematic review of small abdominal aortic aneurysm
growth rates
The methods and results of our systematic review are presented in Chapters 3 and 4. This is the ﬁrst
systematic review of small aneurysm growth rates since their inclusion in the earlier surgical management of
aneurysms review of Hallin et al.,76 which covered the literature from 1990 to 1997. Unlike this earlier study,
which included only 816 patients from 13 different studies, we did not have to relax the eligibility criteria
for studies (50 or more patients) and this allowed the identiﬁcation of 15 suitable studies with
7630 persons for inclusion in a meta-analysis (see Table 2).
There are many reasons which might explain the large heterogeneity in growth rates between studies,
particularly methodological and patient population issues. The methodological issues include the fact that
patients have been entered into these studies since 1976, a 35-year time window during which the quality of
aortic imaging has improved dramatically. Second, some recent studies have used imaging modalities
other than US (such as CT) and it is known that there is poor agreement between CT and US aortic diameter
measurements.77,78 Some studies have used both methods of imaging.22,29,32 However, a sensitivity analysis of
studies that used only US imaging after 1990 was not associated with a reduction in heterogeneity. Third,
aortic diameter has been measured in a variety of different planes, measurement cursors have been
positioned on both the external and internal walls of the aorta (see Table 2) and only a minority of studies
speciﬁed the standardisation of imaging protocol between observers (see Table 3). Fourth, growth rates have
been estimated in a variety of different ways using (last–ﬁrst diameter)/(time elapsed), linear regression or
complex or multilevel modelling (see Table 2), and it has been reported that linear regression can
overestimate aneurysm growth by up to 40% compared with multilevel modelling.13 Hierarchical modelling
also resolves the problem of a small number of measurements possibly leading to exaggerated growth
rates.13 There was evidence that some of the heterogeneity is explained by the use of linear regression and, in
particular, (last − ﬁrst diameter)/(time elapsed) to report aneurysm growth rates.
The patient population issues include ethnicity (which was reported rarely), the intervention policy of each
study (which varied from aneurysm repair at 4.5 cm in the Huntingdon study to 6 cm in the Chichester
study34), the variable proportion of women in each study (which ranged from 0% in some studies to 24% in
one Canadian study29) and whether the aneurysm was identiﬁed by population screening or in hospital.
During the period of patient recruitment to these studies, 1976–2005, there have been important
improvements in medical therapy, with some studies reporting that use of statins slows the growth of
aneurysms while ACE inhibitors may increase the growth of small aneurysms.31,79 Medical therapies, smoking
and comorbidities were reported inconsistently across the 15 studies included in our review and frequently
only at study entry; therefore, their inﬂuence on growth rates could not be evaluated (see Table 2).
Although this meta-analysis, based on the published literature, provides very strong evidence that growth
rates increase markedly with aneurysm size, it only provides partial information about appropriate
surveillance intervals for small aneurysms. The growth rate for a 3.5-cm aneurysm is estimated at
1.9 mm/year, whereas that for a 4.5-cm aneurysm is 3.5 mm/year, both rates being somewhat lower than
those presented in the earlier review.76 Given an exponentially increasing aneurysm diameter, as implied from
the meta-regression in Figure 4, it would take on average 6.2 years for a 3.5-cm aneurysm to grow to 5.5 cm,
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whereas a 4.5-cm aneurysm would take only 2.3 years. So surveillance intervals for a 4.5-cm aneurysm
should be of the order of one-third of those for a 3.5-cm aneurysm. However, the meta-regression does not
provide information about the variability of growth rates between individuals necessary to inform the
choice of appropriate surveillance intervals.
Systematic review of small abdominal aortic aneurysm
rupture rates
The methods and results of our systematic review were presented in Chapters 3 and 4. Rupture of an AAA is
deﬁned as blood leaking through the aortic wall into the peritoneal or retroperitoneal spaces; the diagnosis
of rupture therefore depends on imaging (usually CT), ﬁndings at laparotomy or autopsy. A particular
constellation of clinical symptoms including circulatory collapse, in the presence of a known aneurysm, also
will give rise to the reporting of death from aneurysm rupture without autopsy. Contained or intramural
rupture also may occur, when either the leak has sealed spontaneously or the bleeding remained intramural
(the intramural blood from these ruptures usually can be detected by CT imaging). In contrast, abdominal or
back pain and aortic tenderness in the presence of a known aneurysm does not necessarily imply rupture,
although such aneurysms may be repaired urgently and listed as an emergency hospital admission. Very
surprisingly, none of the eligible studies for this review reported their diagnostic criteria for aneurysm rupture
and only 322,23,41 of 14 studies reported the evidence from which a diagnosis of rupture was made. This lack
of clarity about the diagnosis of rupture is a major limitation of these studies. In the European Society for
Vascular Surgery Guidelines for the management of AAAs,80 a clear deﬁnition of ruptured aneurysm is
provided and hopefully this will be used in future studies: ‘AAA rupture is deﬁned as bleeding outside the
adventitia of a dilated aortic wall. Rupture is further classiﬁed into free rupture in the peritoneal cavity and
retroperitoneal rupture where the retroperitoneal tissues provide tamponade and reduce temporarily the
volume of blood loss’.
Although many studies report the number of aneurysm ruptures, few studies have length of follow-up
information to permit the estimation of rupture rates. Nevertheless, there are many more studies, with
almost 10,000 patients, describing rupture rates of small aneurysms than were available for a recent
systematic review of rupture rates in large aneurysms.20 The latter, including only 533 patients in total,
reported a rupture rate of 10.3 (95% CI 7.5 to 14.3) per 100 person-years for aneurysms 5.0–5.9 cm in
diameter in those considered unﬁt for aneurysm repair.20 The rupture rates reported here, for aneurysms of
3.0–5.5 cm in diameter, are much lower at 0–1.61 per 100 person-years, with a trend for rupture rates
to increase with increasing diameter.
As no study reported the diagnostic criteria for rupture, the evidence from post-mortem studies was
examined. There are limited data from post-mortem studies and because the post-mortem diameter is lower
than any in vivo measurement, post-mortem data may be unreliable. A prospective autopsy series of
78 aneurysms where the autopsy aorta was subject to pressure inﬂation at 80–100mmHg did not show any
ruptures in specimens of ≤5.0 cm.81 This same study reported that without pressure inﬂation post-mortem
diameters were usually smaller than any in vivo measurement, probably by 0.4–0.5 cm or in some cases
by almost 50%. Therefore, data from the only large-scale autopsy series, which reported retrospectively on
the rupture of aortic aneurysms in almost 24,000 consecutive autopsies at the Massachusetts General
Hospital in the period 1952–75, are unreliable.82
Both the PIVOTAL and CAESAR trials of endovascular repair compared with surveillance for small aneurysms
reported in 2010 after the search for this review closed.51,83 In the PIVOTAL trial51 the rupture rate in
the surveillance was 0.17 per 100 patient-years (although this includes some follow-up after aneurysm
repair, which occurred in 31%). In the CAESAR trial,83 although mean conditional follow-up was not
reported, the rupture rate appears to be < 1 per 100 person-years. These are in keeping with the
results reported here.
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A new large prospective study based on population screening would be the most robust method of assessing
the rupture rates of small aneurysms in the twenty-ﬁrst century. Such a study would take time to set up
and several years of follow-up before it could report. For now, an alternative way to assess the rupture rates
of small aneurysms is through synthesis of a large amount of IPD from relevant studies. This is the
strategy we pursued.
Analysis of individual patient data surveillance data sets
We presented our analysis of overall growth and rupture rates in men and women from 18 surveillance data
sets in Chapters 5 and 6. Key results are shown in Table 8. This research has deﬁnitively quantiﬁed the extent
to which AAA growth rates and risk of rupture increase with AAA diameter, to provide a scientiﬁc basis
for selecting surveillance intervals for patients with small AAAs. For example, we have shown that the
time taken for an AAA of ≤4.0 cm to have a 10% chance of growing to 5.5 cm is at least 3 years. For men
with an AAA of ≤4.0 cm, it takes over 3.5 years to have a risk of rupture > 1%.
These results are based on the largest collection of IPD made to date, and consistent methods of statistical
analysis across multiple studies. Although three additional studies84–86 have been published up to September
2012, since the literature search that identiﬁed the studies for this meta-analysis was completed, one84
had fewer than 100 patients, and another85 appears to have considerable overlap with data already included
in our analysis. The third study86 includes 453 patients with 12 months of follow-up and would be
unlikely to alter our ﬁndings which are based on 15,475 patients with longer follow-up.
Our ﬁndings have important implications for AAA surveillance programmes. As screening for AAA is
becoming established in many countries there will soon be large cohorts of individuals under surveillance for
AAAs. For example, the NAAASP provides yearly scans for 3.0–4.4-cm diameter AAAs and 3-monthly scans
for 4.5–5.4-cm AAAs.9 The 95% conﬁdence estimates for rupture risk from our study suggest that
these surveillance intervals could safely be extended to 3 years for AAAs < 4.5 cm and yearly for
4.5–5.4-cm AAAs. The risk of rupture would be maintained at < 1%, a ﬁgure that appears to be acceptable
to patients with AAAs. This would reduce the average number of surveillance scans from approximately 22 to
only 7 for a patient with a 3.0-cm AAA detected by screening. Even if the lower 95% prediction limits of our
estimates are applied, to acknowledge that the populations in each study may have different growth and
rupture rates, these surveillance intervals could be reduced to 2-yearly for 3.0–3.9-cm AAAs, yearly
for 4.0–4.9-cm AAAs and 6-monthly for 5.0–5.4-cm AAAs. Using the same example as above,
this would reduce the average number of surveillance scans required for a 3.0-cm AAA from approximately
22 to 10.
Most population-based screening programmes for AAA are focused on the elderly male population, aged
≥ 65 years. This study, which included 1743 women (11%), showed that overall there was no difference
in aneurysm growth rates between men and women. Interestingly, when aneurysm growth rate was
estimated using hierarchical modelling, allowing for accelerating growth rate with increasing aneurysm
diameter, data from Tromsø no longer showed that growth rates were faster in women.38 Only Edinburgh54
and Leeds (Professor D Julian A Scott, personal communication) showed a signiﬁcantly different growth rate
in women. This underscores the heterogeneity observed both in this meta-analysis of the inﬂuence of sex
and many other covariates and in previously published meta-analyses based on varied methods for
estimating growth rate.19,87
The fourfold higher rupture rate found for women compared with men is intriguing, particularly given that
these data demonstrate that both sexes have similar growth rates. The sex imbalance in the risk of
rupture has been identiﬁed in previous studies;48 differences in anatomy, structure, sex steroids and smoking
habits have all been suggested to play a role.88 The clinical implication is that a lower AAA diameter threshold
for surgery should be adopted for women, a recommendation already made by the joint council of the
American Association for Vascular Surgery and Society for Vascular Surgery,89 but one not yet supported by
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randomised trial evidence. As the rupture rate for women with a 4.5-cm AAA is about the same as that
for a man with a 5.5-cm AAA, a threshold for surgery of 4.5 cm might seem appropriate in women.
However, the operative mortality and discharge outcomes appear to be worse in women than men. For
instance, the US Medicare database shows that operative mortality after endovascular repair (now the
majority procedure) is 3.2% in women compared with 1.8% in men, and similar ﬁndings have been reported
in other studies.90–92 Therefore, competing risks must be carefully considered before amending guidelines or
recommendations for intervention in women.
Despite the strong conclusions that can be drawn from this study, there remain some areas of uncertainty
where future research efforts could be focused. The most obvious need is for further evidence for women
with aneurysms in the diameter range 4.5–5.4 cm. Second, the substantial heterogeneity between studies
we identiﬁed in growth and rupture rates could not be explained by adjustment for individual factors or
study-level characteristics. If the underlying causes for these differences are biological rather than simply
methodological, these may yield insights for developing interventions to lower growth rates in patients with
small AAA; such treatments have been sadly lacking up to the present time.18,19 Such advances will only be
possible through the analysis of large data sets, most likely to become available from surveillance within the
national AAA screening programmes that are currently being set up. Third, recommended surveillance
intervals may be lengthened in the future given the generally falling national rates of AAA rupture currently
being experienced.48,93 Last, more research is needed on the acceptable risk to patients of exceeding 5.5 cm
or rupture before the next scan. An alternative approach is to consider the cost-effectiveness of different
surveillance policies. Decreasing surveillance frequency would reduce surveillance costs. However, it may also
very slightly increase rupture rates, thereby decreasing overall life expectancy in AAA patients under
surveillance and increasing the burden and cost of emergency surgery. Hence, we conducted a formal
evaluation to identify which surveillance intervals for different sized AAAs would be most cost-effective, as
reported in Chapters 7 and 8.
Factors inﬂuencing growth and rupture rates
Factors apart from sex that inﬂuence growth and rupture rates were systematically examined in the analysis
of the IPD surveillance data sets (see Chapters 5 and 6). Aneurysm growth rates were consistently increased
by about one-sixth in current smokers and decreased by about one-quarter in patients with diabetes. There
was no evidence of any change in aneurysm growth rates over time and neither age, mean arterial pressure
nor cardioprotective drugs, had a signiﬁcant effect on growth rates. In contrast, small aneurysm rupture rates
were doubled in current smokers, with age, mean arterial pressure and calendar year of enrolment being
additional factors inﬂuencing rupture rates. These data suggest that the follow-up and management of the
patient with small AAA could potentially be tailored to factors such as current smoking, diabetes and blood
pressure, in addition to aneurysm diameter.
In every study, the growth rate of aneurysms in patients with diabetes was on average lower than in patients
without diabetes, with no heterogeneity observed in the meta-analysis. Furthermore, the magnitude of the
change in growth rate (approximately 25%) associated with diabetes was far greater than for any other
covariate tested. This suggests that routine surveillance of small aneurysms might safely be less frequent in
patients with diabetes. The biology of the aortic wall may be altered in diabetes with increased glycosylation,
which together with other changes might underlie the reduced aneurysm growth rate in patients with
diabetes. Most of these studies did not discriminate between type I and type II diabetes, although
unpublished data from the United Kingdom Small Aneurysm Trial (UKSAT) suggest that most of the patients
with diabetes (78%) were not taking insulin and in the Leeds study only type II diabetes was reported
(Professor D Julian A Scott, personal communication). This might explain the trend for increased BMI to be
associated with a reduced aneurysm growth rate in the unadjusted analysis. However, overall the patients
with diabetes were few, concordant with the observation that diabetes is negatively associated with AAA.94
As there were only four ruptures reported in patients with diabetes, it was not possible to reliably evaluate
the inﬂuence of diabetes on aneurysm rupture.
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Smoking was second only to diabetes in the magnitude of its effect on aneurysm growth but while the effect
of current smoking on aneurysm growth was modest (∼16%), current smoking doubled aneurysm rupture
rates. The direction of the effect of smoking on aneurysm growth was consistent among all studies,
except Leeds (Professor D Julian A Scott, personal communication). A limitation of our study, impacting on
heterogeneity, is that non-smoking or ex-smoking status might have been deﬁned differently in the
different studies, particularly with respect to time from smoking cessation or very light tobacco usage.
The studies included in this meta-analysis span patients studied over a > 25-year period, since 1983. The
prevalence of smoking has been decreasing since the mid-1970s and at the same time awareness of
cardiovascular risk prevention in patients with small aneurysms has been increasing and the quality of US has
improved dramatically. For these reasons, we explored whether or not the recruitment date of patients within
each study (as a proxy for changing environmental, ultrasonographic and drug factors) might inﬂuence
either aneurysm growth or rupture rates. Interestingly, although aneurysm growth rates appeared to be
unchanged over time, rupture rates appeared to decrease. This is consistent with better control of
hypertension (higher mean arterial pressure increases rupture rates) and lower prevalence of smoking as well
as with the decreasing incidence of aneurysm rupture, which is being reported from several different
countries.95–97 The contrasting effects of enrolment date on growth and rupture rates also may indicate that
although cardioprotective drugs might inﬂuence rupture rates they are unlikely to have any strong inﬂuence
on aneurysm growth.
Individually, none of the cardioprotective drugs (lipid-lowering drugs, aspirin, beta blockers, calcium channel
blockers or ACE inhibitors) showed signiﬁcant associations with aneurysm growth, and the magnitude of any
individual effect was very small (about 0.2 mm/year for statins and 0.1 mm/year for other drugs). One of the
included studies was a formal evaluation of the effect of propranolol on aneurysm growth rate in about
500 patients.40 Based on the ﬁndings reported here, this trial was very underpowered and trials of
approximately 3700 patients would be necessary to show a reduction in aneurysm growth rates of
0.2 mm/year at 80% power, assuming growth rates have a SD 2.2 mm/year. The ﬁndings reported here for
lipid-lowering drugs are consistent with other meta-analyses showing a possible association between statin
usage and slower aneurysm growth rate.18,19,98 The ﬁnding that ACE inhibitors increased growth rates in
the UKSAT79 was not substantiated by other studies. Particularly in the older studies, few of the patients
included in the current meta-analysis were taking cardioprotective medications and even if patients were
taking these drugs at baseline, there is no evidence about continued patient compliance with medication.
This is pertinent since both of the randomised trials assessing the effect of beta blockers on aneurysm growth
illustrated the poor compliance with these drugs in patients with small aneurysms.40,99
This individual patient meta-analysis of the inﬂuence of demographic factors and drugs on small aneurysm
growth and rupture rates overcomes a number of limitations found in meta-analyses of published
data.18,19,87,100 First, data are strictly limited to the aneurysm diameter size range of 3.0–5.5 cm, the range
which is relevant to most population screening programmes. Second, the study uses a single statistical
method of estimating aneurysm growth rates, to overcome some of the heterogeneity associated with using
different methods of growth rate estimation, particularly the use of (last–ﬁrst diameter)/(time elapsed).
Third, through application of an adjustment for overestimation of diameters using CT scans compared with
ultrasonography, studies using both CT and US data could be included. Fourth, as rupture is a rare
event in small aneurysms, there is an opportunity to study important factors, other than aortic diameter,
which may inﬂuence rupture rates and alter patient management.
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Chapter 10 Conclusions
Clinical and policy conclusions
In our systematic reviews of the growth and rupture rates of small AAA we primarily identiﬁed that both
of these outcomes were related to AAA size, with larger AAA having higher rates of growth and higher
rates of rupture. We estimated that the average time for a 3-cm AAA to grow to 5.5 cm is 9.6 years and
for a 5-cm AAA is 1.1 years. We were unable to provide the same size-based estimates for risk of rupture
from our systematic review since the data informing such an analysis were insufﬁcient. We can only
conclude that the rupture rate of small AAAs (3.0–5.5 cm in diameter) appears to lie between 0 and 1.61 per
100 person-years.
In order to address the deﬁciencies of the systematic reviews we went on to obtain IPD for 15,475 patients in
AAA surveillance programmes. We harmonised and combined the data from these individual patients to
obtain estimates of AAA growth and rupture rates. As expected, we identiﬁed that AAA growth and rupture
rates were related to AAA size. In this analysis we determined outcomes for men and women separately.
For men with a 3.0-cm AAA, the time taken to have a 10% chance of exceeding 5.5 cm was 7.4 years, and
for a 5.0-cm AAA the time was 0.7 years. For women these times were 6.9 years and 0.7 years. We also
assessed the time for small AAAs to exceed a 1% per annum rupture risk. In men with 3.0-cm and 5.0-cm
AAAs these times were 9.3 years and 1.4 years, respectively. The times for women were 3.5 years and
0.7 years. These data highlight the sex difference in AAA rupture rates, with women more likely to rupture at
lower AAA sizes than men, suggesting that the threshold for surgical intervention in women should be
lower than in men.
From our analysis of IPD we identiﬁed that smoking was independently associated with both accelerated
AAA growth and the risk of AAA rupture. Although all patients with AAA are routinely offered smoking
cessation therapy in the majority of clinical practices, this ﬁnding underlines the importance of instituting
measures to reduce tobacco consumption among patients with AAA and provides the most robust evidence
to date with which to counsel patients. This information is also of importance to the non-specialist NHS
practitioner, as the majority of patients with small AAAs will be managed in surveillance programmes with
little or no physician contact.
Although we identiﬁed that higher mean arterial pressure was associated with a higher risk of AAA rupture,
we were unable to demonstrate an effect of antihypertensive drugs. The appropriate use of antihypertensive
medications, with targets of 130/80 mmHg, is nevertheless important in AAA patients. Although this
strategy will require further investigation to determine any effect on rupture rates, the expected beneﬁts in
terms of overall cardiovascular mortality reduction justify its recommendation.
Our study has implications for surveillance strategies. From our IPD meta-analysis, we have demonstrated
that most of the smallest AAAs will remain quiescent over many years. This suggests that current surveillance
strategies for small AAAs could be reﬁned to reduce the number and frequency of surveillance scans
required and therefore the costs associated with AAA surveillance.
In theory the individual characteristics that inﬂuence growth or rupture rates, such as smoking and diabetes,
could be taken into account to tailor surveillance intervals for each individual. However, the effects of
such variables are not substantial enough to justify the organisational difﬁculty that such personalised
surveillance strategies would involve, despite the desire for this from patients. Similarly, AAA measurements
before the current one are informative about a person's rate of AAA growth17 and could, in principle, also be
taken into account.
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Our cost-effectiveness investigations showed that lengthening the surveillance intervals from 1 year for
3.0–4.4-cm AAAs was cost-effective, whereas lengthening the 3-month interval for 4.5–5.4-cm AAAs
was neutral with respect to cost-effectiveness. However, the differences in costs were small, up to about £4
within an overall cost of £300 per man invited to AAA screening. Also our results may be susceptible to
the detailed modelling assumptions made and parameter estimates used, and the fact that our updated
health economic model did not validate very well on the 10-year MASS trial data. Nevertheless, the
cost-effectiveness analyses support the lengthening of surveillance intervals for the smallest aneurysms,
in line with our clinical conclusions.
Research implications
From the work we have undertaken, we draw a number of conclusions about future research priorities,
as follows.
We identiﬁed that the deﬁnition and diagnostic criteria of AAA rupture were poorly reported in published
studies. There is a need for standardised deﬁnitions and reporting, so that rupture rates can be more
reliably estimated. One major hurdle to overcome is the determination of whether or not AAA rupture is
reported accurately in mortality statistics. Many sudden deaths, particularly in elderly populations who are at
the highest risk of AAA rupture, are likely to be recorded on death certiﬁcates as due to cardiac or
cerebrovascular causes, missing many cases of AAA rupture. Declining post-mortem examination rates will
contribute to the potential under-reporting of AAA-related mortality.
We demonstrated that surveillance intervals for most small aneurysms can be extended safely, with such
extension being cost-effective for the smallest aneurysms. These recommendations are based on opinions
from a single patient focus group rather than a more widespread patient preference study. Given the current
knowledge, there is a need to investigate patient preferences concerning extending surveillance intervals,
especially in the upper half of the small aneurysm diameter range where such extension could be clinically
acceptable but without cost-effectiveness beneﬁt.
We have determined that hierarchical modelling provides a methodologically appropriate framework for
analysing data on AAA growth rates and recommend that this method be used in future studies.
Based on the observation of growth rates in patients with 3.0-cm diameter aneurysms, modelling could be
conducted to indicate appropriate recall intervals for men identiﬁed as having an aortic diameter of
2.5–2.9 cm at initial aneurysm screening visit.
We observed large variation in growth rates between studies, which was largely unexplained. The
identiﬁcation of both methodological reasons, for example how AAA diameters are measured, and biological
causes for this variation are important. The latter could lead to the identiﬁcation of factors and biological
pathways related to increased growth rates or rupture rates that were amenable to intervention. Such
interventions might then be assessed in randomised trials.
We have shown that the clinical progression of an AAA is different in women compared with men, with
women at substantially higher risk of rupture. Currently women are not screened for AAAs in the UK, and
those with opportunistically detected AAAs are usually entered into generic rather than sex-speciﬁc
surveillance programmes. In addition to obtaining evidence to investigate the efﬁcacy and cost-effectiveness
of AAA screening in women, surveillance programmes and criteria for considering surgery need to be
tailored for women. Formal evaluation of a lower intervention threshold for women, either via a randomised
trial or modelling studies, is a research priority.
We have shown that increasing mean arterial blood pressure increases the risk of aneurysm rupture. There is
a need to formally evaluate whether or not reducing blood pressure to ≤130/80 mmHg would reduce the
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risk of rupture, in both small aneurysms managed in surveillance programmes and in high-risk patients with
larger aneurysms who, as part of the National Quality Improvement Programme, are being turned down for
elective aneurysm repair in increasing numbers.
The ﬁndings that age, sex and blood pressure appear to have strong associations with aneurysm rupture
but not aneurysm growth are intriguing and hint at the presence of differential mechanisms promoting
aneurysm growth and aneurysm rupture. The association of diabetes with retarded AAA growth rates
reiterates the intriguing negative association between diabetes and AAA prevalence and further exploration
of the mechanistic pathways leading to diabetes may provide insights into the pathogenesis of AAA.
Although we have provided evidence about appropriate surveillance intervals for small AAAs, we have
always used the currently accepted diameter of 5.5 cm for considering elective surgery. Related research
could aim to determine whether it is possible to develop personalised criteria or patient-speciﬁc
thresholds for elective surgery.
Comparable studies with substantial patient numbers are required for the kind of research undertaken here.
Future research should focus on the collection and use of large, well-structured and internationally
compatible data sets, along with statistical and epidemiological methods needed for their harmonisation and
analysis. For example, work is required to determine how to combine data based on different methods of
AAA size measurement. The recent inception of national AAA screening programmes in several
countries may facilitate such research.
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Appendix 1 Protocol, search strategy and list of
excluded studies for systematic review of growth of
small abdominal aortic aneurysms
1.0 Protocol
1.1 Introduction
From spring 2009, the UK National aneurysm-screening programme has been slowly launched across
England. The programme uses ultrasonography to detect and measure the diameter of abdominal aortic
aneurysms (AAAs) to reduce the number of deaths. However, the programme still needs clear policies for
their intervention and surveillance protocols. The policies, which are currently under development, will in
large depend on the growth rate (GR) and rupture rate of aneurysms. At present, large aneurysms (over
5.5 cm in diameter) are referred to elective surgery (open surgery or endovascular aneurysm repair, EVAR),
while optimal management of small aneurysms (less than 5.5 cm in diameter), which represents ca. 90 per
cent of all screen-detected AAAs,1 seems to be in favour of surveillance.2–5
A number of studies have reported on growth rates of small aneurysms and recommended the following
frequencies of follow-up examinations (Table 1). The reported growth rates of small aneurysms (3.0 cm to
3.9 cm in aortic diameter) ranged from 0.2 to 0.41 cm per year,6,7 while Santilli et al. reported a lower rate of
0.11 cm per year.8 In many cases, simple linear regression has been used to estimate growth rates. However,
this does not take into account that aneurysmal growth rate may accelerate with an increased diameter.9 In
addition, it has been reported that aneurysm growth is faster in smokers and slower in patients with
diabetes, while differences between genders are still unclear.9–13 There have been several trials, using
antibiotics and beta blockers, to reduce AAA growth (Table 2). None of these trials provide persuasive
evidence that a treatment to slow aneurysm growth has been identiﬁed, but they should provide good
quality data for aneurysm growth.
Most of these studies of aneurysm diameter surveillance have used ultrasonography for monitoring.
A few studies have used CT scanning3 or a mixture of CT scanning and ultrasonography. In some
comparative studies, the measurements recorded by CT scanning were different to those recorded by
ultrasonography.14–16 This observation will have to be accounted for in the systematic review and meta-
analyses proposed. Therefore, it will be useful to assess the mean difference between ultrasonographic and
CT diameter measurements to inform the analysis of this systematic review.
This systematic review will be made up of three elements, i.e. literature searching, summary of data, and
meta-analysis (Figure 1). Studies will also be identiﬁed for an individual patient data (IPD) meta-analysis. The
published data on GR for small AAA has not yet been synthesized nor has safe surveillance intervals been
determined, especially in women. Therefore, further to the systematic review we will aim to re-analyse all the
available individual patient data to achieve more precise estimates of growth rates and determine
probabilities of growth within different ranges of aortic diameter. This, in turn, will have an impact on the
re-screening intervals for patients with small AAAs.
1.2 Speciﬁc Aims
The aims of this study are to systematically review published and unpublished data of growth rates of small
AAA, as measured by ultrasound or a computed tomography (CT) scan.
We will focus on the following question:
l What are the growth rates of small AAAs?
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TABLE 1 Summary of follow-up data of small abdominal aortic aneurysms
Author Aortic diameter Follow-up Additional info
Santilli et al., 20028 3.0cm to 3.9cm After 3 years Male patients
McCarthy et al., 200317 3.0cm to 3.4cm At 3 years n/a
Lindholt et al., 20006 3.0cm to 3.5cm At 3 years n/a
Lindholt et al., 20006 3.5cm to 3.9cm Every other year n/a
McCarthy et al., 200317 3.5cm to 3.9cm At 1 year n/a
Lindholt et al., 20006 4.0cm Every year n/a
TABLE 2 Selection of trials to reduce AAA growth (antibiotics and beta blockers)
Author Agent Aortic expansion rate
Mosorin et al., 200118 Doxycycline Doxycycline may positively change the outcome of patients with small AAA.
Vammen et al., 200119 Roxithromycin Roxithromycin reduced the expansion rate of AAAs, in comparison to
placebo.
Baxter et al., 200220 Doxycycline Doxycycline is linked with a gradual reduction in plasma MMP-9 levels.
Additional studies are needed to determine effects of doxycycline on
aneurysm growth.
Karlsson et al., 200921 Azithromycin Azithromycin had no effect on AAA expansion.
Propranolol Aneurysm Trial
Investigators, 200222
Propranolol The agent did not signiﬁcantly affect growth rate of small AAAs.
Lindholt et al., 199923 Propranolol Only 22% of small AAA was treatable with propranolol (40mg twice a day)
for two years, in comparison to placebo. Need large-scale studies.
Titles
Abstracts
Articles
Summary of
data
Meta-analysis
Reporting 
IPD Meta-
analysis
Pers. Comm.
Unpublished data
Statistical analysis plan
Narrative
Review
Cleaning up data
Meta-analysis
if possible
1993
onwards
FIGURE 1 An outline of the strategy behind the systematic review.
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We are also interested in two related questions:
l Given a particular aneurysm diameter, what is the probability of the aneurysm growth at speciﬁed time
points (3 months, 6 months, or twelve months)?
l Which factors (size, statins, etc.) inﬂuence growth rates?
1.3 Methods
Narrative review
This protocol will be approved by a review committee in order to answer the above questions and the
protocol will be followed rigorously by the systematic reviewers (JTP, SMG). A systematic search of the
literature will be performed. Search strategies will be designed for MEDLINE, EMBASE and CENTRAL using a
combination of controlled vocabulary (MeSH or EMTREE) terms and free text terms. Clinicaltrials.gov (http://
clinicaltrials.gov), Current Controlled Trials (http://www.controlled-trials.com/) and the National Research
Register (UK) will also be searched for details of ongoing or unpublished trials.All articles between 1950
(MEDLINE) or 1980 (EMBASE) and up until 2009, which matched the inclusion and exclusion criteria (see
below), will be selected for the systematic review.
Other sources of information will also be searched:
l Reference lists of published key articles
l Books and conference notes.
l Key authors will be contacted to identify additional sources of publications/data.
The restriction on language of publications applies to English, German, French, Swedish, Danish,
and Norwegian.
IPD meta-analysis review
Same as above, except for the following:
All articles between 1993 (MEDLINE) or 1993 (EMBASE) and up until the end of 2009, which matched
the inclusion and exclusion criteria (see below), will be selected for the IPD meta-analysis. The IPD reviews will
be limited by data availability and age of study (e.g. a 15 year cut off for paper inclusion because older
papers are unlikely to provide us with IPD information).
1.4 Study Selection
The exclusion criteria (see below) will be applied to all the accumulated sources of information, such as
peer-reviewed articles, conference notes, books, and unpublished data. The initial rejection or inclusion will
be based on the study title. However, if the study title is obscure, the abstract will be reviewed. In cases
where abstracts are unavailable or inconclusive, the full article will be acquired and reviewed.
Exclusion criteria:
l Review articles.
l Editorials.
l Letters.
l Case reports.
l Studies where patient data have been duplicated.
l Non-human studies (animal, in-vitro, post-mortem).
l Less than 100 patients.
Full text-versions of the selected shortlist of documents will be obtained. The two reviewers (JTP, SMG) will
individually assess them to make sure that they adhere to the initial eligibility criteria. The two reviewers will
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then individually select studies that meet the inclusion criteria (see below). If an agreement cannot be
reached, a third author (LCB) will cast the deciding vote.
The inclusion criteria will be as follows:
l Men or women ≥ 50 years of age.
l All ethnic groups.
l Studies must include participants with a baseline infrarenal AAA (from 3.0 to < 6.0 cm in diameter).
l Studies must include 500-patient years of observation for small aneurysms (IPD).
l For studies reporting duplicated patient data, the most recent or most comprehensive publication will
be included.
l Serial ultrasound or CT scans (with size assessed on at least two occasions separated by at
least 6 months).
We will focus on retrieving additional information from studies with more than 500-patient years. All studies
will be included in the narrative review.
1.5 Data Extraction and Quality Scoring
A data extraction form or a scoring system, which identiﬁes technical details, patient characteristics and
potential biases etc., in the selected documents, will be designed independently by the reviewers (JTP, SMG).
Any disagreement will be resolved by a third person (LCB). The results of the checklist will be summarised
for each study and any study publication that fails to provide sufﬁcient details will be either rejected or the
study authors will be contacted for completion of the checklist. The demographic details (age, gender,
ethnicity, cigarette smoking status) will also be described. Any study in which authors who does not respond
to the reviewer's repeated correspondence for essential information will be withdrawn from the selected
shortlist of documents.
Criteria for quality control are as follows:
l Prospective/retrospective.
l Source: population screening versus hospital.
l Consecutive patients entered.
l Deﬁned surveillance policy.
l Deﬁned intervention policy.
l Description of outcomes how growth was ascertained, points of censorship (e.g. rupture, aneurysm
repair and death) and how the study was evaluated (multiple, blinded, observation).
l Reporting methods: graphic, descriptive, tables, statistical uncertainty.
Other data to be extracted:
l Heterogeneity (men versus women; chronological time; country).
l Description of baseline characteristics (speciﬁcally; age, sex, ethnicity, smoking status, diabetes).
1.6 Data synthesis and analysis
Narrative review
The data synthesis will summarise the extracted data of the included and eligible studies. All the relevant
information (e.g. intervention, population, outcomes) will be tabulated. The ineligible studies will also be
tabulated (giving reasons for exclusion).
Studies will present their results in many different ways, and so a semi-quantitative review is the most feasible
option. For example, some studies present mean growth rate whilst others present the probability of
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exceeding a certain threshold within a speciﬁed time period. The nature in which the outcome is reported
together with the statistical analysis used to calculate growth rates will be tabulated for each study.
If feasible, an estimate of the average growth rate (mm/year) together with its standard error will be
extracted from each study. Where 95% conﬁdence intervals are quoted in place of standard errors, these will
be converted by assuming normality and using the formula SE = (UCL–LCL)/3.92, where UCL and LCL are the
upper and lower limits of the 95% conﬁdence interval.24
If a sample standard deviation and the number of patients is quoted then this will be converted to a
standard error of the mean using the formula SE = SD /sqrt(n). If a 95% reference range is quoted, then this will
ﬁrst be converted to a standard deviation using the formula SD = (URR–LRR)/3.92, where URR and LRR are the
upper and lower limits of the 95% reference range, and then to a standard error of the mean as above.
A random-effects meta-analysis will be conducted on the rate scale (or on the log rate scale with standard
errors transformed using the delta method) using the method of DerSimonian and Laird.25 Heterogeneity will
be assessed using the I2 statistic. Further exploration of between study heterogeneity will be investigated
using meta-regression, for example using the mean baseline diameter as a study level covariate. Results will
be presented with forest plots, and small study/ publication bias investigated using funnel plots.
IPD review
For studies that provide individual patient data the analysis of growth rates will proceed as follows. Linear
random-effects models will be ﬁt to the IPD data allowing for a random baseline diameter and growth
rate for each individual in a study. To synthesise the evidence, if feasible, a three-level hierarchical model will
be used, with levels for study, individual, and observation. The mean pooled growth rate can be estimated
and predictions about the probability of crossing the 55mm threshold can be made for a number of
baseline diameters at different time points following screening. If a three-level model is not feasible then a
two-stage approach will be implemented where the estimated mean baseline diameter and growth rate from
each study will be synthesised using a bivariate meta-analysis to allow for the correlated outcomes.
Variables that may affect growth rates will be investigated by entering them into the growth model as
covariates. However, such analyses may be considered secondary since covariate information will not be
available from all studies.
2.0 Search strategy for systematic review of growth rates of small abdominal
aortic aneurysms
Database: Ovid MEDLINE(R) <1950 to September Week 4 2009>
Search Strategy:
1. Aortic Aneurysm, Abdominal/ (9934)
2. Aortic Rupture/ (6705)
3. ((abdominal or aort$) adj5 aneurysm?).ti,ab. (21792)
4. AAA.ti,ab. (5659)
5. or/1-4 (29273)
6. di.fs. (1607182)
7. ra.fs. (507926)
8. us.fs. (148151)
9. or/6-8 (2132304)
10. exp Ultrasonography/ (198667)
11. Mass Screening/ (65350)
12. Aortography/ (9130)
13. Angiography/ (48487)
14. exp Tomography/ (450036)
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15. (survei$ or screen$ re-screen$ or rescreen$ or monitor$ or scan$ or ultrasound or ultra-sound or CT or
angiography or ultrasonograph$).ti,ab. (919931)
16. or/10-15 (1401499)
17. 5 and (9 or 16) (13876)
18. (grow$ or expan$ or diameter? or ruptur$ or size?).ti,ab. (1556989)
19. 17 and 18 (5589)
Database: EMBASE <1980 to 2009 Week 51>
Search Strategy:
1. exp abdominal aorta aneurysm/ (9971)
2. exp aorta rupture/ (2109)
3. exp aneurysm rupture/ (6116)
4. ((abdominal or aort$) adj5 aneurysm?).ti,ab. (16134)
5. or/1-4 (23719)
6. di.fs. (1441356)
7. dm.fs. (92679)
8. exp echography/ (252641)
9. screening/ or mass screening/ (47280)
10. disease surveillance/ (2250)
11. exp angiography/ (139893)
12. exp tomography/ (344103)
13. ultrasound/ (40545)
14. (survei$ or screen$ or re-screen$ or rescreen$ or monitor$ or scan$ or ultrasound or ultra-sound or CT or
angiography or ultrasonograph$).ti,ab. (1029589)
15. or/6-14 (2426670)
16. 5 and 15 (13915)
17. (grow$ or expan$ or diameter? or ruptur$ or size?).ti,ab. (1264858)
18. 16 and 17 (6819)
CENTRAL Issue 3, 2009
#1 MeSH descriptor Aortic Aneurysm, Abdominal explode all trees 499
#2 MeSH descriptor Aortic Rupture explode all trees 83
#3 ((abdominal or aort*) near aneurysm*) 872
#4 (AAA) 327
#5 (#1 OR #2 OR #3 OR #4) 984
#6 MeSH descriptor Ultrasonography explode all trees 5740
#7 MeSH descriptor Mass Screening explode all trees 4314
#8 MeSH descriptor Aortography explode all trees 94
#9 MeSH descriptor Angiography explode all trees 4680
#10 MeSH descriptor Tomography explode all trees 7584
#11 (survei* or screen* re-screen* or rescreen* or monitor* or scan* or ultrasound or ultra-sound or CT or
angiography or ultrasonograph*)
81185
#12 (#6 OR #7 OR #8 OR #9 OR #10 OR #11) 89654
#13 (grow* or expan* or diameter* or ruptur* or size*) 51035
#14 (#5 AND #12) 377
#15 (#13 AND #14) 190
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Clinical Trials Registers
ClinicalTrials.gov and Current Controlled Trials – search term “abdominal aortic aneurysm” or AAA.
3.0 List of studies excluded from systematic review of growth rate of small
abdominal aortic aneurysms
Study Title First author Journal/Year
Reasons for
exclusion
(1) AAA in high-risk patients. Outcome of selective
management based on size and expansion rate.
Bernstein, E.F. Ann Surg 1984 3
(2) Actuarial analysis of variables associated with
rupture of small AAAs.
Cronenwett, J.L. Surgery1985 3, 7
(3) How Fast do Very Small AAAs Grow. Collin, J. Eur J Vasc Surg
1989
2, 3, 7
(4) Prognosis of AAAs. A population-Based Study. Nevitt, M.P. N Engl J Med 1989 3
(5) Wachstumskurven von
Bauchaortenaneurysmen.
Kremer, H. Bildgebung/
Imaging 1989
1, 2
(6) The Natural History of Small AAAs: an US study. Walsh, A.K.M. Eur J Vasc Surg
1990
3, 7
(7) Natural History of Patients with AAA. Glimaker, H. Eur J Vasc Surg
1991
3, 4
(8) Growth rates of subclinical AAAs – implications
for review and rescreening programmes.
Collin, J. Eur J Vasc Surg
1991
3
(9) The Natural History of AAAs. Guirguis, E.M. Am J Surg 1991 3, 7
(10) Determination of the expansion rate and
incidence of rupture of AAA.
Limet, R. J Vasc Surg 1991 3, 6
(11) The Spontaneous Course of Small AAAs.
Aneurysmal Growth Rates and Life Expectancy.
Zollner, Z. Klin Wochenschr
1991
7
(12) Aortic Aneurysms: Growth Rates Measured
with CT.
Hirose, Y. Radiology 1992 8
(13) The selective management of small AAA: The
Kingston Study.
Brown, P.M. J Vasc Surg 1992 2
(14) Expansion pattern and risk of rupture of AAA
that were not operated on.
Bengtsson, H. Eur J Surg 1993 3, 7
(15) Morphology of small aneurysms: deﬁnition and
impact on risk of rupture.
Faggioli, G.L. Am J Surg 1994 3, 4
(16) A statistical analysis of the growth of small
AAAs.
Grimshaw, G.M. Eur J Vasc Surg
1994
3, 4
(17) Screening for AAA. Law, M.R. J Vasc Surg 1994 9
(18) AAA expansion rate: Effect of size and beta-
adrenergic blockade.
Gadowski, G.R. J Vasc Surg 1994 3, 5, 6
(19) Selective management of AAAs in a prospective
measurement program.
Brown, P.M J Vasc Surg 1996 2
(20) A prospective study to deﬁne the optimum
rescreening interval for small AAA.
Cook, T.A. CardiovascSurg
1996
2, 4
(21) Growth Rate of Infrarenal Aortic Aneurysms. Stonebridge, P.A. Eur J Vasc Endovasc
Surg 1996
2
(22) What is the Long-term Outcome for Patients
With Very Small AAAs.
Watson, C.J.E. Eur J Vasc Endovasc
Surg 1997
3, 7
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Study Title First author Journal/Year
Reasons for
exclusion
(23) Expansion rates of small AAAs. Englund, R. Aust N Z J Surg
1998
6, 7
(24) Mortality results for randomised controlled trials
of early elective surgery or ultrasonographic
surveillance for small AAAs.
UK Small Aneurysm
Trial Participants
Lancet 1998 2
(25) AAA Wall Mechanics and their relation to Risk
of Rupture.
Sonesson, B. Eur J Vasc Endovasc
Surg 1999
4, 7
(26) The relationship between AAA wall
compliance, maximum diameter and growth
rate.
Wilson, K. Cardiovasc Surg
1999
2, 3
(27) Watchful waiting in cases of small AAAs -
appropriate for all patients?
Valentine, R.J. J Vasc Surg 2000 3, 4
(28) Optimal interval screening and observation of
AAAs.
Lindholt, J.S. Ugeskr Laeger
2001
2
(29) The incidence of Small AAAs and the Change in
Normal Infrarenal Aortic Diameter: Implications
for Screening.
Wilmink, A.B.M. Eur J Vasc Endovasc
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Appendix 2 Protocol, search strategy and list of
excluded studies for systematic review of rupture of
small abdominal aortic aneurysms
1.0 Protocol
1.1 Introduction
From spring 2009, the UK National aneurysm screening programme has been slowly launched across
England. The programme uses ultrasonography to detect and measure the diameter of abdominal aortic
aneurysms (AAAs) to reduce the number of deaths. However, the programme still needs clear policies for
their intervention and surveillance protocols. The policies, which are currently under development, will in
large depend on the rupture rate (RR) and growth rate of aneurysms. At present, large aneurysms (over
5.5 cm in diameter) are referred to elective surgery (open surgery or endovascular aneurysm repair, EVAR),
while optimal management of small aneurysms (less than 5.5 cm in diameter), which represents ca. 90 per
cent of all screen-detected AAAs,1 seems to be in favour of surveillance. Three trials showed that survival in
patients with small AAAs is not signiﬁcantly improved by elective surgery,2–4 while other trials focused on
whether early endovascular repair offer a survival beneﬁt to patients with small AAAs.5,6 Thus, there are a
number of published trials that investigated rupture rates and growth rates of both large and small
aneurysms. The consensus is that aneurysms, which are 4.0–5.5 cm in diameter, have a RR of 1% per annum
or less,2,7 while smaller aneurysms have an even lower RR.8
This systematic review will be made up of three elements, i.e. literature searching, summary of data, and
meta-analysis (Figure 1). Studies will also be identiﬁed for an IPD meta-analysis. The published data on RR has
not yet been synthesised nor has safe surveillance intervals been determined. Therefore, further to the
systematic review we will aim to re-analyse all the available individual patient data to achieve more precise
estimates of rupture rates and determine probabilities of rupture within different ranges of aortic diameter.
This, in turn, will have an impact on the re-screening intervals for patients with small AAAs.
1.2 Speciﬁc Aims
The aims of this study are to systematically review published and unpublished data of rupture rates of small
AAA, as measured by ultrasound or a computed tomography (CT) scan.
We will focus on the following question:
l What are the rupture rates of small AAAs?
We are also interested in two related questions:
l Given a particular aneurysm diameter, what is the probability of the aneurysm rupturing before the next
scan appointment if it is timed, for example, at 3 months, 6 months, or a year?
l What factors (size, etc.) inﬂuences rupture rates?
1.3 Methods
Narrative review
This protocol will be approved by a review committee in order to answer the above questions and the
protocol will be followed rigorously by the systematic reviewers (JTP, SMG). Initially, a systematic search of
the literature will be performed using databases, such as MEDLINE, EMBASE, Clinicaltrials.gov and Controlled
Clinical Trials (including archived registers). In addition, an optimised search strategy will be generated for
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each database. All articles between 1950 (MEDLINE) or 1980 (EMBASE) and up until 2009, which matched
the inclusion and exclusion criteria (see below), will be selected for the systematic review.
Other sources of information will also be searched:
l Reference lists of published key articles.
l Books and conference notes.
l Key authors will be contacted to identify additional sources of publications/data.
The restriction on language of publications applies to English, German, French, Swedish, Danish,
and Norwegian.
IPD meta-analysis review
Same as above, except for the following:
All articles between 1993 (MEDLINE) or 1993 (EMBASE) and up until the end of 2009, which matched the
inclusion and exclusion criteria (see below), will be selected for the IPD meta-analysis.
1.4 Study Selection
The exclusion criteria (see below) will be applied to all the accumulated sources of information, such as
peer-reviewed articles, conference notes, books, and unpublished data. The initial rejection or inclusion will
be based on the study title. However, if the study title is obscure, the abstract will be reviewed. In cases
where abstracts are unavailable or inconclusive, the full article will be acquired and reviewed.
Exclusion criteria:
l Review articles.
l Editorials.
l Letters.
l Case reports.
l Studies where patient data have been duplicated.
l Non-human studies (animal, in-vitro, post-mortem).
Full text-versions of the selected shortlist of documents will be obtained. The two reviewers (JTP, SMG) will
individually assess them to make sure that they adhere to the initial eligibility criteria. The two reviewers will
Titles
Abstracts
Articles
Summary of
data
Meta-analysis
Reporting 
IPD Meta-
analysis
Pers. Comm.
Unpublished data
Statistical analysis plan
Narrative
Review
Cleaning up data
Meta-analysis
if possible
1993
onwards
FIGURE 1 An outline of the strategy behind the systematic review.
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then individually select studies that meet the inclusion criteria (see below). If an agreement cannot be
reached, a third author (LCB) will cast the deciding vote.
The inclusion criteria will be as follows:
l Men or women ≥ 50 years of age.
l All ethnic groups.
l Studies must include participants with a baseline infrarenal AAA (from 3.0 to < 6.0 cm in diameter).
l All papers on rupture will be retrieved to include low rupture rates. Instead of minimum rupture number,
we will focus on 500 patient-years of observation for small aneurysms for collecting IPD data. Papers
reporting on aneurysms of all sizes, including mainly those > 5.5 cm and having < 10 ruptures will
be excluded.
l For studies reporting duplicated patient data, the most recent or most comprehensive publication will
be included.
We will focus on retrieving additional information from studies with more than 500-patient years. All studies
will be included in the narrative review.
1.5 Data Extraction and Quality Scoring
A data extraction form or a scoring system, which identiﬁes technical details, patient characteristics and
potential biases etc., in the selected documents, will be designed independently by the reviewers (JTP, SMG).
Any disagreement will be resolved by a third person (LCB). The results of the checklist will be summarised
for each study and any studies that fail to provide all details will be either rejected or the study authors
will be contacted for completion of the checklist. The demographic details (age, gender, ethnicity, cigarette
smoking status) will also be described. Any study authors who does not respond to the reviewer's
repeated correspondence will be withdrawn from the selected shortlist of documents.
Criteria for quality control are as follows:
l Prospective/retrospective.
l Source: population screening versus hospital.
l Consecutive patients entered.
l Deﬁned surveillance policy: patients must be monitored at least annually (protocol or attendance) for
aortic diameter by ultrasound or CT scan.
l Deﬁned intervention policy.
l Description of outcomes (how ruptures was ascertained) and how the study was evaluated (multiple,
blinded, observation). Ruptures must have occurred within 15 months of the previous measurement of
aortic diameter.
l Reporting methods: graphic, descriptive, tables, statistical uncertainty.
Other data to be extracted:
l Heterogeneity (men versus women; chronological time; country).
l Description of baseline characteristics (speciﬁcally; age, sex, smoking status, diabetes).
1.6 Data synthesis and analysis
Narrative review
The data synthesis will summarise the extracted data of the included and eligible studies. All the relevant
information (e.g. number of ruptures, prophylactic interventions, population, outcomes) will be tabulated.
The ineligible studies will also be tabulated (giving reasons for exclusion). The way in which the outcome is
reported together with the statistical analysis used to calculate rupture rates will be tabulated for each study.
If feasible, an estimate of the rupture rate (ruptures per person-year) will be calculated from each study by
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extracting the number of reported ruptures and person-years of follow-up. An ideal study would calculate
length of follow-up by censoring individuals at death, aneurysm repair, or when the aneurysm becomes too
large (> 54mm or lower diameter e.g. 50 mm if relevant). We will describe the censoring mechanism for
each study from which rupture rate data have been extracted.
The standard error of a log rate estimate will be calculated using the formula
seðlogðrupture rateÞÞ¼
ﬃﬃﬃﬃﬃﬃﬃﬃ
1=d
p
,
where d is the number of observed ruptures for that study.
A random-effects meta-analysis will be conducted on the log rate scale using the method of DerSimonian
and Laird.9 Heterogeneity will be assessed using the I2 statistic. Further exploration of between study
heterogeneity will be investigated using meta-regression, for example using the mean baseline diameter as a
study level covariate. Results will be presented with Forest plots, and small study/publication bias investigated
using funnel plots.
IPD review
For studies that provide individual patient data on both the rupture and growth of aneurysms, the analysis
will proceed as follows. A joint longitudinal and survival model will be ﬁt to the IPD data for each study
to allow the relationship between the underlying AAA diameter and rate of rupture to be modelled.
A joint model avoids the problem of using AAA diameter as a time-dependent covariate in a survival model,
which can be problematic if AAA diameters are measured infrequently since an effect of diameter on
hazard of rupture may be attenuated. Instead, the growth of the aneurysm is modelled for each individual
and the estimated size at the time of rupture/censoring event is related to the hazard of rupture.
To synthesise the evidence, a two-stage approach is probably the most feasible approach. To extract
estimates of the baseline hazard, parametric survival models will be considered. The suitability of a
parametric model will be assessed by plotting log(– log(S(t))) against log t, where S(t) is estimated
non-parametrically. A straight line suggests that a Weibull model is appropriate, whilst a straight line with
gradient 1 suggests that an Exponential model is feasible. For a parametric survival model, estimates of
the baseline hazard of rupture, and the log hazard ratio can be extracted from the joint model for each study.
A multivariate random-effects meta-analysis of the model parameters can then be performed to obtain a
pooled baseline hazard and log hazard ratio. Heterogeneity will be assessed, and results presented using
forest plots.
2.0 Search strategy
Database: Ovid MEDLINE(R) <1950 to December Week 4 2009>
Search Strategy:
1. Aortic Aneurysm, Abdominal/ (9934)
2. Aortic Rupture/ (6705)
3. ((abdominal or aort$) adj5 aneurysm?).ti,ab. (21792)
4. AAA.ti,ab. (5659)
5. or/1-4 (29273)
6. di.fs. (1607182)
7. ra.fs. (507926)
8. us.fs. (148151)
9. or/6-8 (2132304)
10. exp Ultrasonography/ (198667)
11. Mass Screening/ (65350)
12. Aortography/ (9130)
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13. Angiography/ (48487)
14. exp Tomography/ (450036)
15. (survei$ or screen$ re-screen$ or rescreen$ or monitor$ or scan$ or ultrasound or ultra-sound or CT or
angiography or ultrasonograph$).ti,ab. (919931)
16. or/10-15 (1401499)
17. 5 and (9 or 16) (13876)
18. (grow$ or expan$ or diameter? or ruptur$ or size?).ti,ab. (1556989)
19. 17 and 18 (5589)
Database: EMBASE <1980 to 2009 Week 51>
Search Strategy:
1. exp abdominal aorta aneurysm/ (9971)
2. exp aorta rupture/ (2109)
3. exp aneurysm rupture/ (6116)
4. ((abdominal or aort$) adj5 aneurysm?).ti,ab. (16134)
5. or/1-4 (23719)
6. di.fs. (1441356)
7. dm.fs. (92679)
8. exp echography/ (252641)
9. screening/ or mass screening/ (47280)
10. disease surveillance/ (2250)
11. exp angiography/ (139893)
12. exp tomography/ (344103)
13. ultrasound/ (40545)
14. (survei$ or screen$ or re-screen$ or rescreen$ or monitor$ or scan$ or ultrasound or ultra-sound or CT or
angiography or ultrasonograph$).ti,ab. (1029589)
15. or/6-14 (2426670)
16. 5 and 15 (13915)
17. (grow$ or expan$ or diameter? or ruptur$ or size?).ti,ab. (1264858)
18. 16 and 17 (6819)
CENTRAL Issue 3, 2009
#1 MeSH descriptor Aortic Aneurysm, Abdominal explode all trees 499
#2 MeSH descriptor Aortic Rupture explode all trees 83
#3 ((abdominal or aort*) near aneurysm*) 872
#4 (AAA) 327
#5 (#1 OR #2 OR #3 OR #4) 984
#6 MeSH descriptor Ultrasonography explode all trees 5740
#7 MeSH descriptor Mass Screening explode all trees 4314
#8 MeSH descriptor Aortography explode all trees 94
#9 MeSH descriptor Angiography explode all trees 4680
#10 MeSH descriptor Tomography explode all trees 7584
#11 (survei* or screen* re-screen* or rescreen* or monitor* or scan* or ultrasound or ultra-sound or CT or
angiography or ultrasonograph*)
81185
#12 (#6 OR #7 OR #8 OR #9 OR #10 OR #11) 89654
#13 (grow* or expan* or diameter* or ruptur* or size*) 51035
#14 (#5 AND #12) 377
#15 (#13 AND #14) 190
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Clinical Trials Registers
ClinicalTrials.gov and Current Controlled Trials – search term “abdominal aortic aneurysm” or AAA.
3.0 List of studies excluded from systematic review of rupture of small
abdominal aortic aneurysms
Study Title First author Journal/Year
Reasons
for
exclusion
(1) Abdominal Aortic Aneurysms. A Reappraisal. Schatz, I.L. Circulation 1962 4,7
(2) Contribution of Abdominal Aortic
Aneurysmectomy to Prolongation of Life.
Szilagyi, D.E. Ann Surg 1996 4,5
(3) The Unoperated Abdominal Aortic Aneurysm. Klippel, A.P. Am J Surg 1966 7,8
(4) Comparative study of elective resection and
expectant treatment of abdominal aortic aneurysm.
Foster, J.H. Surg Gyn Obs 1969 4
(5) Results of surgical versus non-surgical treatment of
Abdominal Aortic Aneurysm.
Stanford, J.R. Vasc Surg 1978 4,7
(6) Das infrarenale Bauchaorten-Aneurysma. Klinik,
Therapie, und Langzeitprognose.
Ruckert, R.F. Schweiz Med Wschr
1981
1,4
(7) Abdominal aortic aneurysms: The changing
natural history.
Bickerstaff, L.K. J Vasc Surg 1984 4
(8) Sonographische Verlaufsbeobachtungen von
Bauchaortenaneurysmen.
Kremer, H. Klin Wschr 1984 1,8
(9) Abdominal Aortic Aneurysm in High-Risk Patients.
Outcome of Selective Management Based on Size
and Expansion Rate.
Bernstein, E.F. Ann Surg 1984 4
(10) Abdominal Aortic Aneurysm in Elderly Patients.
Selective Management Based on Clinical Status and
Aneurysmal Expansion Rate.
Sterpetti, A.V. Am J Surg 1985 4,6
(11) Wachtumskurven von Bauchaortenaneurysmen Kremer, H. Bildgebung 1989 1
(12) Determination of the expansion rate and incidence
of rupture.
Limet, R. J Vasc Surg 1991 5,6
(13) Abdominal Aortic Aneurysm in High-Risk Patients.
Outcome of Selective Management Based on Size
and Expansion Rate.
Bengtsson, H. Eur J Surg 1993 3,7
(14) Morphology of small aneurysms: deﬁnition and
impact on Risk of Rupture.
Faggioli, G.L. Am J Surg 1994 4
(15) Abdominal aortic aneurysm expansion rate: Effect
of size and beta-adrenergic blockade.
Gadowski, G.R. J Vasc Surg 1994 6,7
(16) Screening for abdominal aortic aneurysms. Law, M.R. J Med Screen 1994 3
(17) Inﬂuence of Selective Management on the
Prognosis and the Risk of Rupture of Abdominal
Aortic-Aneurysms.
Schewe, C.K. ClinicalInvestigator
1994
4
(18) The cost-effectiveness of early surgery versus
watchful waiting in the management of small
abdominal aortic aneurysms.
Katz, D.A. J Vasc Surg 1994 3
(19) Actuarial analysis of variables associated with
rupture of small abdominal aortic aneurysms.
Cronenwett, J.L. Surgery 1995 7
(20) Inﬂuence of screening on the incidence of ruptured
abdominal aortic aneurysm: 5-year results of a
randomized controlled study.
Scott, R.A.P. Br J Surg 1995 2
APPENDIX 2
110
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Study Title First author Journal/Year
Reasons
for
exclusion
(21) Selective management of abdominal aortic
aneurysms in a prospective measurement program.
Brown, P.M. J Vasc Surg 1996 2
(22) Growth rates and risk of rupture of abdominal
aortic aneurysms.
Vardulaki, K.A. J Vasc Surg 1996 3
(23) Abdominal aortic aneurysm rupture rates: A 7-year
follow-up of the entire abdominal aortic aneurysm
population detected by screening.
Scott, R.A.P. J Vasc Surg 1998 2
(24) The inﬂuence of screening on the incidence of
ruptured abdominal aortic aneurysms.
Wilmink, A.B.M. J Vasc Surg 1999 4
(25) Quantitative Evaluation of Abdominal Aortic
Aneurysm.
Kanaoka, Y. Vasc Surg 1999 4, 7
(26) Abdominal Aortic Aneurysm Wall Mechanics and
their Relation to Risk of Rupture.
Sonesson, B. EJVES 1999 4
(27) In vivo analysis of mechanical wall stress and
abdominal aortic aneurysm rupture risk.
Fillinger, M.F. J Vasc Surg 2002 4,7
(28) Randomized clinical trial of screening for abdominal
aortic aneurysm in women.
Scott, R.A.P. Br J Surg 2002 4
(29) Long-term outcomes of immediate repair
compared with surveillance of small abdominal
aortic aneurysms.
Brady, A.R. N Engl J Med 2002 2,7
(30) The relationship between aortic wall distensibility
and rupture of infrarenal abdominal aortic
aneurysm.
Biancari, F.B. Am J Surg 2002 6,8
(31) Follow-up of small aneurysms in the infrarenal
abdominal aorta.
Barba-Vellez, L. Angiologia 2002 2
(32) Ten-year outcome of patients with very small
abdominal aortic aneurysm.
Wilson, K.A. J Vasc Surg 2002 4
(33) Four-year follow-up of patients with untreated
abdominal aortic aneurysms.
Aziz, M. ANZ J Surg 2004 7
(34) Fifteen-year follow-up of a randomized clinical
trial of ultrasonographic screening for abdominal
aortic aneurysms.
Ashton, H.A. Br J Surg 2007 3,4
(35) Abdominal Aortic Aneurysms, Increasing Infrarenal
Aortic Diameter, and Risk of Total Mortality and
Incident Cardiovascular Disease Events. 10-Year
Follow-Up Data From the Cardiovascular Health
Study.
Freiberg, M.S. Circulation 2008 4,5
(36) Activated protein C-protein C inhibitor complex in
Patients With Abdominal Aortic Aneurysms: Is it
Associated With Diameter and Growth Rate.
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Study Title First author Journal/Year
Reasons
for
exclusion
(39) Abdominal Aortic Aneurysm Development in Men
Following a “normal” Aortic Ultrasound Scan.
Hafez, H. EJVES 2008 4
(40) The effect of azithromycin and Chlamydophilia
pneumonia infection on expansion of small
abdominal aortic aneurysms – A prospective
randomized double-blind trial.
Karlsson, L. J Vasc Surg 2009 4
The reasons for exclusion are: 1. Language; 2. Duplicated data/patients; 3. Modelling, no original data; 4. Incidence of
rupture only, rates not available; 5. Inaccurate diagnostic criteria of either aneurysm size or rupture; 6. Patient selection
bias; 7. Ruptures in incorrect size range; 8. Small studies (< 50 patients collected over a long period of time)
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Appendix 3 Statistical methods and excluded
studies for individual patient data meta-analysis
Statistical methods
Growth
For each study separately, the AAA diameter for patient i at time t, yi(t), is modelled using a linear
random-effects growth model:
yiðtÞ¼b0iþb1i tþεiðtÞ
ðb0i, b1iÞT∼N2ððβ0, β1ÞT , ΣÞ
εiðtÞ∼Nð0, σ2wÞ
Σ¼ σ
2
0 ρσ0σ1
ρσ0σ1 σ21
 
;
ð1Þ
where b0i and b1i are the random intercept and slope, respectively, for patient i. The random effects have mean β0
and β1 and variance–covariance matrix Σ, and εi(t) is the residual error term. The time origin (t= 0) is deﬁned as the
time of the baseline measurement for each individual (ﬁrst measurement recorded between 3.0 and 5.4 cm).
Given this model, the expected growth rate, b1, for an individual with a single diameter measurement u
taken at baseline, can be expressed as follows:
E½b1jyð0Þ¼u¼β1þ
ρσ0σ1
σ20 þ σ2w
ðu−β0Þ: ð2Þ
Bayesian Markov chain Monte Carlo (MCMC) methods are used to ﬁt the model to each data set. The
median, SD, and 2.5th and 97.5th percentiles of the posterior distribution are then obtained for the expected
growth rate given baseline diameter u, using Equation 2.
A random-effects meta-analysis is then conducted in a second stage using the growth rates obtained from
each study and separately for each possible millimetre increase in baseline diameter from 3.0 to 5.4 cm.
Speciﬁcally, let xk(u) be the posterior median estimate of growth for study k given baseline diameter u and
sk(u) the corresponding posterior SD. Then the random-effects meta-analysis model is:
xkðuÞ∼NðθkðuÞ, skðuÞÞ
θkðuÞ∼NðɸðuÞ, τ2ðuÞÞ ; ð3Þ
where τ2(u) is the between-study heterogeneity variance and ɸ(u) is the overall pooled effect for baseline
diameter u.
The estimated time after baseline for which there is a 10% chance of crossing the threshold for surgery
(5.5 cm) is calculated as follows. First, the expected AAA diameter at time t is μy(t) = β0+β1t, the variance is
vy(t) = σ02+t2σ12+2tρσ0σ1+σw2, and the covariance between a measurement taken at time t > 0 and one taken
at baseline (on the same individual) is cy(t) = σ02+tρσ0σ1. Using these results, the expected AAA diameter at
time t given a single diameter measurement u taken at baseline is:
μyjyð0Þ¼uðtÞ¼μyðtÞþ
cyðtÞ
vyð0Þ ðu−μyð0ÞÞ; ð4Þ
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using the properties of a bivariate normal distribution, and the variance of the measurement at t given baseline
diameter u is:
vyjyð0Þ¼uðtÞ¼vyðtÞ−
cyðtÞ2
vyð0Þ : ð5Þ
Hence, the probability of a measurement at time t being over the threshold for surgery (5.5 cm) given baseline
diameter u can be found from the tail area of a Gaussian distribution, as follows:
PT ðtjyð0Þ¼uÞ¼1−Φ
5:5−μyjyð0Þ¼uðtÞﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
vyjyð0Þ¼uðtÞ
p
 !
; ð6Þ
where Φ is the standard normal cumulative distribution function. The probability in Equation 6 is calculated
repeatedly over a ﬁne grid of times for different baseline diameters. The chosen grid is shown in Table 26 and is
dependent on the baseline diameter:
For each grid time, the median, 2.5th and 97.5th percentiles of the posterior distribution for PT are obtained.
Since quantiles are invariant to one-to-one transformations, the posterior median time at which there is a
10% chance of being over the threshold is the grid time at which the posterior median probability is closest
to 0.10. Similarly, the posterior 95% credibility range are the grid times where the 2.5th and 97.5th
percentiles are closest to 0.10.
To obtain pooled estimates from a random-effects meta-analysis, the log of the posterior median time is used
as the effect estimate, whose SE on the log-scale is approximated as:
s≈
ðlogðt97:5Þ−logðt50ÞÞ
1:96
; ð7Þ
where t50 and t97.5 are the posterior median and 97.5th percentile of time. A random-effects meta-analysis is
then conducted using the log-estimate of time and its SE separately for the baseline diameters 3.0, 3.5, 4.0,
4.5 and 5.0 cm as speciﬁed in Equation 3.
TABLE 26 Grid of times used for calculating the probability of a AAA measurement being >5.5cm
Baseline
diameter (cm) Grid of times to search over
3.0 200 equally spaced times starting at 4 years, ending at 20 years (approximate grid spacings of 1 month)
3.5 200 equally spaced times starting at 3 years, ending at 10 years (approximate grid spacings of 1/2 month)
4.0 200 equally spaced times starting at 2 years, ending at 6 years (approximate grid spacings of 1/4 month)
4.5 200 equally spaced times starting at 1 year, ending at 4 years (approximate grid spacings of 1/6 month)
5.0 200 equally spaced times starting at 0 years, ending at 2 years (approximate grid spacings of 1/8 month)
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Rupture
A joint model for the longitudinal (growth) and time-to-event (rupture) processes is used to estimate the
rupture rate conditional on baseline diameter. The model is as follows:
Longitudinal process
yiðtÞ¼b0iþb1i tþεiðtÞ¼miðtÞþεiðtÞ
ðb0i, b1iÞT∼N2ððβ0, β1ÞT , ΣÞ
εiðtÞ∼Nð0, σ2wÞ
Σ¼ σ
2
0 ρσ0σ1
ρσ0σ1 σ21
 
Time-to-event process
hiðtÞ¼expðγþαmiðtÞÞ
;
ð8Þ
where the longitudinal process is as speciﬁed previously in Equation 1, and the time-to-event process is
deﬁned by the hazard of rupture hi(t) for patient i at time t. The association parameter, α, is the log-hazard
ratio for the effect of an underlying diameter on risk of rupture, whereas γ is the baseline log-hazard.
The hazard of rupture at baseline given baseline diameter u is therefore calculated as:
hð0jyð0Þ¼uÞ¼expðγþαuÞ: ð9Þ
Bayesian MCMC methods are used to ﬁt the model and to obtain the median, SD, 2.5th and 97.5th
percentiles of the posterior distribution of the hazard (see Equation 9) and log-hazard for each millimetre
diameter from 3.0 cm to 5.4 cm. The posterior median log-hazard and its SD are extracted from each study
and combined in a random-effects meta-analysis as described in Equation 3.
Given baseline diameter, u, the predicted hazard, cumulative hazard and survival functions at time t> 0 are:
hðtjyð0Þ¼uÞ¼expðγþαμyjyð0Þ¼uðtÞÞ
Hðtjyð0Þ¼uÞ¼ ∂μyjyð0Þ¼uðtÞ
∂t
 −1
ðhðtjyð0Þ¼uÞ−hð0jyð0Þ¼uÞÞ
Sðtjyð0Þ¼uÞ¼expð−Hðtjyð0Þ¼uÞÞ
; ð10Þ
where the integrated hazard, H, can be written in a closed form since μyIy(0) = u(t) is a linear function of t. The
probability of rupture by time t given baseline diameter u can therefore be written as:
PRðtjyð0Þ¼uÞ¼1−Sðtjyð0Þ¼uÞ: ð11Þ
The probability of rupture is evaluated over a ﬁne grid of possible times. The posterior median, 2.5th and
97.5th percentiles of the probability PR are obtained at each time. The posterior median time at which there is
a 1% chance of rupturing is then the grid time at which the posterior median probability is closest to 0.01.
Similarly, the posterior 95% credibility range are the grid times where the 2.5th percentile and 97.5th
percentile of PR are closest to 0.01.
Pooled estimates from a random-effects meta-analysis are obtained as before by taking the log of the
posterior median time as the effect estimate, whose SE on the log-scale is approximated as in Equation 7.
The meta-analysis is conducted separately for the baseline diameters 3.0, 3.5, 4.0, 4.5 and 5.0 cm as
speciﬁed in Equation 3.
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Excluded studies
TABLE 27 List of excluded studies from which IPD were not available
Author Number of patients Country Study type
Brown et al.a 476 Canada Observational
Bjorck (unpublished) 179 Sweden Prospective observational
Cao et al.b 178 Italy RCT
Lederle et al.c 567 USA RCT
Santilli et al.d 790 USA Screening
Schlosser et al.e 147 Netherlands Prospective observational
Schouten et al.f 150 Netherlands Retrospective observational
Total number of patients 2487
a Brown PM, Zelt DT, Sobolev B. The risk of rupture in untreated aneurysms: the impact of size, gender, and expansion
rate. J Vasc Surg 2003;37:280–4.
b Cao P, De Rango P, Verzini F, Parlani G, Romano L, Cieri E, et al. Comparison of surveillance versus aortic endografting
for small aneurysm repair (CAESAR): results from a randomised trial. Eur J Vasc Endovasc Surg 2011;41:13–25.
c Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN, Acher CW, et al. Immediate repair compared with
surveillance of small abdominal aortic aneurysms. N Engl J Med 2002;346:1437–44.
d Santilli SM, Littooy FN, Cambria RA, Rapp JH, Tretinyak AS, d'Audiffret AC, et al. Expansion rates and outcomes for
the 3.0-cm to the 3.9-cm infrarenal abdominal aortic aneurysm. J Vasc Surg 2002;35:666–71.
e Schlosser FJ, Tangelder MJ, Verhagen HJ, van der Heijden GJ, Muhs BE, van der Graaf Y, et al. Growth predictors
and prognosis of small abdominal aortic aneurysms. J Vasc Surg 2008;47:1127–33.
f Schouten O, van Laanen JH, Boersma E, Vidakovic R, Feringa HH, Dunkelgrun M, et al. Statins are associated with a
reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 2006;32:21–6.
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Appendix 4 Statistical methods for
cost-effectiveness analysis
Calculation of growth transition probabilities for health
economic models
We wish to estimate 3-month transition probabilities between 5-mm-wide size states as shown in Figure 23.
The state occupancy prevalence for each of the states at any time t following screening given baseline
diameter y(0) < 5.5 can be calculated using the ﬁtted mixed-effects models described in Appendix 3.
Speciﬁcally, assume a discrete Markov chain with cycles of 3 months with states 0–6 as shown in Figure 23.
This model is a simpliﬁed version used in the health economic analyses and does not consider any competing
risks, such as surgery or death. Let S(t) represent the state occupied in this model at time t, t = 0,1,2,... ,T.
The probability of making a transition from state 0 to state 1 in any 3-month period is assumed to remain
constant, and is given by q01 = 0.00207. It is also assumed that the probability of being screened normal
(i.e. in state 0 at time t = 0) is π0 = 0.983, and the probability of having a small aneurysm of size u at screening
is denoted by π(u), where π(u) is taken from the Chichester study baseline distribution of AAA diameters. For
these calculations, no AAAs are assumed to be large at screening.
Then the (occupancy) probability of remaining in state 0 (< 3.0 cm) after t time periods is given by:
P0ðtÞ¼π0ð1−q01Þt : ð12Þ
The occupancy probabilities of being in states s (s = 1,... , 6) at time t are expressed as the weighted sums of
probabilities conditional on screened diameter:
PsðtÞ¼π0Psðtjyð0Þ<3:0Þþ ∑
5:4
u¼3:0
πðuÞPsðtjyð0Þ¼uÞ; ð13Þ
where Ps(t|y(0) < 3.0) and Ps(t|y(0) = u) are the occupancy probabilities of being in state s at time t given the
screened diameter is normal or a small aneurysm of size u, respectively.
Given an AAA is detected at screening (≥ 3.0 cm), the occupancy probability of being in state s at time t is
calculated using the tail areas of the predictive distribution from each ﬁtted mixed-effects model separately
as follows:
Psðtjyð0Þ¼uÞ¼Φ
Us−μyjyð0Þ¼uðtÞﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
vyjyð0Þ¼uðtÞ
p
 !
−Φ
Ls−μyjyð0Þ¼uðtÞﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
vyjyð0Þ¼uðtÞ
p
 !
; ð14Þ
where Us and Ls are the upper and lower cut-points of state s, respectively (e.g. 3.5 cm and 3.0 cm for
state 1), and μy|y(0) = u(t) and vy|y(0) = u(t) are the predicted mean and variance as deﬁned in Appendix 3. Note that
U6 =∞. Meanwhile, the occupancy probability of being in state s at time t given being screened normal,
assuming that all newly developed aneurysms are initially measured at 3.0 cm, is:
Psðtjyð0Þ<3:0Þ¼∑
t
l¼1
ð1−q01Þl−1q01PsðtjyðlÞ¼30Þ
¼∑
t
l¼1
ð1−q01Þl−1q01Psðt−ljyð0Þ¼30Þ;
ð15Þ
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where the second line follows if we further assume that once screened normals develop an aneurysm, they
follow the same growth trajectory as the screen detected patients when they were screened, that is we
assume a time-stationary Markov chain, i.e. Ps(t|y(l) = 30) = Ps(t– l|y(0) = 30).
The occupancy probabilities can now be related to the one-step (3-month) transition probabilities via the
Chapman–Kolmogorov equations, which state that:
PsðtÞ¼Ps−1ðt−1Þqs−1, sðtÞþPsðt−1Þð1−qs, sþ1ðtÞÞ; ð16Þ
where qs,s+1(t) is the 3-month transition probability at time t from state s to state s+1, recalling that q01 is
independent of time. Rearranging the equation above gives an expression for qs,s+1(t) in terms of qs–1,s(t).
Hence, starting with calculating q12(t) in terms of q01, we can recursively estimate all the 3-month transition
probabilities for any time t.
Calculation of ‘equivalence’ probabilities for different health
economic models
We wish all the Markov models considered in the health economic analyses to be comparable in terms of the
probability of developing large AAA, in the absence of any interventions. To achieve this, we recognise that
all Markov models being considered will be collapsed versions of the general 5-mm size model.
Consider a collapsed Markov model with S* states and a known mapping from these states to those from
the general 5-mm state model. For example, a two-state Markov model with states 3.0–4.4 cm and
4.5–5.4 cm has the mappings {{1}→ {1,2,3},{2}→ {4,5},{3}→ {6}} from this model to the general 5-mm state
model. The occupancy probabilities in each size state at time t for the collapsed model can be written in
terms of the general 5-mm model and, hence, the new ‘equivalence’ transition probabilities can be derived.
For example, in the two-state model the occupancy probability in state 1 at time t is as follows and is set
equal to the occupancy probability in the ﬁrst three states of the general 5-mm state model.
P*1 ðtÞ¼P*0 ðt−1Þq*0, 1þP*1 ðt−1Þð1−q*1, 2ðtÞÞ¼∑
3
s¼1
PsðtÞ: ð17Þ
Rearranging and solving the recursive equation we can ﬁnd values for q1,2* (t), noticing that P0*(t) = P0(t),
q0,1* = q0,1 and P1*(0) = P1(0). A similar strategy is then used to ﬁnd values for q2,3* (t). This approach can be
extended and used for any collapsed model of interest.
1.
3.0–3.4
2.
3.5–3.9
3.
4.0–4.4
0.
< 3.0
4.
4.5–4.9
5.
5.0–5.4
6.
5.5+
FIGURE 23 Five-mm-wide Markov transition model.
∑
3
s¼1
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